ANALYSIS OF GnRH RECEPTOR GENE EXPRESSION IN LINES OF SWINE WITH DIVERGENT OVULATION RATES by Smith, Jacqueline E.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Theses and Dissertations in Animal Science Animal Science Department 
5-2008 
ANALYSIS OF GnRH RECEPTOR GENE EXPRESSION IN LINES OF 
SWINE WITH DIVERGENT OVULATION RATES 
Jacqueline E. Smith 
University of Nebraska - Lincoln, jsmith19@unlnotes.unl.edu 
Follow this and additional works at: https://digitalcommons.unl.edu/animalscidiss 
 Part of the Animal Sciences Commons 
Smith, Jacqueline E., "ANALYSIS OF GnRH RECEPTOR GENE EXPRESSION IN LINES OF SWINE WITH 
DIVERGENT OVULATION RATES" (2008). Theses and Dissertations in Animal Science. 7. 
https://digitalcommons.unl.edu/animalscidiss/7 
This Article is brought to you for free and open access by the Animal Science Department at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Theses and Dissertations in 
Animal Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
 
 
 
 
ANALYSIS OF GnRH RECEPTOR GENE EXPRESSION IN LINES OF SWINE 
WITH DIVERGENT OVULATION RATES 
 
by 
 
 
Jacqueline E. Smith 
 
 
 
A THESIS 
 
 
 
Presented to the Faculty of 
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Master of Science 
 
 
Major: Animal Science 
 
 
 
 
Under the Supervision of Professor Brett R. White 
 
 
 
Lincoln, Nebraska 
 
 
May, 2008 
 
 
i 
 
TABLE OF CONTENTS 
Page 
 
LIST OF FIGURES ………………………………….………………………………….v 
LIST OF TABLES ………..………………………….………………………………...vii 
 
CHAPTER I: Introduction 
 Introduction………………………………………………………………………..1 
 
CHAPTER II: Literature Review 
Gonadotropin-Releasing Hormone 
Role in Reproductive Axis ………………………..……....………………5 
Production and Secretion…….……………………………………………7 
Structure of Gonadotropin-Releasing Hormone Isoforms 
Gonadotropin-Releasing Hormone.……………………………...10 
Gonadotropin-Releasing Hormone-II.…………………………...11 
Gonadotropin-Releasing Hormone-III ……………………..........14 
Gonadotropin-Releasing Hormone Receptor 
Cloning and Isolation of Gene 
Coding Sequence ……………..............…………………………14 
5’ Flanking Sequence………….........……………………………15 
Structure of Gonadotropin-Releasing Hormone Receptor Isoforms 
Gonadotropin-Releasing Hormone Receptor……………...……..17 
Gonadotropin-Releasing Hormone Receptor-II………………….17 
Other Isoforms ……………………………….………………….20 
Tissue Expression 
Anterior Pituitary ……………………………………………..…21 
Hypothalamus ……………………………………….………..…23 
Placenta ……………………………….…………………………24 
Ovary ……………………….……………………………………25 
Testis ………………………………………………………….....27 
Other Tissues …………………...…………………………….....28 
Cancer Cell Lines ……………….…………………………….....29 
Activation of Cell Signaling Pathways Following GnRH Binding 
G-protein Coupled Receptors ……......………………………….31 
G-proteins ……………………………...………………..............33 
Protein Kinase C............................................................................33 
Protein Kinase A ………………....……………………………...37 
Mitogen-Activated Protein Kinases 
General …………….…………………………………….40 
ERK1/2……....……………………………………….….40 
JNK …………………………...…………………………43 
p38………………………………………………………..44 
ERK5 (BMK)………………………....………………….45 
ii 
 
Hormonal Regulation 
GnRH ……………………………………………………………46 
Gonadotropic Hormones ………………………………………...48 
   Steroid Hormones 
General …………...…………………………………...…49 
Estradiol-17β..……………………………………………50 
Glucocorticoids ……………………………………….…52 
Progesterone ………….……………………………….…52 
Testosterone ……….………………………………….…53 
Activin/Follistatin …………………………………………….…54 
Inhibin ……………………..………………………………….…55 
Transcriptional Regulation 
General …………………………………..………………………56 
GnRH Receptor Activating Sequence …..………………………59 
Octamer Transcription Factor-1………….....……………………60 
LIM-Related Factors ……………………..……………………62 
Steroidogenic Factor-1 …………………..………………………63 
Activating Protein-1 ……………………..………………………64 
GATA Factors …….……………………..………………………66 
Nuclear Factor-κB ……………...………..………………………68 
Specificity Protein Family ……………....………………………70 
Progesterone Receptor …………………..………………………72 
Gonadotropin-Releasing Hormone Receptor in Swine…..………………74 
Gene Influencing Prolificacy 
Sheep ………………………………………………...…………………..75 
Mice ……………………………………….…………………………….77 
Swine ……………………………………….……………………………79 
 
CHAPTER III: Materials and Methods 
Lines of Swine …………………………………………………………………..80 
GnRHR Gene Promoter Isolation ……………......................…………………...80 
Plasmid Preparation 
Reporter Vectors ………………….……………………………………..81 
Block Replacement Mutations ……………...…………………………...83 
Gel Extraction …………………………...………………………………86 
Transformation …......................................................................................87 
Alkaline Lysis Mini Plasmid Preparation…………….………………….87 
Midi Plasmid Purification …………………………...…………………..88 
Cell Culture ………………………………………..…………………………….90 
Transient Transfections  
Day 1…………………………….…………………….…………………90 
Day 2…………………………….…………………….…………………91 
Day 3…………………………….…………………….…………………91 
Protein Extraction ………….……………………………………………………92 
iii 
 
Electrophoretic Mobility Shift Assays ……………………………………..……94 
Statistical Analysis ………………………………………………………………97 
  
CHAPTER IV: Three Steroidogenic Factor-1 Binding Sites Confer Gonadotrope-
Specific Activity Whereas GATA-4 and Nuclear Factor-κB 
Elements Contribute to Divergent Line-Specific Activity of the 
Porcine GnRH Receptor Gene Promoter 
 Abstract…………………………………………………………………………..98 
 Introduction……………………………………………………………………99 
Materials and Methods 
Materials ……………………………………………………………….104 
Plasmids …………….………………………………………………….105 
Cell Culture and Transient Transfections ..…………………………….106 
Electrophoretic Mobility Shift Assays………………………………….107 
Statistical Analysis ……………………………….…………………….108 
Results 
A single bp alteration unique to the Meishan GnRHR gene promoter 
allows for divergent binding of GATA-4………………………………108 
Block replacement mutation of the GATA-4 binding site located at  
-845 bp of proximal promoter reduced luciferase activity of the 
Meishan GnRHR gene promoter …………………...………………….109 
Binding of SF-1 to a recognition site located at -1760/-1753 bp of 
proximal promoter represents the first factor comprising the swine 
upstream promoter enhancing region (SUPER)………………………..111 
The SF-1 binding site within SUPER is functionally significant to the 
porcine GnRHR gene promoter ………….…………………………….114 
Putative Oct-1 and NF-κB elements identified within SUPER do not 
contribute to functional activity of the porcine GnRHR 
gene promoter ……………...…………………………………………..114 
A single bp substitution within SUPER confers divergent  
binding between the Meishan and Control/Index GnRHR 
gene promoters ……………………………...………………………….116 
Block replacement mutations of the GATA-4 and NF-κB binding  
sites in the Meishan and Control/Index promoters, respectively,  
reduced luciferase activities of both the Meishan and Control/Index 
GnRHR gene promoters ……………………….……………………….118 
The working models for cell- and line-specific activity of the  
porcine GnRHR gene promoter have been updated as a result  
of these studies ………………………...……………………………….120 
Discussion ………………..…………………………………………………….122 
 
 
 
 
iv 
 
APPENDICES 
I ………………..……………………………………………………………….129 
II ………………..………………………………………………...…………….130 
 
LITERATURE CITED …………………………….………………………………...131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF FIGURES 
Page 
  
Figure 1.1. Differential GnRHR gene promoter activity among swine lines 
with divergent ovulation rates ……………………………………..……...4 
 
Figure 2.1. Schematic of the reproductive axis ………..……………………………...6 
 
Figure 2.2. Comparison of the 3 isoforms of GnRH………………………………....12 
 
Figure 2.3. Structural diagram of the receptors specific to GnRH-I and -II …...……18 
 
Figure 2.4. Activation of the protein kinase C (PKC) pathway following GnRH 
stimulation ……………………………………………..……………….. 36 
 
Figure 2.5. Activation of the protein kinase A (PKA) pathway following GnRH 
stimulation ……………………………………………..……………….. 38 
 
Figure 2.6. A general schematic of mitogen-activated protein kinase (MAPK) 
signaling cascades following GnRH binding to its cognate receptor...….41 
 
Figure 2.7. Schematic representation of elements conferring basal and  
  hormonal regulation of the GnRHR gene promoter in the human,  
mouse and rat ……………………………….…………………………...57 
 
Figure 2.8. Cell-specific expression of the mouse GnRHR gene is regulated by  
  a tripartite enhancer which consists of three elements; steroidogenic  
  factor-1 (SF-1), activator protein-1 (AP-1) and GnRH receptor  
activating sequence (GRAS)………...…………………………………...58 
 
Figure 3.1. The full-length porcine GnRHR gene promoter was sub-cloned  
 into the pGL3-basic vector by SacI and SmaI restriction  
endonuclease recognition sequences ………….…………………………82 
 
Figure 4.1. The transcription factor, GATA-4, comprises the specific complex  
binding to the sequence spanning a bp substitution (-845) unique to 
the Meishan GnRHR gene promoter …………………………….…..…110   
 
Figure 4.2. Functional significance of the GATA-4 binding site specific to the 
Meishan GnRHR gene promoter ………………………………..…..…112 
 
 
 
 
vi 
 
Figure 4.3. The oligonucleotide spanning the region located at -1779/-1749  
bp of the porcine GnRHR gene promoter binds SF-1 in   
αT3-1 cells ……………………………………………………………..113 
 
Figure 4.4. Functional significance of the SF-1 binding site within the porcine 
GnRHR gene promoter ……….………………………………….…….115 
 
Figure 4.5. The p65 and p52 subunits of NF-κB bind to the homologous 
Control/Index promoters, whereas GATA-4 binds to the Meishan 
promoter within the 5’ flanking region spanning the  
-1690 bp substitution ………………….…………………………….....117 
 
Figure 4.6. Functional significance of the GATA-4 and NF-κB elements  
  specific to the Meishan and Control/Index GnRHR gene 
promoters, respectively ……………………………………….......……119 
 
Figure 4.7. Working models for (A) cell- and (B) line-specific activity of the 
porcine GnRHR gene promoter ………………..………………………121   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES  
 
Page 
 
TABLE 3.1. PRIMERS USED TO GENERATE BLOCK REPLACEMENT     
MUTATIONS IN VECTORS CONTAINING THE PORCINE  
GnRHR GENE PROMOTER …………………..………………….……84 
 
TABLE 3.2. OLIGONUCLEOTIDES CONTAINING CONSENSUS 
TRANSCRIPTION FACTOR BINDING SITES USED AS        
COMPETITORS IN ELECTROPHORECTIC MOBILITY    
SHIFT  ASSAYS …………………………….………………………….96 
           
 
  
1 
 
CHAPTER I 
 
 
INTRODUCTION 
 
 
 Litter size is one of the most important factors in swine production, averaging 9 
piglets per sow in the U.S. (USDA-National Agricultural Statistical Services, 2007).  
Increasing litter size by 1 piglet per sow could have a dramatic economic impact on the 
pork industry.  For example, given a live basis price of $0.35/lb and a 250 lb market 
weight, a producer with 10,000 sows could increase income by $875,000 per farrowing.  
Although many factors influence prolificacy, including ovulation rate, embryonic 
survival and uterine capacity, ovulation rate is one of the major determinants of litter size 
(Christenson et al., 1993).  Similar to other reproductive traits, ovulation rate is regulated 
by gonadotropin-releasing hormone (GnRH) binding to its specific receptor on the 
plasma membrane of gonadotrope cells located in the anterior pituitary gland. 
 Gonadotropin-releasing hormone is released in a pulsatile manner from 
hypothalamic neurons and binds to its cognate receptor on the surface of gonadotrope 
cells within the anterior pituitary gland.  This causes the synthesis and secretion of the 
gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH; Clayton 
and Catt, 1981; Clarke et al., 1983).  The gonadotropins, in turn, act at the level of the 
gonads to promote gamete maturation, ovulation and steroid hormone production.  The 
steroid hormones may act in a negative or positive feedback manner to control the 
production of GnRH and the gonadotropins at the level of the hypothalamus and anterior 
pituitary gland, respectively (Nakai et al., 1978; Conn and Crowley, 1994; McNeilly et 
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al., 2003).  Focusing on the mechanisms within gonadotrope cells, binding of GnRH to its 
cognate G-protein coupled receptor, stimulates the up-regulation of at least 4 
gonadotropic genes; the common glycoprotein hormone α-subunit, the unique β-subunits 
specific to both LH and FSH (Hamernik and Nett, 1988; Gharib et al., 1990), as well as 
its own receptor (Sealfon and Millar, 1995).  Thus, the interaction between GnRH and its 
receptor represents a central point for regulation of reproductive function. 
 In addition to the physiological relevance of the interaction between GnRH and its 
receptor, the porcine GnRH receptor (GnRHR) gene is located on chromosome 8 and is 
in close proximity to a quantitative trait locus (QTL) for ovulation rate (Rohrer et al., 
1999).  Thus, the porcine GnRHR gene represents both a physiological and positional 
candidate for genes influencing ovulation rate.  To study the transcriptional regulation of 
the porcine GnRHR gene and its possible effects on ovulation rate, our laboratory has 
utilized 3 lines of swine with divergent ovulation rates; the Control white-crossbred, 
Index, and Chinese Meishan.  The Index line, developed at the University of Nebraska-
Lincoln was selected for over 14 generations based on an index of ovulation rate and 
embryonic survival.  These females ovulate approximately 7.4 more oocytes than females 
from the Control line (Johnson et al., 1999).  The Chinese Meishan is a highly prolific 
breed, producing 4 to 5 more piglets per litter compared to occidental breeds, largely due 
to ovulation rate (Christenson et al., 1993; White et al., 1993). 
To examine the relationship between the molecular mechanisms underlying 
ovulation rate and transcriptional regulation of the porcine GnRHR gene, our laboratory 
has isolated the GnRHR gene promoter from the Control, Index and Meishan lines 
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(McDonald, 2005).  Previous work in our laboratory has indicated divergent luciferase 
activity among reporter vectors containing 5000 bp of 5’ flanking region for the porcine 
GnRHR gene from all three genetic lines transiently transfected into gonadotrope-derived 
αT3-1 cells (Fig 1.1; McDonald, 2005).  This suggests differential mechanisms involved 
in the transcriptional regulation of the GnRHR gene among pig strains. 
 Additionally, our laboratory identified a single base alteration between the 
Meishan and homologous Control/Index promoters located at -1235 bp of 5’ flanking 
region.  This single bp substitution allows for the binding of the p65 and p52 subunits of 
NF-κB and an Sp1-like protein in the Meishan promoter, events that are absent in the 
Control/Index promoters (McDonald, 2005).  Transient transfections with vectors 
containing block replacement mutations of these binding sites, either singly or in 
combination, decreased luciferase activity by approximately 25%.  Despite a significant 
reduction in promoter activity, however, luciferase values were not reduced to levels 
exhibited by reporter constructs containing the full-length Control promoter.  This 
suggests that other unidentified element(s) within the Meishan proximal promoter 
contribute to its enhanced activity.  Therefore, we need to identify additional elements 
and transcription factors that contribute to the line-specific activity of the porcine 
GnRHR gene. 
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Figure 1.1.  Differential GnRHR gene promoter activity among swine lines with 
divergent ovulation rates.  Luciferase reporter constructs containing 5000 bp of proximal 
promoter for the Index (I5000pGL3) and Meishan (M5000pGL3) GnRHR genes display 
2- and 4-fold increased activity compared to those containing the Control (C5000pGL3) 
promoter.  Bars with alternate superscripts differ (P < 0.05).  From McDonald (2005).  
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
 
Gonadotropin-Releasing Hormone  
 
Role in Reproductive Axis 
The decapeptide, gonadotropin-releasing hormone (GnRH), was first isolated 
from mammalian hypothalamic tissue (Amoss et al., 1971; Matsuo et al., 1971; Schally et 
al., 1971) and determined to be essential to reproductive function.  It is released in a 
pulsatile manner from the hypothalamus into the hypothalamo-hypophyseal portal 
vascular system and travels to the anterior pituitary gland (Figure 2.1; Carmel et al., 
1976; Levine et al., 1982).  Here, GnRH binds to specific G protein-coupled receptors 
(GPCRs) located on the plasma membrane of gonadotrope cells within the anterior 
pituitary gland.  The GnRH receptor (GnRHR) is a member of the GPCR family, 
characterized by an extracellular N-terminus and intracellular C-terminus linked by seven 
transmembrane helices and connected by three extracellular and intracellular loops.  
However, the GnRHR is a unique member of the GPCR family because it lacks a C- 
terminal tail (Tsutsumi et al., 1992; Probst et al., 1992; Davidson et al., 1994; Wess, 
1997).  Gonadotropin-releasing hormone binding to its receptor stimulates the up-
regulation of at least 4 gonadotropic genes: the common α-subunit; the unique β-subunits 
specific to the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone
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Figure 2.1.  Schematic of the reproductive axis.  Gonadotropin-releasing hormone 
(GnRH) is produced in the hypothalamus and acts on gonadotropes within the anterior 
pituitary gland. This leads to the production of the gonadotropins, follicle stimulating 
hormone (FSH) and luteinizing hormone (LH).  These hormones, in turn, have an effect 
on the gonads, causing release of steroid hormones. The steroid hormones then act in a 
negative or positive feedback loop to control the production of GnRH and the 
gonadotropins. 
 
GnRH
LH & FSH
Steroid Hormones
Gonads
Anterior 
Pituitary
Hypothalamus( + )
( + )
( - )
( + )
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 (FSH; Hamernik and Nett, 1988; Gharib et al., 1990); and its own receptor (Sealfon and 
Millar, 1995). 
The binding of GnRH to its receptor causes the synthesis and secretion of the 
gonadotropins, LH and FSH (Figure 2.1; Clayton and Catt, 1981; Clarke et al., 1983).  
Luteinizing hormone induces ovulation in the female (Velardo, 1960) and testosterone 
production in the male (Veyssiere et al., 1977), whereas FSH is involved in follicular 
recruitment and maturation in the female (Velardo, 1960) and spermatogenesis in the 
male (Weissenberg et al., 1982).  Next, the gonadotropins act on the gonads to cause the 
production of steroid hormones such as androgens, progesterone (P4) and estradiol-17β 
(E2).  The steroid hormones can provide negative or positive feedback to control 
production of both GnRH at the level of the hypothalamus and gonadotropins from the 
anterior pituitary gland (Figure 2.1; Nakai et al., 1978; Conn and Crowley, 1994; 
McNeilly et al., 2003). 
 
Production and Secretion 
 Gonadotropin-releasing hormone is released in a pulsatile manner from 
hypothalamic neurons and binds to specific receptors on the plasma membrane of 
gonadotrope cells within the anterior pituitary gland.  This specific release of GnRH is a 
prerequisite for fertility during the female reproductive cycle (Moenter et al., 1991).  
Gonadotropin-releasing hormone is released in different frequencies throughout the 
follicular and luteal phases of the estrous cycle.  Studies in the ewe have indicated that 
during the start of the follicular phase, E2 levels rise causing GnRH pulse frequency to 
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increase and pulse amplitude to decrease (Clarke et al., 1987; Moenter et al., 1991).  
During the luteal phase of the estrous cycle, GnRH release in the ewe occurs in high 
amplitude, low frequency pulses, whereas the frequency of GnRH pulses increased at the 
end of the luteal phase as P4 levels decreased (Clarke et al., 1987; Moenter et al., 1991; 
Clarke, 1995).  Administration of GnRH in a pulsatile manner to lactating sows increased 
LH, stimulating follicular development and inducing sows into estrus (Britt et al., 1985).  
Bracken and associates (2007) administered GnRH in a pulsatile manner 4 days prior to 
weaning, for 2 consecutive days, causing a wave of follicular growth that was not 
sustained post-weaning.  Knox and associates (2003) analyzed gilts with high or low 
ovulation rates and measured the levels of gonadotropins and steroid hormones during 
their estrous cycle.  Swine with elevated ovulation rates had higher FSH levels during the 
ovulatory period as well as the mid- and late-luteal phases.  During the ovulatory period, 
the gilts with an increased ovulation rate had greater LH levels.  Thus, increased 
synthesis and secretion of GnRH caused an increase in FSH and LH, resulting in 
amplified ovulation rates during various stages of the estrous cycle (Knox et al., 2003). 
 Effects of puberty, aging, season/photoperiod, nutrition and stress may cause 
changes in GnRH synthesis and secretion.  During postnatal development in rats (Sisk et 
al., 2001) and monkeys (Plant and Shahab, 2002), there is a steady increase in the 
hypothalamic levels of GnRH content and release.  Post-pubertal hamsters have increased 
levels of GnRH mRNA in GnRH neurons within the brain compared to pre-pubertal 
hamsters, possibly due to an alteration of GnRH neuronal activity or central mechanisms 
controlling GnRH secretion (Parfitt et al., 1999).  Gonadotropin-releasing hormone 
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secretion can impact the selection of follicles in post-pubertal gilts.  Therefore, GnRH 
secretion may be important in regulating a pulsatile release of LH, critical for follicular 
growth in post-pubertal gilts (Knox, 2005).   
Gonadotropin-releasing hormone secretion is also affected by increasing age, 
resulting in reduced preovulatory GnRH/LH surges and attenuation of pulsatile LH 
secretion.  Wise et al. (2002) utilized middle-aged rats to understand the interactions 
between the ovary and brain during menopause.  Subtle changes in GnRH secretion in 
middle-aged rats decreased E2.  Eventually, the inability of GnRH to travel to the anterior 
pituitary disabled the LH surge, leading to irregular estrous cycles and ultimately ending 
their reproductive cycles.  Therefore, menopausal women are unable to coordinate E2 
with the regular preovulatory GnRH surges, resulting in irregular estrous cycles and 
eventually acyclicity (Wise et al., 2002).  An additional study suggested that a loss of 
ovarian cyclicity causes an absence of E2 negative feedback on GnRH neurons within the 
brain in aging female mice (Thanky et al., 2003).   
Seasonal breeders such as sheep, horses and hamsters utilize photoperiod and 
other cues to regulate their circannual pattern of reproduction (Thiery et al., 2002).  
Melatonin plays an important role in the regulation of seasonal reproductive behavior, but 
responsiveness of the hypothalamus to melatonin dictates the difference between long 
and short day breeders (Gerlach and Aurich, 2000).  In long day breeders, (horse and 
hamster) increased levels of melatonin secretion are associated with decreased GnRH 
secretion.  However, increased melatonin levels are associated with an increase in GnRH 
in short day breeders (sheep; Grosse et al., 1993).  Reproduction is repressed by increased 
10 
 
melatonin in long day breeders, whereas it is stimulated by elevated melatonin in short 
day breeders (Grosse et al., 2003).    
Nutritional status can also have an effect on GnRH production and secretion.  For 
instance, plasma levels of LH are reduced in sheep during food deprivation as a result of 
inhibitory influences on secretion of GnRH (Henry et al., 2001).  Another study 
suggested that food restricted, male prairie voles had increased numbers of GnRH 
neurons, as detected by immunohistochemistry, probably due to reduced secretion of 
GnRH (Kriegsfeld et al., 2001).  Restricting food to pre-pubertal bulls delayed puberty, 
reducing the pituitary response to GnRH and hindering testicular steroidogenesis (Brito et 
al., 2007).  However, supplemental feeding did not stimulate puberty (Brito et al., 2007).   
Finally, stress can have detrimental effects on the reproductive axis.  
Administration of a bacterial endotoxin, which induces immune/inflammatory stress, to 
ovariectomized ewes reduced pulsatile GnRH/LH secretion (Debus et al., 2002).  Lapot 
and associates (2007) indicated that short and prolonged footshock stimulation to sheep 
activated both the GnRH and GnRHR genes in the preoptic area of the hypothalamus and 
the GnRHR gene in the anterior pituitary of anestrous ewes.  However, there was in 
increase in LH secretion in animals that were stressed for a short period of time.  Thus, 
short amounts of stress can have a positive effect on reproduction (Lapot et al., 2007). 
  
Structure of Gonadotropin-Releasing Hormone Isoforms 
 Gonadotropin-Releasing Hormone.  Mammalian GnRH is a decapeptide 
consisting of the following amino acids: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-
11 
 
NH2 (Figure 2.2; Schally et al., 1971; Matsuo et al., 1971; Baba et al., 1971).  
Gonadotropin-releasing hormone has 23 known isoforms from vertebrate and 
protochordate species and has been conserved for more than 500 million years of 
evolution (Millar, 2005).  The NH2-terminal sequence has been highly conserved, 
suggesting that is critical for both receptor binding and activation, whereas the COOH-
terminus is no longer present in the first isoform of GnRH (Millar, 2005).  In order to 
enhance binding affinity for its specific receptor, the mammalian GnRH peptide is folded 
to a specific tertiary conformation (Millar et al., 2004; Millar, 2005), whereas the non-
mammalian GnRH peptide maintains a more extended structure (Guarnieri and 
Weinstein, 1996; Maliekal et al., 1997).  Following subsequent isolation of GnRH 
isoforms, the original form of GnRH has been termed GnRH-I.   
 
Gonadotropin-Releasing Hormone-II.  Another form of GnRH, first identified 
from chicken brain, is ubiquitous in vertebrates from primitive bony fish to man (GnRH-
II; Millar et al., 1987; Millar and King, 1988; Sherwood et al., 1993; White et al., 1994; 
Lescheid et al., 1997).  The second form of GnRH is a decapeptide consisting of the 
following amino acids: pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2.  This structure 
differs from GnRH-I at the fifth, seventh and eighth amino acids (Figure 2.2; Chen et al., 
2001).  The GnRH-II gene has been isolated in cartilaginous and bony fish (Powell et al., 
1986; Lovejoy et al., 1992; Kim et al., 1995; Powell et al., 1996), amphibians (King and 
Millar, 1986; Licht et al. 1994; Pinelli et al., 1997), reptiles (Powell et al., 1985; 
Sherwood and Whittier, 1988), birds (Miyamoto et al., 1984; Van-Gils et al., 1993), 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 2.2.  Comparison of the 3 isoforms of GnRH.  Amino acids in bold are different 
from the originally identified form, GnRH-I. 
 
 
GnRH Isoforms Amino Acid Sequence 
GnRH-I pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
GnRH-II pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2
GnRH-III pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2
13 
 
monkeys (Lescheid et al., 1997; Urbanski et al., 1999), humans (Chen et al., 1998; White 
et al., 1998) and pigs (Millar, 2003).  Although mice do not apparently make the GnRH-
II ligand (Millar, 2003), previous studies identified GnRH-II immunopositive cells in 
various locations of the mouse and rat brain (Chen et al., 1998; Gestrin et al., 1999).  
Gonadotropin-releasing hormone-II has been identified in many tissues including the 
brain, pituitary gland (Chen et al., 2001), kidney, bone marrow (White et al., 1998), 
immune system (Chen et al., 2002a), and reproductive tissues such as the ovary (Choi et 
al., 2001), breast (Chen et al., 2002b), uterine endometrium (Cheon et al., 2001) and 
prostate (White et al., 1998).  The GnRH-II ligand contains a preconformed β-II turn, 
making it more stable than GnRH-I.  It may also differ from GnRH-I in its 
pharmacological bioavailability because GnRH-II is believed to be more susceptible to 
peptidase degradation (Pawson et al., 2003).   
Although the function of GnRH-II is still unknown, unlike GnRH-I, it is likely 
involved in more biological systems than the reproductive system because of its 
ubiquitous expression.  Kauffman and associates (2006) suggested that food restricted 
musk shrews expressed fewer reproductive behaviors which was correlated with reduced 
levels of GnRH-II in various brain nuclei.  Barnett and associates (2006) analyzed the 
reproductive behavior of female marmosets in the presence of a male and concluded that 
GnRH-II and its receptor play a role in stimulating female reproductive behavior.  
Additional studies also proposed that GnRH-II may be important for hormone regulation 
during pregnancy (Siler-Khodr and Grayson, 2001) and maintaining normal ovarian 
function (Siler-Khodr et al., 2003).   
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Gonadotropin-Releasing Hormone-III.  Additional isoforms of GnRH have 
been cloned from lamprey; lamprey GnRH-I (l-GnRH-I) and lamprey GnRH-III (l-
GnRH-III).  Lamprey-GnRH-III (l-GnRH-III) is also a decapeptide with the following 
amino acid sequence: pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 (Figure 2.2; 
Mezo et al., 2007).  With 60% homology to GnRH-I, l-GnRH-III contains different 
amino acids in positions five to eight (Sower et al., 1993).  This natural isoform of GnRH 
isolated from sea lamprey is considered to be a weak agonist of GnRH-I within the 
pituitary.  Lamprey-gonadotropin-releasing hormone-III is not a natural ligand in humans 
but inhibits the growth of human cancer cells (Heredi-Szabo et al., 2006).   
 
Gonadotropin-Releasing Hormone Receptor 
 
Cloning and Isolation of Gene 
 Coding Sequence.  The GnRHR was first isolated from gonadotrope-derived 
αT3-1 cells of mouse origin (Tsutsumi et al., 1992).  The αT3-1 cell line endogenously 
produces GnRHRs; therefore, it represents a good cell line for in vitro studies of the 
GnRHR (Windle et al., 1990).  Following isolation of the mouse GnRHR, it was 
identified in other mammalian species including the cow (Kakar et al., 1993), human (Chi 
et al., 1993; Kakar et al., 1992), pig (Weenser and Matteri, 1994), sheep (Illing et al., 
1993; Brooks et al., 1993), marmoset (Byrne et al., 1999), rat (Eidne et al., 1992; Kaiser 
et al., 1992) and guinea pig (Fujii et al., 2004).  Some differences are present in the 
GnRHR cDNA sequence among these species but their amino acid sequence has 85% 
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homology to the mouse GnRHR.  One of the differences among these species is the 
addition of one amino acid in the cow, human, pig and sheep in comparison to the rat and 
mouse (Cheng and Leung, 2000).  
The GnRHR is highly conserved among mammalian species (Kakar et al., 2002).  
For example, the rat and mouse GnRHR cDNAs are very similar (Millar, 2005; 
Schneider et al., 2006).  The human GnRHR contains 328 amino acids and is 90% 
identical to the mouse GnRHR (Chi et al., 1993).  The bovine GnRHR also contains 328 
amino acids, exhibiting 91 and 86% identity to the human and mouse/rat receptors, 
respectively (Kakar et al., 1993).  The porcine, bovine and ovine GnRHRs are 
comparable in length to the human, with all containing an additional amino acid at 
position 191 in the second extracellular loop that is not present in rodents (Schneider et 
al., 2006; Millar, 2005; Weenser and Matteri, 1994).  The porcine GnRHR is 88% 
identical to the bovine and ovine, 87% similar to the human, and has 81% homology to 
the rat.  In addition, the marmoset GnRHR has an 85 and 95% homology to the rat and 
human GnRHR, respectively (Schneider et al., 2006).   
 
5’ Flanking Sequence.  The 5’ flanking region of the GnRHR gene has been 
isolated in many different mammalian species such as mouse (Albarracin et al., 1994), rat 
(Reinhart et al., 1997; Pincas et al., 1998), human (Fan et al., 1995; Kakar, 1997), sheep 
(Campion et al., 1996), and pig (Jiang et al., 2001; Cederberg et al., unpublished data).  
Isolation of the GnRHR gene promoter from various species has led to examination of the 
transcriptional regulation of this gene.  The promoters among each of species contain 
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some homology.  For instance, the rat and mouse promoters share 80% homology, 
whereas the rat promoter shares 55% homology with the human promoter.  In addition to 
sharing homology with the human promoter, the rat also shares 63% homology with the 
sheep promoter (Pincas et al., 1998).  Within 500 bp of proximal promoters from the 
mouse, rat, human, sheep and pig there are several highly homologous regions (Pincas et 
al., 1998).   
The mouse GnRHR 5’ flanking sequence was the first to be analyzed.  The 
transcriptional start site is located at -62 bp, not in proximity to a consensus TATA box 
(Albarracin et al., 1994).  The transcriptional start site for the rat GnRHR proximal 
promoter is located 103 bp upstream from the start codon, with a putative TATA box 
situated 23 bp upstream from the transcriptional start site (Reinhart et al., 1997).  
However, the human and sheep GnRHR proximal promoters are more complex compared 
to the rat and mouse.  For example, they contain multiple transcriptional start and 
catabolite activator protein (CAP) sites (Campion et al., 1996; Ngan et al., 2000).  The 
sheep GnRHR promoter is similar to the mouse; however, it is more homologous to the 
human promoter sequence (Campion et al., 1996).  The human promoter contains 18 
transcription initiation sites and several TATA and CAAT boxes located close to one 
another (Fan et al., 1995; Kakar, 1997) compared to the mouse that only contains one 
transcriptional start site (Sadie et al., 2003).  Lastly, Jiang et al. (2001) isolated 
approximately 1200 bp of the porcine GnRHR proximal promoter.  The porcine GnRHR 
5’ flanking sequence contains 7 putative CAAT boxes and 3 potential TATA boxes in 
close proximity to each other.   
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Structure of Gonadotropin-Releasing Hormone Receptor Isoforms 
 Gonadotropin-Releasing Hormone Receptor.  The GnRHR is a member of the 
GPCR family which is characterized by an extracellular N-terminus and an intracellular 
C-terminus.  These termini are linked by 7 transmembrane helices which are connected 
by 3 intracellular and extracellular loops (Reinhart et al., 1992; Wess, 1997; Ji et al., 
1998).  These intracellular and extracellular loops are important for ligand binding and 
signal transduction, respectively (Counis et al., 2005).  However, the GnRHR also has a 
short third intracellular loop and lacks an intracellular C-terminal tail (Figure 2.3; 
Tsutsumi et al., 1992; Probst et al., 1992; Davidson et al., 1994; Wess, 1997).  The 
absence of a C-terminal tail is unique to the mammalian GnRHR because it is present in 
all other G-protein coupled and non-mammalian GnRHRs.  Addition of a C-terminal tail 
to the rat GnRHR resulted in increased internalization rates.  Thus, the lack of an 
intracellular C-terminal tail in the mammalian GnRHR may help maintain many active 
receptors on the surface of gonadotrope cells following a GnRH surge (Heding et al., 
1998). 
 
Gonadotropin-Releasing Hormone Receptor-II.  An additional member of the 
GnRHR family of GPCRs is GnRHR-II.  Unlike the first form of GnRHR, GnRHR-II 
contains a C-terminal tail, critical for receptor internalization (Figure 2.3; Faurholm et al., 
2007; Ronacher et al., 2004).  The cDNA and genomic sequences for the human GnRHR-
II have been isolated (Faurholm et al., 2001; Morgan et al., 2003).  Additionally, the pig 
(Neill et al., 2004), marmoset (Millar et al., 2001), African green monkey and rhesus 
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Figure 2.3.  Structural diagram of the receptors specific to GnRH-I and -II.  
Gonadotropin-releasing hormone receptor-II contains an intracellular C-terminal tail that 
is critical for receptor internalization.  However, GnRHR-I lacks an intracellular, C-
terminal tail.  From Neill (2002). 
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monkey (Neill et al., 2001) GnRHR-II cDNA sequences have been identified.  Only the 
genes encoding GnRHR-II have been sequenced in the sheep (Gault et al., 2004), bovine 
(Morgan et al., 2006), and chimpanzee (Morgan and Millar, 2004) and coding regions 
have been predicted.  Sheep and bovine GnRHR-II have an 80 and 67% amino acid 
identity, respectively, whereas both sheep and bovine have a 41% amino acid homology 
to human GnRHR-II.  Most primates have a 90-93% amino acid homology amongst each 
other for GnRHR-II (Faurholm et al., 2007).  In addition, the pig and old world monkey 
GnRHR-II proteins have a 91% amino acid homology (Neill et al., 2004).   
The marmoset, African green monkey, rhesus monkey, and pig gene sequences 
produce functional GnRHR-IIs.  The marmoset GnRHR-II gene contains 3 exons and 2 
introns with a similar structure to the mammalian GnRHR-I gene (Faurholm et al., 2007).  
Neill et al. (2004) isolated and sequenced cDNA encoding a protein for the 7 
transmembrane porcine GnRHR-II.  Additionally, they identified a 5 transmembrane 
receptor formed by alternative splicing in exon 1.  However, the bovine, sheep, human, 
and chimpanzee GnRHR-II genes encode a non-functional protein (Faurholm et al., 
2007).  The human GnRHR-II contains a premature stop codon (UAA) that is located in 
frame within exon 2, suggesting the receptor is non-functional (Morgan et al., 2003).  The 
premature codon identified within the human GnRHR-II gene is also conserved in the 
chimpanzee (Morgan et al., 2003).  Additionally, the human and chimpanzee genes have 
the same stop codon in exon 2 and the same frame shift in exon 1 (Faurholm et al., 2007).  
The bovine GnRHR-II gene has a 2 bp deletion within exon 1, resulting in a frame shift.  
In comparison to the sheep GnRHR-II gene, the bovine has an alteration of 21 codons in 
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the first exon, including 5 silent changes, 14 amino acid modifications and 2 amino acid 
deletions (Morgan et al., 2006).  The sheep has a major deletion in exon 2 and a 
premature stop codon in exon 1, whereas the bovine contains a premature stop codon in 
exon 2 (Morgan et al., 2003).  
 
 Other Isoforms.  Moncaut and associates (2005) identified 5 GnRHRs in teleost 
fish.  Gonadotropin-releasing hormone and GnRHRs are important in cellular functions 
other than the classical role within the anterior pituitary gland (Moncaut et al., 2005).  
The lamprey GnRH receptor (l-GnRHR) is highly unique because it has the longest 
intracellular C-terminal tail (120 amino acids) of any previously identified GnRHR 
(Silver et al., 2005).  This unusual C-terminal tail may be required for efficient ligand 
binding, stimulation of another unknown signaling pathway and/or structural stability.  
Activation of this receptor with either l-GnRH-I or l-GnRH-III promoted cAMP 
production in a dose-dependent manner.  Additionally, the l-GnRHR displayed rapid 
ligand-dependent internalization compared to the truncated tailless form of l-GnRH-III 
(Silver et al., 2005; Silver and Sower, 2006).  The l-GnRHR has similar characteristics of 
both GnRHR-I and -II, therefore it has maintained ancestral characteristics of the 
vertebrate GnRHR family.  However, lampreys have become a unique model system for 
analyzing and understanding the evolution of the neuroendocrine regulation of 
reproduction (Sower, 2003; Silver and Sower 2006). 
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Tissue Expression 
  
Anterior Pituitary.  The GnRHR gene is expressed in gonadotrope cells of the 
mammalian anterior pituitary gland and plays an important role in the reproductive axis.  
The number of GnRHRs within the anterior pituitary gland is regulated during fetal 
development (Granger et al., 2004), sexual maturation (Zapatero-Caballero et al., 2003) 
and the reproductive cycle (Bauer-Dantoin et al., 1993).  During fetal development, 
GnRHR gene expression is regulated by changes in levels of E2 and P4 as well as an 
increase in GnRH secretion (Granger et al., 2004).  Zapatero-Caballero and associates 
(2003) determined that the activation of genes for GnRHR and gonadotropic subunits 
within the anterior pituitary gland depended on GnRH secretion, contributing to sexual 
development in male rats.  Also, the number of GnRHRs on gonadotrope cells varies 
during the rat estrous cycle.  More receptors were present during the follicular phase of 
the estrous cycle than the luteal phase, suggesting a positive effect of E2 and a negative 
effect of P4 on GnRHR gene expression (Bauer-Dantoin et al., 1993).   
Gonadotropin-releasing hormone secretion by the hypothalamus may control the 
number of GnRHRs within the anterior pituitary by increasing mRNA levels, protein 
amounts or a combination of the two (Clayton and Catt, 1981).  Administration of a 
GnRH antagonist in vivo induced a reduction in pituitary GnRHR mRNA levels (Pinski 
et al., 1996).  Furthermore, treatment with increasing concentrations of a GnRH agonist 
elevated GnRHR mRNA levels in a dose-dependent manner, eventually resulting in 
decreased expression of the GnRHR gene due to desensitization (Lerrant et al., 1995).  
Alternatively, administration of GnRH agonists to αT3-1 cells at low concentrations 
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stimulated, whereas high concentrations inhibited translation of GnRHR mRNA without 
changing GnRHR mRNA levels (Tsutsumi et al., 1995). Thus, the regulation of GnRHR 
numbers within the anterior pituitary gland may utilize both transcriptional (Tsutsumi et 
al., 1993) and post-transcriptional mechanisms (Tsutsumi et al., 1995).     
Many studies investigating expression of the GnRHR gene have been performed 
in gonadotrope-derived cell lines (Windle et al., 1990; Thomas et al., 1996).  Weiss et al. 
(2006) indicated that treatment of αT3-1 cells with E2 or E2 in combination with P4 
decreased GnRHR mRNA levels.  Additionally, administration of the GnRH agonist, 
triptorelin, in a pulsatile fashion, increased GnRHR mRNA levels.  However, continuous 
treatment with triptorelin eventually resulted in decreased GnRHR mRNA amounts due 
to desensitization (Weiss et al., 2006).  Mason and associates (1994) also indicated that 
continuous administration of the GnRH agonist, des-Gly10-[D-Ala6] GnRH N-ethylamide, 
in αT3-1 cells down-regulated GnRHR mRNA levels.  Conversely, other studies have 
demonstrated that there was no alteration in levels of GnRHR mRNA following a 
continuous treatment with the GnRH agonist, [im-Bzl-D-His6, Pro9-N-ethyl-amide] 
GnRH, in αT3-1 cells (Tsutsumi et al., 1993; Alarid and Mellon, 1995).  Therefore, these 
contradictory results suggest that GnRHR mRNA levels depend on both the type and 
concentration of GnRH agonist being administered.   
Fewer studies analyzing the expression of the GnRHR gene have been performed 
in the LβT2 cell line.  Similar to the characteristics of normal pituitary cells, LβT2 cells 
treated with either GnRH or steroid hormones altered GnRHR gene expression (Turgeon 
et al., 1996).  Administration of GnRH in a pulsatile manner to LβT2 cells increased 
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GnRHR mRNA levels (Turgeon et al., 1996), similar to that of αT3-1 cells (Weiss et al., 
2006).  Conversely, treatment with E2 alone did not significantly increase GnRHR 
mRNA levels.  However, in combination with a dexamethasone treatment, GnRHR 
mRNA levels were increased by E2, suggesting that E2 may need to interact with other 
factors in order to maintain or increase GnRHR mRNA levels (Turgeon et al., 1996).   
 
Hypothalamus.  To date, very few studies have been performed to identify the 
role of GnRHRs within the hypothalamus.  Gonadotropin-releasing hormone receptor 
mRNA has been detected in human neuronal cells (GT1-7 and TE-671).  Li et al. (1996) 
reported that treatment of GT1-7 neurons with human chorionic gonadotropin (hCG) 
down-regulated expression of the GnRHR gene via a post-transcriptional mechanism.  
Due to decreased numbers of GnRHRs, LH/hCG may alter the self-stimulatory 
mechanism of GnRH synthesis and secretion in hypothalamic neurons (Li et al., 1996).  
Treatment of TE-671 cells with a GnRH agonist caused the phosphorylation of 
extracellular signal-regulated kinase (ERK1/2) and jun N-terminal kinase (JNK), 
suggesting that functional GnRHRs are expressed within this cell line.  Also, treatment of 
TE-671 cells with the protein kinase C (PKC) inhibitor, staurosporine, stimulated 
GnRHR promoter activity.  Therefore, the GnRHR gene is down-regulated by the PKC 
pathway within TE-671 cells (Yeung et al., 2005).  Additionally, deletion of two specific 
regions within the human GnRHR promoter located at -1300/-1018 and -2197/-1900 bp 
decreased promoter activity within the TE-671 cell line, indicating that there are 
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important basal regulatory elements within these promoter sequences (Yeung et al., 
2005).   
In addition to neuronal cell lines, GnRHR mRNA has been detected in native 
hypothalamic neurons.  Wilson and associates (2006) detected GnRHR on pyramidal 
neurons of the hippocampus, neocortical neurons of the entorhinal cortex and 
occipitotemporal gyrus of the human brain.  The presence of GnRHR in these regions of 
the human brain suggests that GnRH signaling may play a critical role in the function of 
hippocampal neurons (Wilson et al., 2006).  However, the function of GnRH signaling 
through receptors within neurons of the brain is still unknown.   
 
Placenta.  Gonadotropin-releasing hormone and its receptor are also present in 
the human placenta and both are structurally and biochemically identical to their 
hypothalamic and pituitary counterparts, respectively.  However, GnRH binds with a 
lower affinity to receptors in the placenta compared to the anterior pituitary gland (Currie 
et al., 1981; Escher et al., 1988; Bramley et al., 1992).  Gonadotropin-releasing hormone 
may be associated with hCG secretion within the placenta because hCG secretion has 
been inhibited in the presence of a GnRH antagonist, suggesting that it may be regulated 
through a GnRHR-mediated process (Cheng et al., 2001b).  Studies indicated that 
GnRHR expression may be regulated at the transcriptional level in the placenta by the 
activation of protein kinase A (PKA) and C pathways (Cheng et al., 2000a).  This 
conclusion was made because a GnRH-induced increase in GnRHR expression was 
attenuated as a result of treatment with PKC, adenylate cyclase or PKA inhibitors.  
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Likewise, up-regulation of GnRHR mRNA in placental cells occurred following 
treatment with either a GnRH agonist or forskolin, whereas GnRHR mRNA levels in 
gonadotrope-derived αT3-1 and ovarian cells decreased following both stimuli.  
Therefore, regulation of the GnRHR gene is different in the placenta compared to the 
pituitary (Cheng et al., 2000a) and ovary (Peng et al., 1994; Kang et al., 2000).   
Human GnRHR mRNA has been detected in various placental cell lines 
including: a choriocarcinoma cell line (JEG-3), immortalized extravillous trophoblasts 
(IEVT) and first trimester cytotrophoblast cells in primary culture (Cheng et al., 2000a; 
Cheng et al., 2001b).  In 1995, Lin and associates isolated GnRHR mRNA from both 
syncytiotrophoblast and cytotrophoblast layers of the placenta.  Consistent with this, both 
of these layers of the placenta expressed the common glycoprotein α- and specific hCGβ-
subunits.  This indicated that GnRH regulates hCG secretion by both autocrine and 
paracrine modes of action (Lin et al., 1995).  Using transient transfection and gel mobility 
shift assays in JEG-3 cells, these investigators identified 4 putative elements located in 
upstream promoter regions of the human GnRHR gene including: octamer transcription 
factor-1 (Oct-1), cAMP response element (CRE), GATA, and activating protein-1 (AP-
1).  However, only the CRE and GATA binding sites were determined to be placental 
specific (Cheng et al., 2001b). 
 
 Ovary.  Both GnRH and its receptor have also been identified in the ovary, 
regulating steroidogenesis (Hsueh and Jones, 1981), oocyte maturation, ovulation 
(Hillensjo and LeMaire, 1980), follicular atresia/apoptosis (Billig et al., 1994) and gene 
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expression (Richards, 1994).  Investigation of downstream signaling events indicated that 
binding of GnRH to GnRHR stimulates mitogen-activated protein kinase (MAPK) 
cascades in ovarian tissues.  Additionally, GnRH inhibits FSH-induced, cAMP-dependent 
responses in ovarian function (Leung and Steele, 1992).  Thus, similar to the placenta, 
GnRH may regulate reproductive mechanisms in the ovary by an autocrine and/or 
paracrine factor (Cheng et al., 2002a). 
In addition, mRNA for GnRH and GnRHR have been isolated from human 
(Latouche et al., 1989; Peng et al., 1994) and rat granulosa (Billig et al., 1994), 
immortalized human granulosa-luteal, (SVOG-4o and SVOG-4m; Cheng et al., 2002a), 
preovulatory rat granulosa (Olofsson et al., 1995) human ovarian (OSE; Kang et al., 
2000; Choi et al., 2001) and human luteal cells (Popkin et al., 1983; Bramley et al., 
1985).  Studies utilized these various ovarian cell lines to analyze GnRHRs within the 
ovary.  Olofsson et al. (1995) indicated that GnRHR mRNA levels are negatively 
influenced by LH and not affected by FSH.  However, GnRH stimulation resulted in 
increased GnRHR mRNA levels, suggesting an important role for ovarian GnRHR 
before, during and after ovulation (Olofsson et al., 1995).  Peng and associates (1994) 
demonstrated that GnRH up-regulated GnRHR gene expression, whereas hCG down-
regulated GnRHR gene expression.  Lastly, Kang and associates (2000) suggested that a 
growth inhibitory effect regulated via the GnRHR in human OSE cells may cause GnRH 
to act as an autocrine/paracrine regulator.   
In addition to hormonal regulation of GnRHR mRNA levels, basal expression of 
the GnRHR gene has also been studied in ovarian cell lines.  Cheng et al. (2002a) 
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identified two specific binding sites, C/EBP and GATA, important in regulating basal 
expression of the GnRHR gene in human granulosa-luteal cells.  In addition to their 
function within ovarian cells, GnRH and GnRHR also play an important role in the ovary 
during development.  For instance, GnRH and GnRHR mRNA levels increased during 
late fetal development within ovary.  Therefore, ovarian GnRH and its receptor may be 
important in the regulation of gonadal development (Botte et al., 1998).   
 
 Testis.  In addition to the ovary, GnRH and its receptor have been found in the 
testis.  Previous studies have isolated GnRH-like substances from the interstitial fluid of 
rat testis (Petersson et al., 1989).  Receptors are located in the gonads of adult rats (Hseuh 
and Jones, 1981) and in rat and mouse testicular germ cells (Bull et al., 2000).  Receptor 
binding studies indicated that a GnRH agonist bound to human testicular tissue, 
specifically on Leydig cells within the interstitial space of the testis (Clayton et al., 1980; 
Lefebvre et al., 1980; Sharpe and Fraser, 1980).  These receptors in the testis had an 
identical mRNA sequence to pituitary GnRHRs (Botte et al., 1998).  Also, GnRH analogs 
negatively influenced GnRHR mRNA levels by direct binding to testicular GnRHRs 
(Botte et al., 1999).  The presence of specific GnRHRs in Leydig cells could potentially 
play a role in the anti-fertility effects of GnRH agonists as well as physiological control 
of testicular function (Lefebvre et al., 1980).  Bahk and associates (1995) suggested that 
GnRH produced in Sertoli cells could react with GnRHRs in Leydig cells via a paracrine 
action.  To examine the effect of LH, which also has receptors within Leydig cells, on 
GnRHR gene expression, Botte et al. (1999) administered hCG, an agonist of LH, to 
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adult male rats.  The administration of hCG resulted in decreased GnRHR mRNA levels 
in the testis.  Following testosterone administration, GnRHR mRNA levels increased in 
the testis, an effect that may be related to negative feedback of testosterone on LH release 
(Botte et al., 1999).  Thus, LH could inhibit GnRHR gene expression or mRNA stability 
in the testis (Botte et al., 1999).  In addition to the role of GnRH and its receptor in 
testicular function, the GnRHR gene is expressed during early fetal development within 
the testis.  Similarly, GnRH and GnRHR mRNA levels increased within the testis during 
development.  Therefore, testicular GnRH and its receptor may play a potential role in 
regulation of gonadal development (Botte et al., 1998).   
The regulation of GnRHR mRNA levels is different in the testis compared to the 
anterior pituitary gland.  For instance, treatment with a GnRH agonist induced an earlier 
and more prolonged inhibition of GnRHR mRNA levels within the pituitary (Kaiser et 
al., 1993) compared to the testis (Botte et al., 1999).  Also, GnRH antagonists increased 
GnRHR mRNA levels in the testis (Botte et al., 1999), whereas they decreased 
expression of the receptor in the pituitary (Kaiser et al., 1993).  Characteristics of 
testicular GnRHR binding sites are low affinity and high capacity, indicating less specific 
binding sites in comparison to the classical receptor (Petersson et al., 1989).  Thus, 
GnRHRs within the anterior pituitary may have a different function compared to the 
GnRHRs within the testis.   
 
Other Tissues.  In addition to the anterior pituitary gland, GnRHR has been 
isolated in various tissues such as: breast (Casan et al., 1998), prostate (Dondi et al., 
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1994), and uterine endometrium (Casan et al., 1998; Raga et al., 1998) and myometrium 
(Chegini et al., 1996).  Furthermore, the receptor has been detected in cancer cell lines 
derived from the pituitary (La Rosa et al., 2000), prostate (Dondi et al., 1994), uterine 
endometrium (Emons et al., 2000), ovary (Yin et al., 1998; Emons et al., 2000), breast 
(Sedgley et al., 2006) and placenta (Cheng et al., 2000a; Cheng et al., 2001b).  In addition 
to these tissue types, mRNA for GnRH and its receptor have also been found in rat 
oocytes (Dekel et al., 1988) as well as developing murine (Raga et al., 1999) and human 
(Casan et al., 1999) pre-implantation embryos.   
 
 Cancer Cell Lines.  In addition to normal tissues, various cancer cell types also 
express GnRHRs.  Treatment of cancer cell lines with GnRH agonists and antagonists 
can inhibit their proliferation, potentially leading to new therapeutic options in cancer 
therapy (Emons et al., 2000).  Gonadotropin-releasing hormone receptor mRNA is 
present in a breast cancer cell line (MCF7; Sedgley et al., 2006).  The human GnRHR is 
present mostly within the endoplasmic reticulum in both MCF7 and gonadotrope-derived 
αT4 cells.  However, signaling in MCF7 cells allows for the human GnRHR, an 
intracellular protein, to traffic to the cell surface.  Presence of GnRHRs on the cell 
surface is dependent on both the receptor and cell type.  For instance, the receptor type 
(type I GnRHR without a C-terminal tail, type II GnRHR with a C-terminal tail or type I 
GnRHR with an added C-terminal tail) varied in expression of GnRHR on the cell 
surface (Sedgley et al., 2006).  It was determined that human GnRHRs had a lower 
affinity for GnRH compared to mouse and sheep GnRHRs, type II marmoset GnRHRs 
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and chimeric GnRHRs with added C-terminal tails in MCF7 cells.  In addition to the 
presence or absence of a C-terminal tail, glycosylation within the amino-terminal 
sequence can affect the number of GnRHRs at the cell surface.  Cell type (such as MCF7 
or αT4 cells) also affected the number of GnRHRs on the cell surface.  Receptor numbers 
were increased 10-fold in αT4 cells compared to MCF7 cells.  However, addition of a C-
terminal tail increased receptor binding by 20-fold in MCF cells but only 5-fold in αT4 
cells (Sedgley et al., 2006).   
Gonadotropin-releasing hormone receptor mRNA has also been found in ovarian 
cancer cell lines (OVCAR-3 and SKOV-3; Yin et al., 1998; EFO-21, EFO-27; Emons et 
al., 2000).  It has been suggested that approximately 80% of human ovarian cancer cell 
lines express both GnRH and its receptor (Emons et al., 2000).  In addition, GnRHR 
mRNA has also been detected in a prostate cancer cell line (DU 145; Dondi et al., 1994).  
Treatment with a GnRH antagonist resulted in increased cell proliferation, suggesting an 
inhibitory role for GnRH in the regulation of cell growth via an autocrine and/or 
paracrine mechanism (Dondi et al., 1994; Emons et al., 2000).  In addition, Cheng et al. 
(2000a) isolated GnRHR mRNA from a placental choriocarcinoma cell line (JEG-3).  
Sequence analysis of the placental GnRHR mRNA indicated that it was 100% identical to 
its pituitary counterpart.  Treatment with a GnRH agonist resulted in an up-regulation of 
GnRHR mRNA levels in the placental choriocarcinoma cell line compared to down-
regulation of GnRHR mRNA levels in pituitary-derived αT3-1 cells.  Thus, there may be 
a different mechanism of regulation in the placenta compared to the pituitary.   
31 
 
Finally, La Rosa and associates (2000) detected GnRHRs in normal pituitary cells 
and pituitary adenomas.  Growth hormone, FSH/LH, adrenocorticotropic hormone, 
thyroid-stimulating hormone, prolactin and non-hormone secreting (α-subunit/null) cells 
identified within pituitary adenomas expressed GnRHR mRNA and protein, suggesting 
that GnRHR may be present in somatotrope, gonadotrope, corticotrope, thyrotrope and 
lactotrope cells.  Therefore, there may be other roles for GnRHRs within the pituitary as 
well as regulation of gonadotropins.  In addition to the GnRHR, normal and adenomatous 
pituitary cells also express GnRH.  Thus, the interaction between GnRH and its receptor 
may have a role in the regulation of these cell types through a paracrine and/or autocrine 
mechanism (La Rosa et al., 2000).  
 
Activation of Cell Signaling Pathways Following GnRH Binding 
  
 G-protein Coupled Receptors.  G-protein coupled receptors activate several cell 
signal transduction pathways.  The stimulus that activates these receptors is a small 
peptide, the ligand, which binds to the N-terminus (Fredriksson and Schioth, 2005; Ridge 
and Palczewski, 2007).  The characteristic structure of GPCRs includes 7 transmembrane 
domains that are connected by intracellular loops.  It has been suggested that portions of 
these loops are adequate to bind and activate G-proteins.  An example of a GPCR is 
rhodopsin, a highly organized GPCR important for biosynthesis of photoreceptor cells 
and optimal activation and signaling involved in light perception (Ridge and Palczewski, 
2007).  Rhodopsin is made up of 7 transmembrane helices linked together by 3 
extracellular and 3 cytoplasmic loops.  The N-terminal tail is extracellular and it also 
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contains a cytoplasmic C-terminal tail (Sakmar, 2002).  Metarhodopsin II is the active 
form of rhodopsin which stimulates changes to the retinal G-protein, transducin (Gt; 
Ridge et al., 2003).  Transducin is responsible for initiating a biochemical cascade of 
reactions in the process of phototransduction (Ridge and Palczewski, 2007).  Another 
example of a unique GPCR is the GnRHR.  Gonadotropin-releasing hormone receptors 
have an N-terminus situated near 7 α-helical transmembrane domains that are connected 
by 3 intracellular and 3 extracellular loop domains (Baldwin, 1993; Ballesteros et al., 
1998; Miller, 2005).  The intracellular loop domains interact with G-proteins and other 
proteins involved in signal transduction pathways and the extracellular loop domains are 
involved in conformational changes to assist in receptor activation (Baldwin, 1993; 
Ballesteros et al., 1998; Millar, 2005).   
Most GPCRs, including the non-mammalian GnRHR, contain a C-terminal tail.  
However, the mammalian GnRHR is an exception, lacking a cytoplasmic tail.  In 
addition, the mammalian GnRHR possesses a relatively short third intracellular loop.  
Both of these features are important for desensitization of many other GPCRs (Davidson 
et al, 1994; Cheng and Leung, 2000).  Unlike most GPCRS, the mammalian GnRHR 
does not rapidly desensitize inositol (1,4,5)-triphosphate (IP3) production and has very 
slow internalization kinetics (Heding et al., 1998) because the signal promoting 
internalization is located on the C-terminal tail.  Introduction of the C-terminal tail into 
the rat GnRHR increased internalization rates.  This implied that the lack of a C-terminal 
tail may be important to maintain large numbers of active receptors on the plasma 
membranes of gonadotropes following the GnRH surge (Heding et al., 1998).   
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G-proteins.  G-proteins are attached to the intracellular surface of cell 
membranes that contain GPCRs and are activated once the receptor is bound to a ligand.  
However, inactive G-proteins are heterodimers that consist of α, β, and γ subunits 
(Koelle, 1997).  When GnRH binds to its GPCR, it induces a conformational change in 
the receptor, allowing the exchange of guanosine diphosphate (GDP) for guanosine 
triphosphate (GTP) on the Gα subunit.  Subsequently, dissociation of the Gα subunit from 
the Gβγ dimer occurs, releasing the Gα subunit to activate different signaling cascades 
within the cell (Koelle, 1997; Millar et al., 2004).  The receptor is bound to the specific 
G-protein subunit leading to activation.  Eventually the attached GTP will hydrolyze to 
GDP and the Gα subunit and Gβγ dimer will re-associate into its inactive heterodimer, 
starting a new cycle (Koelle, 1997; Millar et al., 2004).   
 The complex consisting of hormone, receptor, and G-protein is related to the 
active conformation of GPCRs (De Lean et al., 1980; Samama et al., 1993).  Receptor 
activation is dependent on the formation of a “tertiary complex” in addition to 
isomerization.  For instance, receptors rotate between active and inactive regulatory 
conformation (Samama et al., 1993).  The complex dissociates and the receptor returns to 
low affinity conformation upon binding of GTP to the G-protein.  However, GnRH 
analogues and intracellular signaling pathways are selected by different GnRHR active 
conformations (Millar, 2005). 
 
Protein Kinase C.  The PKC family of serine/threonine protein kinases is 
comprised of at least 11 isoenzymes (Nishizuka, 1992; Junoy et al., 2002).  These 
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isoforms play an important role in proliferation, differentiation, gene expression, 
secretion and activation of signal transduction pathways (Nishizuka, 1992).  Isoforms of 
PKC have been classified into three categories: conventional (α, βI, βII and γ; Nishizuka, 
1992; Dutil et al., 1998), novel (δ, ε, η and θ; Gschwendt, 1999), and atypical (ζ and ι/λ; 
Zhou et al., 1994).  Conventional PKCs are required for the activation of (1,2)-
diacylglycerol (DAG) and calcium (Nishizuka, 1992; Dutil et al., 1998), novel PKCs do 
not respond to Ca2+ but are sensitive to DAG (Gschwendt, 1999) and atypical PKCs are 
regulated through phosphoinositides (Zhou et al., 1994).  Junoy and associates (2002) 
studied the down-regulation of specific PKC isoforms following treatment of primary 
pituitary cell cultures, αT3-1 and LβT2 cells with either a GnRH agonist or a PKC 
activator (12-O-tetradecanoyl-phorbol-13 acetate; TPA) continuously for 2 to 6 hours.  
The PKC isoforms α, βII, δ and ε were down-regulated by TPA in LβT2 and primary 
pituitary cell cultures.  However, TPA down-regulated the PKC isoforms α and ε in αT3-
1 cells.  Treatment with a GnRH agonist down-regulated the PKC isoforms ε and δ in 
LβT2 cells, whereas only PKC ε was depleted in αT3-1 cells.  However, PKC ζ remained 
resistant in primary pituitary cell cultures, αT3-1 and LβT2 cell lines following treatment 
with either TPA or a GnRH agonist.  Additionally, treatment with proteasome inhibitors 
(proteasome inhibitor I and II, lactcystin, β-lactone and calpain inhibitor I) prevented 
TPA and GnRH down-regulation of PKC isoforms in both cell lines.  Therefore, the 
relationship between kinase and proteolytic proteasomal activities that lead to PKC 
degradation may be part of an important regulatory mechanism involved in a timed and 
controlled response to different stimuli in gonadotrope cells (Junoy et al., 2002).   
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The classical pathway activated following binding of GnRH to its receptor is the 
PKC pathway (Figure 2.4).  Previous studies indicated that GnRHR couples to various G-
proteins in different cell lines (Reiss et al., 1997; Cheng et al., 2000b; Chamson-Reig et 
al., 2003).  However, to detect which G-proteins coupled to GnRHR in vivo, the GnRHR 
was studied in primary pituitary cell cultures.  For example, Stanislaus and associates 
(1997) detected that the G-protein complex, Gq/11α was regulated by GnRH, in primary 
pituitary cell cultures and GGH3 cells.  Therefore, GnRH binding to its receptor 
stimulates the G-protein complex, Gq/11α, which activates the membrane bound protein, 
phospholipase Cβ (PLCβ; Cheng et al., 2000b; Chamson-Reig et al., 2003).  Active PLCβ 
hydrolyzes phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate the second 
messengers, IP3 and DAG.  Inositol (1,4,5)-triphosphate causes release of Ca2+ from 
intracellular stores and Ca2+ influx through voltage sensitive channels within the plasma 
membrane (Haisenleder et al., 1997; Willars et al., 2001), whereas DAG activates PKC 
and mitogen activated protein kinase (MAPK) pathways (Figure 2.4; Lin and Conn, 
1999; Cheng et al., 2000b; Chamson-Reig et al., 2003).  In addition to activation of PKC, 
DAG can cause an increase in the influx of Ca2+, whereas IP3 increases cytosolic Ca2+ 
from intracellular stores (Figure 2.4; Millar, 2005).  Pituitary cell cultures treated with 
increased amounts of pertussis toxin, a protein based exotoxin, decreased inositol 
phosphate (IP) turnover, whereas decreased amounts of pertussis toxin did not decrease 
IP levels in response to GnRH.  This suggested that a pertussis toxin sensitive G-protein 
couples with the receptor to initiate IP turnover (Hawkes et al., 1993).  In addition, it was 
determined that Ca2+ entry and PKC activation were both involved in mediating GnRH
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Figure 2.4.  Activation of the protein kinase C (PKC) pathway following GnRH 
stimulation.  Binding of GnRH to its receptor promotes coupling of GnRHR with Gq/11α 
which leads to activation of a classical signaling cascade, the PKC pathway.  The G 
protein complex, Gq/11α, activates phospholipase C (PLC) which hydrolyzes 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate the second messengers, 
inositol (1,4,5)-triphosphate (IP3) and (1,2)-diacylglycerol (DAG).  Inositol (1,4,5)-
triphosphate controls Ca2+ release from the endoplasmic reticulum (ER), whereas DAG 
promotes influx of external Ca2+ and activates PKC pathways.  Adapted from Kaiser et 
al. (1997). 
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stimulation of the human glycoprotein hormone α-subunit gene in αT3-1 and LβT2 cells 
(Saunders et al., 1998; Fowkes et al., 2002).  However, expression of the LHβ- and 
FSHβ-subunit genes is dependent on PKC activation alone following GnRH stimulation 
(Saunders et al., 1998).  
Besides activation of PIP2, phospholipase A2 (PLA2) and D (PLD) are activated 
approximately 1 to 2 minutes after GnRH binds to its receptor, which may help in the 
formation of late DAG activation (Shacham et al., 1999; Chamson-Reig et al., 2003).  
Phospholipase D is regulated by the same G-protein as PLC; however, PKC regulates 
both PLC and PLD by different mechanisms.  Thus, a change from initial activation of 
PLC to continual activation of PLD is due to the phosphorylation of a G-protein 
(Liscovitch, 1992).  Lastly, activation of PLA2 by GnRH binding to GnRHR liberates free 
fatty acids and lysophospolipids and is frequently associated with receptor-mediated cell 
activation (Stojilkovic et al., 1994). 
 
Protein Kinase A.  Gonadotropin-releasing hormone binding to its receptor can 
result in coupling with the G-protein, Gs, activating the PKA pathway (Figure 2.5) or Gi, 
inhibiting the PKA pathway.  The GnRHR undergoes a conformational change, causing 
dissociation of the α-subunit from the β- and γ-subunits.  The α-subunit will stimulate 
activity of adenylate cyclase to produce increased amounts of cAMP.  Next, cAMP will 
activate PKA which consists of two regulatory (R) subunits, which could be any 
heterodimeric combination of the following family members; RIα, RIβ, RIIα and RIIβ 
(Newton and Messing, 2006).  Protein kinase A is also made up of two catalytic (C)
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Figure 2.5.  Activation of the protein kinase A (PKA) pathway following GnRH 
stimulation.  Upon binding of GnRH to its receptor, the GnRHR can couple to the G-
protein, Gs.  This G-protein will then activate adenylate cyclase to produce cAMP.  
Cyclic AMP will activate PKA which is made up of two regulatory (R) and two catalytic 
(C) subunits in its inactive form.  Once cAMP stimulates PKA this will dissociate the R 
subunits from the complex to activate the PKA pathway.  Adapted from Kaiser et al. 
(1997). 
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 subunits (Cα and Cβ).  The α-subunits are expressed ubiquitously, whereas the β-
subunits are not (Brandon et al., 1997).  Garrel and associates (1995) cultured anterior 
pituitary cells and indicated that the direct activation of PKA and PKC changes the 
expression of genes encoding PKA RIIβ- and Cα-subunit isoforms.  In addition, the 
activation of PKA or PKC alone regulates pituitary cell contents for the RI, RII and C 
subunits of PKA (Garrel et al., 1995).  Upon activation by cAMP, the R subunits will 
dissociate from the C subunits, in turn activating the PKA pathway.  The PKA pathway 
will contribute to various actions within the cell including transcription of the GnRHR 
gene (Naor et al., 2000; Millar et al., 2004).  
The GnRHR has been shown to couple to Gs to activate the PKA pathway (Figure 
2.5; Stanislaus et al., 1998).  Long term treatment of rat somatolactotrope cells (GH3) 
with cAMP altered total cAMP-dependent protein kinase activity through effects on 
degradation of the catalytic subunit (Richardson et al., 1990).  Sadie et al. (2003) 
indicated that GnRHR mRNA levels in αT3-1 cells are stimulated by 8-bromo-cAMP and 
forskolin.  In addition, the mouse GnRHR promoter is regulated by PKA through a 
mechanism involving steroidogenic factor-1 (SF-1).  Another indication that SF-1 is 
important in regulating PKA is that treatment with forskolin up-regulated SF-1 mRNA 
levels in αT3-1 cells.  Additional studies indicated that primary pituitary cell cultures also 
utilize the PKA pathway upon GnRHR activation.  Tsujii and associates (1995) reported 
that treatment of both pituitary and αT3-1 cells with pituitary adenylate cyclase-activating 
polypeptide (PACAP), increased α-subunit mRNA levels, implicating activation of 
GnRHRs by the cAMP pathway (Tsujii et al., 1995). 
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Mitogen-Activated Protein Kinases.  General.  Mitogen-activated protein 
kinases consist of protein serine/threonine kinases involved in processes which regulate 
cell growth, division and differentiation.  Once activated, MAPKs are translocated to the 
nucleus, where they phosphorylate transcription factors as well as promote DNA 
synthesis and cell division (Han and Conn, 1999; Lin and Conn, 1999; Bonfil et al., 
2004).  There are generally 3 protein kinases involved in each MAPK cascade: MAPK, 
MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK).  Four MAPK cascades are 
known in mammals: ERK1/2, JNK, p38 MAPK and ERK5/big MAPK (BMK; Naor et 
al., 2000; Bonfil et al., 2004; Morimoto et al., 2007).  GnRH stimulates ERK, JNK and 
p38 MAPK in αT3-1, LβT2 and enhanced GnRHR transfected cells (GGH3; Bonfil et al., 
2004).  Also, GnRH activates ERK5 in primary pituitary and αT3-1 cells (Naor et al., 
2000).  Studies have been done in these different cell lines to determine which MAPKs 
are activated following GnRH stimulation.  For example, Reiss et al. (1997) treated αT3-
1 cells with a GnRH agonist which resulted in the activation of MAPK by Ca2+, protein 
tyrosine kinase (PTK), and PKC.  Treatment with a GnRH agonist or PKC activator 
(TPA) resulted in a sustained response of MAPK activity.  To date, all of the known 
MAPK cascades are activated by GnRH via a PKC-dependent mechanism (Figure 2.6; 
Levi et al., 1998; Naor et al., 2000).   
ERK1/2.  The most widely studied components of signal transduction pathways 
are ERK 1 and 2.  Extracellular signal-regulated kinase 1/2 plays an important role in cell 
survival, motility and secretion.  In addition, transactivation of the epidermal growth 
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Figure 2.6.  A general schematic of mitogen-activated protein kinase (MAPK) signaling 
cascades following GnRH binding to its cognate receptor.  Adapted from Naor et al. 
(2000). 
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factor receptor is responsible for ERK1/2 responses due to the stimulation of specific 
GPCRs (Shah et al., 2003).  Both ERK 1 and 2 are activated by protooncogene products 
and diverse extracellular stimuli that induce proliferation or enhance differentiation 
(Cobb and Goldsmith, 1995).  A member of the Ras family of G-proteins activates Raf 
(MEKK) and MEK1/2, subsequently phosphorylating ERK1/2 (Figure 2.6; Bonfil et al., 
2004).  Gonadotropin-releasing hormone receptor mediates signaling via ERK in the 
Xenopus and human GnRHR.  For example, Xenopus GnRHR mediates signaling to ERK 
by arrestins, whereas human GnRHR is less efficient than Xenopus GnRHR at causing 
MAPKs to translocate to the nucleus.  This suggests that human GnRHR utilizes 
scaffolds other than arrestins to mediate ERK compartmentalization (Caunt et al., 2006).   
Several mechanisms are involved in the attenuation and termination of ERK1/2 
activation.  Inhibitory and stimulatory responses determine the duration and strength of 
signals that start at the cell surface in response to ERK1/2 stimulation (Shah et al., 2003).  
Gonadotrope cells have been used to understand the mechanisms involved in ERK1/2 
activation.  For example, the Per1 gene is expressed in immortalized gonadotrope cell 
lines and is up-regulated by GnRH.  This gene is activated by PKC and ERK1/2, 
representing a novel mechanism of GnRH signaling (Olcese et al., 2006).  Additionally, 
activation of ERK1/2 and tyrosine phosphorylation in αT3-1 and wt28 [a clonal cell line 
consisting of GH3 (somatolactotrope) cells that were transfected with the mouse GnRHR 
and selected for prolactin/growth hormone release and IP production in response to 
GnRH; Johnson et al., 2000] cells differed in response to GnRH.  Extracellular signal-
regulated kinase 1/2 and tyrosine were activated in αT3-1 cells treated with the PKC 
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activator, phorbol 12,13-dibutyrate.  However, the PKA activator, forskolin, stimulated 
ERK 1/2 phosphorylation in wt28 cells.  An increase in tyrosine phosphorylation 
occurred following a treatment of the tyrosine phosphatase inhibitor, pervanadate, in 
wt28 cells.  Treatment with both pervanadate and GnRH to both cell types resulted in an 
additive ERK 1/2 phosphorylation in αT3-1 cells, whereas ERK 1/2 phosphorylation was 
synergistic and sustained in wt28 cells.  This suggests that the GnRHR may be activated 
through different cellular events depending on the tissue that confers its expression 
(Johnson et al., 2000). 
Mitogen activated protein kinase pathways differ in cell lines from other tissues 
which have been used to study the relationship between GnRHR and ERK1/2.  For 
example, expression of GnRHR in human embryonic kidney 293 cells is independent of 
Src and epidermal growth factor receptor transactivation due to GnRH-induced 
phosphorylation of ERK1/2.  However, GnRHR is dependent on PKC in response to the 
activation of ERK1/2 which leads to constant activation and accumulation of ERK1/2 in 
the nucleus (Farshori et al., 2003; Shah et al., 2003).  In addition to kidney cells, the 
activation of ERK1/2 through the PKC pathway is essential for GnRH-induced anti-
proliferation of ovarian cancer cells (Kim et al., 2006). 
 JNK.  Jun N-terminal kinase (stress-activated protein kinase; SAPK) is activated 
by members of the Ras family of G-proteins, MAPK/ERK kinase (MEKK1-4) and 
MAPK kinase (MKK4/7; Figure 2.6; Levi et al., 1998; Bonfil et al., 2004).  In order to 
activate the transcription factors, c-Jun, activating transcription factor 2 (ATF2) and Elk1, 
the JNK cascade stimulates p21-activated kinase 1/mixed lineage kinase (PAK1/MLK), 
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MEKK1, MKK7, and JNK1/2.  In response to GnRH, the JNK cascade involves PKC, c-
Src family protein tyrosine kinase (PTK), cell division cycle 42 (CDC42/Rac1) and 
possibly MEKK1.  As a result, these lead to JNK activation and c-Jun induction in 
response to GnRH in αT3-1 cells (Levi et al., 1998).  In addition to αT3-1 cells, pituitary 
cell cultures from rats were treated with a JNK inhibitor or vehicle to determine if JNK 
directs gonadotropin subunit transcriptional responses to pulsatile GnRH (Haisenleder et 
al., 2008).  The JNK inhibitor minimized both basal and GnRH-induced increases in 
FSHβ-subunit primary transcripts by half but had no effect on LHβ-subunit primary 
transcripts (Haisenleder et al., 2008).  In addition, Xie et al. (2005) demonstrated that 
JNK and ERK work synergistically to regulate the human α-subunit transcriptional 
responses to GnRH.  Besides its role in FSHβ- and α-subunit gene activation, JNK is also 
involved in GnRH signaling to genes encoding the GnRHR.  GnRH regulation of the 
mouse GnRHR is conferred by an AP-1 binding site which binds JunD, FosB and c-Fos.  
Additionally, αT3-1 cells stably expressed with a dominant-negative c-Jun N-terminal 
kinase lost GnRH responsiveness.  Thus, the interaction between GnRH and its cognate 
receptor is regulated by the JNK signaling cascade (Ellsworth et al., 2003b). 
p38.  One of the stress-activated protein kinases, p38 (SAPK2), is made up of four 
subunits, α, β, γ and δ (Bonfil et al., 2004).  Similar to JNK, p38 MAPKs are activated by 
osmotic shock, heat shock, UV light, cellular stress, bacterial infection, pro-inflammatory 
cytokines and DNA-damaging agents.  This stress-activated protein kinase modulates 
transcriptional activity, cell cycle, and programmed cell death in response to ligands that 
bind GPCRs as well as environmental stress and inflammatory cytokines.  Activation of 
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p38 MAPKs occurs via the phosphorylation of a threonine at position 180 and a tyrosine 
in the activation loop positioned at 182 (Kim et al., 2004).  Lastly, Haisenleder and 
associates (2008) treated pituitary rat cell cultures with a p38 inhibitor and indicated that 
p38 had no effect on LHβ- or FSHβ-subunit primary transcripts.     
 ERK5 (BMK).  Extracellular signal-regulated kinase 5 (ERK5), also termed big 
MAPK (BMK), is aptly named because its C-terminus consists of a unique 400-amino 
acid extension.  It plays an important role in biological pathways that modulate 
transcription.  Extracellular signal-regulated kinase 5 is activated by hyperosmolarity, 
growth factors (EGF and nerve growth factor) and oxidative stress (Morimoto et al., 
2007).  Knockout mice for ERK5 died during embryonic stages due to angiogenic failure 
and cardiovascular defects (Regan et al., 2002; Sohn et al., 2002; Yan et al., 2003).  
Hayashi and associates (2004) deleted ERK5 in adult mice which led to death due to 
leakage in blood vessels and hemorrhages in multiple organs which caused apoptosis in 
endothelial cells.  This suggested that ERK5 is responsible for endothelial cell survival 
and maintenance of blood vascular integrity.  Others indicated that ERK5 plays two 
important roles in gene expression; activation of transcription factors by direct 
phosphorylation and enhancement of transcriptional activation activity by 
autophosphorylation of 2 C-terminal regions (Morimoto et al., 2007).  Besides its PKC 
dependency, the involvement of ERK5 in the regulation of gonadotropin subunits and 
GnRHR synthesis as well as whether or not it translocates to the nucleus is still unclear 
(Naor et al., 2000).   
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Hormonal Regulation 
GnRH.   In order to maintain normal reproductive function, GnRH is a key 
regulator of its own receptor.  Gonadotropin-releasing hormone can up-regulate its 
receptor by increasing GnRHR mRNA levels (transcriptional regulation) or altering 
receptor numbers post-translationally (Cheng and Leung, 2000).  For example, pulsatile 
GnRH at a low concentration caused an up-regulation of GnRHRs, whereas continuous 
GnRH at a high concentration resulted in down-regulation and desensitization of 
GnRHRs (Loumaye and Catt, 1982; Katt et al., 1985).  Receptor numbers at the cell 
surface may influence the rate of receptor biosynthesis by regulation at the transcriptional 
level.  However, it may also be regulated at the post-translational level by recycling, 
modification, or degradation of the receptor (Kaiser et al., 1993).  Kaiser and associates 
(1993) detected that treatment of rat primary pituitary cultures with continuous GnRH did 
not alter GnRHR mRNA levels.  However, administration of pulsatile GnRH resulted in 
increased GnRHR mRNA levels.  These studies in vitro revealed that there is 
homologous regulation of GnRHR gene expression (Kaiser et al., 1993).   
A study in wethers indicated that daily administration of a potent GnRH agonist 
decreased GnRHR mRNA levels (Wu et al., 1994).  Adams and associates (1996) also 
detected that administration of high concentrations of GnRH induced a down-regulation 
of GnRHR mRNA levels in wethers.  Recently, it was reported that administration of 
continuous GnRH to primary rat anterior pituitary cells for 6 hours increased the levels of 
GnRHR mRNA (Cheon et al., 2000).  The number of GnRHRs on gonadotrope cells 
varied due to fluctuations in GnRH secretion during the estrous cycle in the rat.  During 
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proestrus in the female rat, GnRHR mRNA levels, receptor numbers and sensitivity to 
GnRH were highest within the anterior pituitary gland (Bauer-Dantoin et al., 1993).  
Further, the anterior pituitary gland contained increased GnRHR mRNA levels during the 
follicular phase in the ewe due to sensitivity of GnRH prior to the preovulatory 
gonadotropin surge (Turzillo et al., 1994).  In addition, Cheon et al. (2000) used a GnRH 
agonist to block transcriptional activity of the GnRHR gene.  Therefore, this suggests that 
homologous up-regulation of GnRHR numbers may occur through transcriptional 
activation of the gene versus mRNA stability (Cheon et al., 2000).  
  Borgeat and associates (1972) treated anterior pituitary tissue of male rats with a 
GnRH agonist which increased the intracellular concentrations of cAMP and also 
released the gonadotropins, LH and FSH.  However, αT3-1 cells treated with a GnRH 
agonist activated PKC pathways, whereas there was no significant change in cAMP 
levels (Horn et al., 1991).  This mechanistic difference may be due to testosterone 
because intact male rats treated with a GnRH agonist increased cAMP levels.  In contrast, 
significant alterations in cAMP levels have not been detected in ovine primary pituitary 
cells following GnRH treatment (Kaiser et al., 1997).  Huckle and associates (1988) 
indicated that GnRH is regulated by Ca2+ and PKC in rat primary pituitary cultures due to 
an increase in GnRHRs.  However, PKC activators can stimulate the synthesis of GnRHR 
by a mechanism independent of GnRH-induced up-regulation (Braden et al., 1991).    
Gonadotropin-releasing hormone receptor promoter activity increased when αT3-
1 cells were treated with a GnRH agonist, whereas treatment with a GnRH antagonist 
reduced mouse GnRHR promoter activity (Norwitz et al., 1999; White et al., 1999).  
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Treatment with the PKC activator, phorbol-12-myristate-13-acetate (PMA), increased 
mouse GnRHR promoter activity, whereas the PKC inhibitor, GF109203X, blocked 
promoter activity, indicating that activation of the PKC pathway is important for GnRHR 
promoter activity.  However, αT3-1 cells treated with the PKA activator, forskolin, did 
not affect GnRHR promoter activity (White et al., 1999).  In contrast, transfection of the 
mouse GnRHR gene promoter into GGH3 cells (GH3 cells stably expressing GnRHR) 
treated with GnRH or a GnRH agonist (buserelin), stimulated promoter activity and 
increased cAMP release (Lin and Conn, 1998).  Similarly, treatment with an adenylate 
cyclase inhibitor, SQ22536, significantly decreased buserelin-activated GnRHR promoter 
activity.  Therefore, GnRH regulation of GnRHRs in the GGH3 cell line occurs via both 
cAMP and PKC pathways (Lin and Conn, 1998).  Two laboratories, (Norwitz et al. 
(1999; White et al., 1999) identified an AP-1 element critical for responsiveness of the 
mouse GnRHR gene to GnRH.  In addition, homologous regulation of GnRHR involve 
PKC activation of the JNK signaling cascade, resulting in the binding of JunD, FosB and 
c-Fos to the AP-1 element (Ellsworth et al., 2003b). 
 
Gonadotropic Hormones.  The gonadotropic hormone, LH, as well as its 
agonist, hCG, can have an effect on GnRHR mRNA levels.  Li et al. (1996) indicated that 
treatment of GT1-7 neurons with hCG down-regulates expression of the GnRHR gene by 
decreasing stability of transcripts.  Therefore, LH/hCG may disrupt the self-stimulatory 
mechanism of GnRH synthesis and secretion of hypothalamic neurons by the down-
regulation of GnRHR (Li et al., 1996).  Additionally, treatment of human granulosa-luteal 
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cells with hCG decreased GnRHR mRNA levels without altering the expression of the 
GnRH gene (Peng et al., 1994).  Similarly, Cheng and Leung (2000) detected a decrease 
in GnRHR mRNA levels in rat granulosa cells following treatment with LH.   
Botte et al. (1999) treated adult male rats with LH and FSH agonists (hCG and h-
rec FSH).  There was no significant alteration in GnRH or GnRHR mRNA levels 
following treatment with h-rec FSH in the rat testis (Tapanainen et al., 1993; Botte et al., 
1999).  However, hCG, a glycoprotein that binds to LH receptors, decreased GnRHR 
mRNA levels in the rat testis.  Luteinizing hormone receptors, GnRHRs and testosterone 
secretion had been detected in Leydig cells.  In addition, LH regulates GnRHR mRNA 
levels within Leydig cells.  In contrast, the lack of an FSH effect on GnRHR mRNA 
amounts may be due to the absence of FSH receptors on Leydig cells (Botte et al., 1999).  
Following testosterone treatment, GnRHR mRNA levels increased, an effect that may be 
associated to negative feedback of testosterone on LH release (Botte et al., 1999).  In 
addition, LH increased following treatment with a GnRH agonist or hCG, resulting in 
decreased GnRHR mRNA levels.  Therefore, this study suggested that LH down-
regulates GnRHR mRNA stability and gene expression in the rat testis (Botte et al., 
1999).    
 
Steroid Hormones.  General.  Steroid hormones play an important role in the 
reproductive axis.  The secretion of steroid hormones by the gonads elicits negative or 
positive effects on gonadotrope cells within the anterior pituitary gland, regulating the 
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production of GnRHRs.  The steroid hormones, E2, glucocorticoids, P4 and testosterone, 
have been shown to regulate levels of GnRHR mRNA and receptor numbers. 
Estradiol-17β.  Studies involving rat primary pituitary cultures indicated that 
treatment with E2 increased the number of GnRHRs.  Estradiol-17β-mediated GnRHR 
induction may involve new protein synthesis (Menon et al., 1985).  Emons and associates 
(1988) indicated that short-term treatment with E2 caused a significant decrease in 
GnRH-induced, LH release that was potentially due to a reduction of available GnRHRs.  
Kaiser et al. (1993) studied the regulation of GnRHR numbers at the pre-translational 
level.  Ovariectomized rats had increased GnRHR mRNA levels; however, replacement 
therapy with E2 significantly decreased GnRHR mRNA levels in ovariectomized 
compared to control rats.  This suggested that GnRHR synthesis was altered at the pre-
translational level due to differences in hypothalamic GnRH secretion (Kaiser et al., 
1993).   
Hypothalamic-pituitary disconnection in ovariectomized ewes resulted in 
decreased GnRHR numbers within the anterior pituitary gland, mainly due to the lack of 
GnRH stimulation (Clarke et al., 1987; Gregg and Nett, 1989; Turzillo et al., 1995), 
whereas GnRHR mRNA levels were not altered in controls.  This suggested that GnRHR 
mRNA levels in ovariectomized ewes do not require continuous stimulation by GnRH 
(Turzillo et al., 1995).  One reason for this may be that there are minor alterations at the 
transcriptional level.  However, more modifications occur during post-transcriptional 
events, resulting in changes in GnRHR numbers.  The situation may be similar in αT3-1 
cells because GnRH agonist treatment significantly increased GnRHR numbers, whereas 
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GnRHR mRNA levels did not change (Tsutsumi et al., 1993; Mason et al., 1994).  
Crowder and Nett (1984) suggested that E2 stimulated an increase in the number of 
GnRHRs, possibly contributing to the preovulatory LH surge in ewes.  Gregg and Nett 
(1989) demonstrated that E2 can independently increase GnRHR numbers following 
hypothalamic-pituitary disconnection in the ewe.  Similarly, Turzillo et al. (1995) 
reported that E2 increased GnRHR RNA levels using the same model system.   
Increased GnRHR mRNA concentrations were detected following treatment with 
E2 in ovariectomized ewes (Gregg and Nett, 1989; Moss et al., 1981; Clarke et al., 1988; 
Turzillo et al., 1994; 1995; Hamernik et al., 1995).  Gonadotropin releasing hormone 
receptor mRNA levels and receptor numbers in ovariectomized ewes treated with both 
GnRH and E2 did not differ from saline injected controls.  However, GnRHR mRNA 
levels and receptor numbers were significantly increased in ewes treated with both GnRH 
and E2 compared to ewes treated with GnRH alone.  This suggested that continuous 
administration of GnRH resulted in a lower baseline for GnRH numbers and mRNA 
levels (Turzillo et al., 1998).  A study in ovariectomized ewes following hypothalamic-
pituitary disconnection indicated that a low amount of E2 and GnRH are required to 
significantly increase GnRHR mRNA levels and receptor numbers.  It was concluded that 
there is a synergistic interaction between E2 and GnRH in the regulation of GnRHR gene 
expression (Kirkpatrick et al., 1998a).  Others also reported that continuous treatment 
with E2 increased pituitary GnRHR numbers in vivo both in ovariectomized sheep (Moss 
et al., 1981) and cows (Schoenemann et al., 1985) and in vitro in rat (Menon et al., 1985) 
and ovine (Laws et al., 1990b; Gregg et al., 1990; Wu et al., 1994) pituitary cell cultures.    
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Glucocorticoids.  In addition to E2, glucocorticoids can stimulate GnRHR gene 
expression.  Administration of dexamethasone to GnRH deficient mice resulted in a 
significant stimulation of GnRHR gene expression (Rosen et al., 1991).  Additionally, the 
glucocorticoid antagonist, RU486, blocked transcriptional activity of the mouse GnRHR 
promoter (Maya-Nunez and Conn, 2003).  Further investigation revealed a putative 
glucocorticoid response element (GRE) within the mouse GnRHR promoter located 
between -331/-225 bp of 5’ flanking region.  In addition to dexamethasone 
responsiveness, this region contains important elements for basal and buserelin- 
stimulated promoter activity.  Mutation of an AP-1 element located within this region 
resulted in enhanced functional activity of the mouse GnRHR promoter following 
treatment with a GnRH agonist or dexamethosone.  Therefore, the dexamethosone 
mechanism that altered GnRHR mRNA levels may be due to direct stimulation of the 
AP-1 binding proteins within the mouse GnRHR promoter (Maya-Nunez and Conn, 
2003).  Additionally, glucocorticoid repression of transcription in the hypothalamic cell 
lines, GT1-3 and GT1-7, suggested that glucocorticoid receptor acts directly within 
GnRH neurons.  This may be responsible for the negative feedback effect of 
glucocorticoids in the reproductive axis (Chandran et al., 1994).   
Progesterone.  In addition to glucocorticoids, GnRHR is regulated by P4.  For 
instance, P4 treatment of ovine pituitary and αT3-1 cells in vitro as well as P4 delivery to 
sheep in vivo reduced levels of GnRHR mRNA (Wu et al., 1994).  Bauer-Dantoin and 
associates (1995) indicated that P4 did not significantly alter GnRHR mRNA levels prior 
to or during the E2-induced LH surge in rats.  However, treatment with P4 decreased 
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GnRHR mRNA levels at the end of the LH surge in comparison to levels in animals 
treated with only E2.  It was concluded that preovulatory P4 secretion may contribute to 
the decreased GnRHR mRNA levels that occur with the decline in gonadotropin levels 
(Bauer-Dantoin et al., 1995).  Progesterone also regulates the GnRHR gene in the human.  
The human GnRHR gene promoter contains a putative progesterone response element 
(PRE; Fan et al., 1995).  The physiological effects of P4 are controlled by a specific 
nuclear receptor protein, progesterone receptor (PR), which has two different isoforms, 
PR-A and PR-B.  These isoforms play different roles in the transcriptional regulation of 
the human GnRHR within the pituitary and placenta (Cheng et al., 2001a). 
Testosterone.  Numerous steroid hormones affect GnRHR numbers and mRNA 
levels.  Compared to other steroid hormones, however, testosterone plays a reduced role 
in the regulation of GnRHRs.  Kaiser and associates (1993) detected increased GnRHR 
mRNA levels following castration of rats.  Replacement therapy with testosterone 
propionate moderately decreased GnRHR mRNA levels compared to control rats.  
However, replacement with E2 in ovariectomized female rats resulted in a significant 
decrease in GnRHR mRNA levels.  This suggested that pituitary GnRHR mRNA levels 
are due to alterations in the pattern of hypothalamic GnRH secretion (Kaiser et al., 1993).  
In contrast, Botte et al., (1999) detected that hCG treatment decreased GnRHR mRNA 
levels in the testis.  However, testicular GnRHR mRNA levels were increased by 
testosterone treatment.  It was suggested that this stimulation was mediated through a 
reduction in LH secretion which may be due to the negative feedback of testosterone. 
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Activin/Follistatin.  Activin and follistatin are members of the transforming 
growth factor-β superfamily.  They control many vital physiological processes important 
for development, growth, and functional integrity of tissues, such as the pituitary 
(Bilezikjian et al., 2006).  Activin is produced by pituitary cells, including gonadotropes, 
to help maintain a normal reproductive axis.  It has the ability to stimulate FSH secretion 
from gonadotropes within the anterior pituitary gland.  Follistatin, also produced in the 
anterior pituitary gland, is a glycoprotein that binds to activin itself, inhibiting the 
synthesis and release of FSH from the pituitary (Bilezikjian et al., 2006).  Overexpression 
of follistatin is linked to infertility, possibly due to a disruption of activin and bone 
morphogenetic protein (BMP) signals at the level of both the gonads and pituitary (Guo 
et al., 1998).   
The gonadotrope derived-cell lines, LβT2 and αT3-1, activate mechanisms 
correlated with the actions of activin in gonadotropes.  Studies in these cell lines have 
revealed that both FSHβ-subunit and GnRHR promoters are modulated by activin 
(Fernandez-Vazquez et al., 1996; Duval et al., 1999; Pernasetti et al., 2001; Norwitz et 
al., 2002; Suszko et al., 2003; Bernard, 2004).  The αT3-1 cell line, which endogenously 
produces activin, was used to study gonadotrope expression of the mouse GnRHR gene 
promoter (Duval et al., 1999).  Activin responsiveness is mediated by the regulatory 
element GnRHR activating sequence (GRAS) in the mouse GnRHR gene (Ellsworth et 
al., 2003a).  Follistatin blocked activin responsiveness of the mouse GnRHR gene 
suggesting that activin stimulates gonadotropes by an autocrine/paracrine manner (Duval 
et al., 1999).  A downstream activin regulatory element (DARE) comprises a unique and 
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complex activin/TGF-β responsive enhancer in the promoter of the mouse GnRHR gene.  
Ellsworth and associates (2003) identified that Smad 3 and 4, AP-1 and a forkhead DNA 
binding protein, FoxL2 bind to the GRAS element.  Both GRAS and DARE are involved 
in activin responsiveness of the mouse GnRHR gene and may be both structurally and 
functionally coupled (Cherrington et al., 2005).  Therefore, activin and follistatin depend 
on one another to regulate FSH suppression or secretion in gonadotrope cells of the 
anterior pituitary gland. 
 
Inhibin.  Inhibin, a peptide that binds to activin receptors, is a member of the 
transforming growth factor-β (TGF-β) superfamily that, much like follistatin, inhibits 
FSH synthesis and secretion from the anterior pituitary (Ethier and Findlay, 2001; 
Gregory and Kaiser, 2004).  Inhibin also regulates other pituitary functions such as the 
synthesis of GnRHRs by gonadotropes (Braden et al., 1990; Fernandez-Vazquez et al., 
1996).  Inhibin up-regulated GnRHR mRNA levels in ovine pituitary cell cultures (Laws 
et al., 1990a; Wu et al., 1994).  Additional studies utilizing ovine pituitary cell cultures 
indicated that E2 and inhibin may have additive effects on the up-regulation of GnRHR 
numbers (Gregg et al., 1991).  However, treatment of rat primary pituitary cultures with 
inhibin decreased GnRHR numbers (Wang et al., 1988) and suppressed GnRH-induced 
up-regulation of GnRHR binding sites (Wang et al., 1989).  Therefore, inhibin utilizes 
different mechanisms in the rat and sheep.   
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Transcriptional Regulation 
General.  The transcriptional activity of the GnRHR gene is regulated by a 
variety of transcription factors in mammalian species such as the human, mouse and rat 
(Figure 2.7).  Transcription factors including GRAS, Oct-1, LIM-related factors, SF-1, 
AP-1, GATA, nuclear factor-κB (NF-κB), specificity protein (Sp) factors and PR play an 
important role in controlling the transcriptional activity of the GnRHR gene and will be 
further described within this section.  The human GnRHR gene promoter contains several 
placenta specific elements located between -1718 and -1509 bp of proximal promoter; an 
Oct-1, cAMP response element (CRE), GATA and AP-1 element (Figure 2.7; Cheng et 
al., 2001b).  The human GnRHR gene promoter also contains another AP-1 element 
regulated by GnRH located at -1000/-994 bp 5’ flanking region and a progesterone 
response element (PRE; Figure 2.7).  Additionally, the human GnRHR promoter contains 
two putative C/EBP motifs and a GATA binding site that are granulosa-luteal cell-
specific (SVOG-4o and SVOG-4m; Figure 2.7; Cheng et al., 2002a).  Lastly, the human 
GnRHR gene promoter contains several cell specific elements downstream including 
AP/CRE -1, AP/CRE-2, SF-1 and AP-1 (Figure 2.7).  The mouse GnRHR promoter is 
also regulated by several elements.  Gonadotrope specific activity is conferred by a 
tripartite basal enhancer consisting of SF-1 (-244/-236), AP-1 (-336/-330) and a novel 
element termed GRAS (-391/-380) binding sites (Figure 2.8; Duval et al., 1997a).  
Approximately 60% of promoter activity was lost when each element was mutated 
individually, whereas about 80% of promoter activity was lost when 2 elements  
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Figure 2.7.  Schematic representation of elements conferring basal and hormonal 
regulation of the GnRHR gene promoter in the human, mouse and rat.  The striped and 
shaded boxes represent CCAAT and TATA boxes, respectively.  Black boxes indicate 
binding sites that have been functionally characterized, whereas white boxes identify 
putative binding sites.  Transcription start sites are represented by arrows and 
translational start sites are indicated with an ‘ATG’.  From Hapgood et al. (2005).   
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Figure 2.8.  Cell-specific expression of the mouse GnRHR gene is regulated by a 
tripartite enhancer which consists of 3 elements; steroidogenic factor-1 (SF-1), activating 
protein-1 (AP-1) and GnRH receptor activating sequence (GRAS).  Transient 
transfections were performed using luciferase (LUC) reporter vectors containing single, 
double, or triple mutations of the elements or promoterless control of -600 bp 5’ flanking 
region of the mouse GnRHR gene promoter in αT3-1 cells.  Cells were harvested 24 
hours following transfection and assayed for both LUC and β-galactosidase (β-gal) 
activity.  Luciferase values were divided by β-gal values to adjust for transfection 
efficiency.  Differences are indicated by the bars with different letters (P < 0.05).  From 
Duval et al. (1997a). 
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were mutated together.  Finally, promoter activity was reduced to that of promoterless 
control when all 3 elements were mutated within the tripartite enhancer (Figure 2.8; 
Duval et al., 1997a).  Additionally, LHX2/3, Oct-1, nuclear factor-Y (NF-Y), DARE and 
SURG-1 regulate both activin and GnRH responsiveness within the mouse GnRHR gene 
promoter (Figure 2.7; Norwitz et al., 2002; Ellsworth et al., 2003a).  Lastly, a CRE in the 
mouse promoter is critical for basal activity in LβT2 and GGH3 cells (Figure 2.7; Maya-
Nunez et al., 1999).  The rat GnRHR gene promoter also contains the tripartite enhancer 
previously described in the mouse (Pincas et al., 2001).  However, the rat promoter is 
regulated by a GnRHR specific enhancer (GnSE) that contains GATA and LIM binding 
sites.  The GnSE helps confer gonadotrope specific expression via its interaction with an 
SF-1 element located at -275/-266 bp of proximal promoter (Figure 2.7; Pincas et al., 
1998; 2001).  Therefore, the human, mouse, and rat GnRHR promoters are regulated by 
multiple binding factors, many of which are unique to each species (Figure 2.7; Hapgood 
et al., 2005).    
 
GnRH Receptor Activating Sequence.  GnRH receptor activating sequence was 
identified as part of a tripartite enhancer that regulates cell-specific expression of the 
mouse GnRHR gene in the gonadotrope-derived αT3-1 cell line (Duval et al., 1997a) and 
work synergistically with an AP-1 and SF-1 binding site.  In addition, GRAS regulates 
activin responsiveness of the mouse GnRHR gene promoter (Ellsworth et al., 2003a).  
The functional activity of GRAS is dependent on the organization of a multi-protein 
complex which is made up of Smad4, Smad3, AP-1, and a member of the forkhead 
60 
 
family of DNA binding proteins, FoxL2.  Using 2 bp transversion mutations within the 
GRAS element, a Smad4 interaction at the 5’ end of GRAS was revealed.  This allowed 
for AP-1 and/or FoxL2 to bind to the remaining sequence.  Furthermore, mutation of 
either the 5’ Smad binding site or a putative forkhead binding site located at the 3’ end of 
the element does not allow for the activation of FoxL2 at GRAS (Ellsworth et al., 2003a).  
Overall, GRAS is an important regulator of both basal activity and activin responsiveness 
of the mouse GnRHR gene promoter.      
  
 
 Octamer Transcription Factor-1.  Octamer transcription factor-1 belongs to the 
POU family of transcription factors.  It binds to target sequences through the POU 
family’s bipartite DNA-binding domains (Sturm et al., 1988; Scheidereit et al., 1988; 
Muller et al., 1988).  Octamer transcription factor-1 is essential for the transcription of 
both mRNA and small nuclear RNA-type RNA polymerase II promoters.  Therefore, the 
promoter-specific activation domains of Oct-1 serve in combination with specific 
coactivators to stimulate gene expression (Yang et al., 1991; Tanaka et al., 1992; Pfisterer 
et al., 1994; Strubin et al., 1995; Gstaiger et al., 1995).  Additionally, Oct-1, can recruit 
transcription factor IIB (TFIIB), critical to basal transcriptional machinery, to the 
initiation site to enhance activity (Nakshatri et al., 1995). 
 The human GnRHR contains an Oct-1 binding site located at -1017/-1009 bp of 
proximal promoter, which was originally referred to as a negative regulatory element 
(NRE; Cheng et al., 2002b).  Deletion of the 3’ end of the human GnRHR promoter 
revealed that the repressive activity of the NRE could be isolated to a putative Oct-1 
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regulatory sequence.  Transient transfection studies indicated that Oct-1 displays 
repressive effects on the human GnRHR promoter in ovarian (OVCAR-3; Kang et al., 
2000), placental (JEG-3; Cheng et al., 2001b), gonadotrope-derived αT3-1 (Kang et al., 
2000) and granulosa-luteal cells (Cheng et al., 2002b).  The transcription factor, Oct-1, 
may play an important role in silencing GnRHR gene transcription across species.  The 
repressive role of the Oct-1 sequence may be evolutionarily conserved because alteration 
of the Oct-1 sequence in the rodent GnRHR promoter by a single bp did not disable its 
silencing activity (Cheng et al., 2002b). 
 Octamer transcription factor-1 can also have a positive effect on the GnRHR gene 
promoter.  The mouse GnRHR gene promoter contains a cis-regulatory element 
designated Sequence Underlying Responsiveness to GnRH 1 (SURG-1; Norwitz et al., 
1999) that is stimulated upon treatment with GnRH (Kam et al., 2005).  Three elements 
have been identified within SURG-1; NF-Y, Oct-1 and AP-1.  Mutations of each element 
alone decreased stimulation following treatment with a GnRH agonist (Norwitz et al., 
1999; Kam et al., 2005).  However, a mutation which consisted of both Oct-1 and AP-1 
resulted in reduced basal transcriptional activity and abolished GnRH stimulation (Kam 
et al., 2005).  In addition, Oct-1 small interfering RNA reduced mouse GnRHR promoter 
activity, confirming that Oct-1 is critical for gene expression.  Therefore, NF-Y and Oct-1 
bind to SURG-1 to direct basal and GnRH-stimulated expression of the mouse GnRHR 
gene (Kam et al., 2005). 
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 LIM-Related Factors.  The LIM-homeodomain (LIM-HD) proteins are a 
subfamily of proteins consisting of a C-terminal DNA binding homeodomain and 2 N-
terminal, cysteine-rich, zinc finger-like LIM motifs that mediate protein-protein 
interactions (Jurata et al., 1998; Bach, 2000).  To date, there are at least 12 LIM-HD 
genes that encode developmental regulatory proteins (Bach, 2000).  LIM related factors 
play important roles in cell lineage specification and are involved in many developmental 
pathways.  This family of proteins consists of Lhx2, Lhx3, Lhx4, Isl-1, Isl-2 and Lmx-1 
(Roberson et al., 1994).  The majority of these factors (Is1-1, Isl-2, Lhx2, Lhx3 and 
Lhx4) have been implicated in pituitary development (Mullen et al., 2007).  The LIM-
homeodomain transcription factors, Lhx3, Lhx4 and Isl-1 are important during the early 
developmental stages within the anterior pituitary gland (Pfaff et al., 1996) and  Lhx3 and 
Lhx4 are also involved in the development of the nervous system (Mullen et al., 2007).  
In addition, Lhx3 is critical during gonadotrope differentiation (Sheng et al., 1996).  
Furthermore, these factors are important for gonadotrope-specific expression of the rat 
GnRHR gene (Granger et al., 2006).   
 Pincas and associates (2001) identified a GnSE located at -1135/-753 bp in the rat 
GnRHR promoter.  Response elements located within the GnSE (-983/-962 and -871/-
862) interact with GATA and LIM-related factors, respectively, indicating the importance 
of these transcription factors in regulation of the rat GnRHR gene (Pincas et al., 2001).  
Recently, it has been indicated that the interaction between Isl-1 and Lhx3 with SF-1 
activates both the rat and human GnRHR promoters, suggesting that this combination of 
transcription factors is evolutionarily conserved among mammals (Granger et al., 2006).  
63 
 
Deletion of the LIM response element decreased rat and human GnRHR promoter 
activity in CHO cells.  Finally, a transgenic model demonstrated that the overlapping 
expression of Isl-1 and Lhx3 in the developing pituitary is associated with GnRHR 
promoter activity (Granger et al., 2006). 
 
 Steroidogenic Factor-1.  Steroidogenic factor-1 is an orphan member of the 
nuclear hormone receptor family that is essential for mammalian gonadogenesis prior to 
sexual differentiation and for normal endocrine development and function.  Nuclear 
hormone receptors usually activate transcription as a homodimer or heterodimer, whereas 
SF-1 activates gene expression in a monomeric form (Nachtigal et al., 1998; Li et al., 
1999).  Steroidogenic factor-1 has a zinc finger motif which is involved in DNA binding 
and an Ftz-F1 box, a region downstream of the zinc finger motif, that assists binding of 
SF-1 to specific DNA sequences.  In addition, SF-1 binds to a gonadotrope specific 
element (GSE; De Santa Barbara et al., 1998; Li et al., 1999). 
 A GSE motif within the human GnRHR gene promoter is located at -142/-134 bp 
of 5’ flanking region and mediates cell-specific expression.  Expression of the antisense 
SF-1 mRNA reduced human GnRHR promoter activity in αT3-1 cells, whereas activity 
in human ovarian adenocarcinoma (SKOV-3) and monkey kidney (COS-7) cells 
remained unaffected (Ngan et al., 1999).  In αT3-1 cells, GnRHR promoter activity is 
conferred by SF-1 binding sites in other species such as the mouse (Duval et al., 1997a, 
1997b), rat (Pincas et al., 2001), sheep (Duval et al., 2000), and pig (Cederberg et al., 
unpublished data).  A GSE also plays an important role in the cell-specific expression of 
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the glycoprotein α- and LHβ-subunit genes, suggesting an important role for GSEs in the 
regulation of genes within the anterior pituitary gland (Horn et al., 1992).  Additionally, 
regulation of the equine LHβ-subunit gene in LβT2 cells is controlled by 2 SF-1 elements 
(Wolfe, 1999).  Furthermore, analysis of the mouse FSHβ-subunit gene in LβT2 cells is 
regulated by a critical interaction among elements, including 2 proximal GSEs and a 
downstream NF-Y element (Jacobs et al., 2003).  
 Steroidogenic factor-1 mRNA levels are increased in αT3-1 cells following 
treatment with forskolin, a cAMP activator (Sadie et al., 2003).  Consistent with this, the 
mouse GnRHR gene promoter utilizes SF-1 to regulate responsiveness to cAMP.  
Therefore, SF-1 is critical to the mouse GnRHR gene promoter, activating the PKA 
pathway.  Also, SF-1 is able to interact with various transcription factors such as GATA 
and LIM related factors (Pincas et al., 2001), AP-1 and GRAS (Duval et al., 1997a), Sp1 
(Liu and Simpson, 1997), C/EBPβ (Reinhart et al., 1999), SOX9 (De Santa Barbara et al., 
1998), and Wilms’ Tumor 1 (Nachtigal et al., 1998). 
  
 Activating Protein-1.  The transcription factor, AP-1, also known as a TPA-
response element (TRE), is mainly comprised of Jun and Fos protein dimers.  Activating 
protein-1 controls gene regulation in response to stimuli of cytokines, growth factors, 
stress signals and bacterial and viral infections (Hess et al., 2004).  These proteins contain 
a basic DNA-binding domain with a leucine zipper region.  The leucine zipper controls 
dimerization such as the specificity and stability of homo- and heterodimers that 
comprise the AP-1 complex (Wagner, 2001; Eferl and Wagner, 2003).  Jun proteins can 
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form either homo- or heterodimers, whereas Fos proteins bind as a heterodimer with Jun 
proteins to increase DNA-binding stability (Hess et al., 2004).  In addition, Jun proteins 
can form heterodimers with many other transcription factors to bind AP-1 elements.     
Cheng et al. (2000b) demonstrated that an AP-1 site located in the human GnRHR 
promoter is responsible for the down-regulation of the GnRHR gene following treatment 
with GnRH.  Although mutation of the AP-1 site abolished down-regulation by GnRH, it 
had no effect on basal promoter activity.  An up-regulation of c-Fos and c-Jun proteins 
following treatment of αT3-1 cells with a GnRH agonist indicated that AP-1 plays a 
critical role in the regulation of GnRH binding to its receptor (Cheng et al., 2000b).  In 
addition, the human GnRHR gene promoter contains 2 putative AP-1/cAMP response 
element binding (CREB) sites; human GnRHR (hGR)-AP/CRE-1 and hGR-AP/CRE-2 
that are involved in cAMP responsiveness of αT3-1 cells (Cheng and Leung, 2001).  
Mutations of these putative elements decreased forskolin-stimulated promoter activity.  
Conversely, there are other transcription factors involved in cAMP responsiveness in 
addition to AP-1 because these mutations did not completely abolish the cAMP 
stimulatory effect (Cheng and Leung, 2001). 
In addition to GnRH responsiveness of the GnRHR promoter, an AP-1 binding 
site in the mouse GnRHR gene promoter is also important in basal expression (Duval et 
al., 1997a), binding fos/jun family members (White et al., 1999).  The mouse GnRHR 
promoter is mediated by GnRH and activin via a multifactor ADP-ribosylation factor 
(ARF) protein complex, including AP-1 (Fos/Jun) and SMAD proteins (Norwitz et al., 
1999).  Ellsworth and associates (2003b) suggested that the AP-1 element which binds 
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JunD, FosB and c-Fos residing within -600 bp of 5’ flanking region in the mouse GnRHR 
gene promoter requires JNK activation upon stimulation by GnRH.  Also, activin 
responsiveness of the mouse GnRHR gene promoter is conferred by an AP-1 element 
residing upstream within the GRAS element (Ellsworth et al., 2003a). 
 Similar to GnRH, estrogen is one of the most critical regulators of GnRHR gene 
expression.  Ovarian cancer (OVCAR-3) and breast cancer (MCF-7) cells treated with E2 
caused repression of the human GnRHR promoter via estrogen receptor (ER) α and AP-1 
elements.  Although, c-Jun and c-Fos bound to the AP-1 element, their DNA binding 
activity was not affected by E2 treatment.  Thus, E2 can regulate expression of the 
GnRHR gene through an ERα-dependent mechanism that utilizes an AP-1 element.  The 
E2 repression of the GnRHR promoter is also regulated by an indirect mechanism 
involving CBP and other potential transcription factors (Cheng et al., 2003). 
 
  GATA Factors.   Two copies of a highly conserved, zinc finger DNA binding 
domain are characteristic of the GATA binding protein family (Steger et al., 1994). The 
GATA factors are comprised of a C-terminal zinc finger and basic domain that is 
conserved within the GATA protein family (Lowry and Atchley, 2000) and each GATA 
member recognizes a specific DNA-binding site, (A/T)GATA(A/G) (Lawson et al., 
1996).  Proteins in the GATA family play important roles in various areas of 
development and are expressed in many different tissues.  They are involved in cell 
differentiation, organ morphogenesis, and tissue-specific gene expression.  These proteins 
67 
 
are expressed in the placenta, pituitary, gonads, brain, heart, hemopoietic system and gut 
(Tremblay and Viger, 2001; La Voie, 2003).   
There are currently 2 classes of GATA proteins; the hematopoietic (GATA-1/2/3) 
and cardiac (GATA-4/5/6) groups (Tremblay and Viger, 2001; La Voie, 2003).  GATA-1 
is involved in the development of erythropoietic stem cells (Evans and Felsenfeld, 1989; 
Steger et al., 1994; Lawson et al., 1996), whereas GATA-2 is expressed in embryonic and 
adult tissues (Yamamoto et al., 1990; Steger et al., 1994; Lawson et al., 1996).  GATA-3 
is highly expressed in developing neural tissue, placenta, pituitary, T cells, and a wide 
variety of other tissues (Yamamoto et al., 1990; Steger et al., 1994; Lawson et al., 1996).  
The fourth member, GATA-4, is mainly involved in developing cardiac tissue and is 
detected in primitive endoderm, intestinal epithelium, and T cells.  It is also expressed in 
reproductive tissues such as the gonads and pituitary-derived cells.  (Arceci et. al., 1993; 
Kelley et al., 1993; Steger et al., 1994; Lawson et al., 1996).  The most recently 
discovered GATA factors, GATA-5 and -6 were originally found in chickens and are 
expressed in the gonadal, gut, and heart tissue (Laverriere et al., 1994; Lawson et al., 
1996). 
 The GATA factors are critical in mammalian reproductive development and 
function.  Reproductive gene expression is regulated in the hypothalamus and anterior 
pituitary gland by GATA family members (La Voie, 2003).  Specifically, GATA-4 
and/or GATA-6 has been found in the granulosa layer of healthy follicles and is involved 
in the transcription of gonadotropin-regulated genes including aromatase (Tremblay and 
Viger, 2001; 2003), steroidogenic acute regulatory protein (StAR), and inhibin (Gillio-
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Meina et al., 2003).  In addition, GATA-4 expression has also been found in a majority of 
germ cells prior to puberty in humans.  It has also been implicated in steroid hormone 
production by gonadal cells (La Voie, 2003).  Several members of the GATA 
transcription factor family regulate GnRH gene transcription through binding sites within 
the GnRH neuron-specific enhancer in the GnRH-secreting hypothalamic neuronal cell 
line, GT1-7.  GATA-4 was detected in an enhancer specific binding complex suggesting 
its importance in regulating neuron-specific expression of the GnRH gene in 
hypothalamic neurons (Lawson et al., 1996).  In summary, the GATA family of 
transcription factors is important in the reproductive axis, impacting the expression and 
function of the hypothalamus, pituitary and gonads.   
 
Nuclear Factor-κB.  Nuclear factor-κB plays an important role in the immune 
system, regulating the expression of cytokines, growth factors, and effector enzymes in 
response to the activation of receptors involved in the immune systems (Silverman and 
Maniatis, 2001; Hayden and Ghosh, 2004).  Recent studies indicated that NF-κB is 
involved in systems other than the immune system.  For example, it is involved in 
embryonic development, the development and physiology of tissues (mammary gland, 
bone, and skin) and the central nervous system (Hayden and Ghosh, 2004).  The 
mammalian NF-κB family consists of 5 members; p65 (RelA), RelB, c-Rel, p50 (NF-
κB1) and p52 (NF-κB2).  They may exist as either homodimers or heterodimers bound to 
IκB family proteins in their inactive state (Siebenlist et al., 1994; Baeuerle and Henkel, 
1994; Hayden and Ghosh, 2004).  The most common form of NF-κB exists as a 
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heterodimer consisting of the p50 and p65 subunits (Hong et al., 2003).  As NF-κB binds 
to IκB proteins, it forms a NF-κB:IκB complex, preventing the complex from 
translocating to the nucleus and maintaining NF-κB in an inactive state.  Phosphorylation 
and degradation of IκB proteins allows NF-κB dimers to translocate into the nucleus, 
where it binds to specific sequences in the promoter or enhancer regions of target genes 
(Baldwin, 1996; Hayden and Ghosh, 2004). 
Nuclear factor-κB is involved in a variety of biological processes and many 
different cell types including the anterior pituitary gland.  Therefore, NF-κB may play an 
important role in gene regulation involved in the anterior pituitary gland, suggesting an 
important role in reproductive functions.  Nuclear factor-κB is involved in the stimulation 
of oxidative stress in the pituitary corticotrope cell line, AtT20 (Karalis et al., 2004).  
Activation of NF-κB complexes via the interaction between interleukin-1 (IL-1) and two 
different receptors, IL-1 receptor type I and type II, was detected in somatotrope cells 
(Parnet et al., 2003).  Delfino and Walker (1998) suggested NF-κB proteins may also 
play a role in stage-specific gene expression during spermatogenesis.  Mullerian 
inhibiting substance (MIS) expression in Sertoli cell cultures is regulated by the 
interaction between SF-1 and NF-κB.  Steroidogenic factor-1 is stimulated by its 
interaction with NF-κB through the p50 subunit; however, SF-1 activation is inhibited by 
the p65 subunit of NF-κB.  Therefore, different subunits of NF-κB play divergent roles in 
the mechanisms underlying MIS expression by meiotic germ cells in the testes (Hong et 
al., 2003).   
  
70 
 
 Specificity Protein Family.  The specificity protein family is comprised of 9 
members; Sp1-9 (Suske, 1999; Suske et al., 2005; Sahara et al., 2007).  Each member of 
the Sp family consists of 3 zinc finger DNA binding domains located at the C-terminus, 
in addition to various serine/threonine domains at the N-terminal region (Wooten and 
Ogretmen, 2005).  The Krüppel-like factor (KLF) proteins represents a subgroup of a 
larger class of transcription factors (Lomberk and Urrutia, 2005).  Similar to members of 
the Sp family, these factors bind to GC-GT rich sites and CACC boxes of many different 
gene promoters (Sogawa et al., 1993; Crossley et al., 1996; Shields and Yang, 1998; 
Lomberk and Urrutia, 2005).  They also share a highly conserved DNA-binding domain, 
the most common transcription factor motif within the human genome.  This binding 
domain consists of 3 Cys2/His2 zinc fingers (Philipsen and Suske, 1999; Bieker, 2001).  
Krüppel-like transcription factors can act as either activators or repressors depending on 
promoter specificity.  In order to regulate transcription of their target genes, they can also 
interact with co-activators and co-repressors via different mechanisms (Lomberk and 
Urrutia, 2005).   
The various specificity proteins play divergent roles throughout many tissues.  
Specificity protein 4 is mainly found in neuronal tissues and abundant in epithelial 
tissues, developing teeth and testes (Philipsen and Suske, 1999), whereas Sp1, Sp2 and 
Sp3 are expressed ubiquitously (Wooten and Ogretmen, 2005).  Specificity protein 1, 3 
and 4 contain similar sequences, binding patterns and structure.  However, the Sp family 
members have some differences among one another.  For example, Sp1 contains an 
inhibitory domain at the N-terminus, whereas Sp4 has an inhibitory domain located near 
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the zinc fingers.  Specificity proteins 1 and 3 both have high affinities for GC-rich 
sequences and are 90% homologous within their zinc finger domains.  On the contrary, 
Sp2 has a high affinity to bind to GT-rich sequences and has the least homology to the 
other Sp family members (Wooten and Ogretmen, 2005).  In addition to activating 
transcription, Sp3 can also act as a repressor (Al-Sarraji et al., 2005; Wooten and 
Ogretmen, 2005).  Specificity proteins 5 and 8 have zinc finger domains that are 93.8% 
similar to one another.  Specificity protein 8 may also bind to Sp1 binding sites due to its 
similarity to the Sp1 zinc finger domain.  During central nervous system development, 
the expression pattern of Sp5 and Sp8 was similar within the mouse (Treichel et al., 
2003).  Specificity protein 5 can act as a transcriptional repressor, containing 3 repressor 
domains.  This Sp family member also represses Sp1-regulated target genes and has a 
similar binding specificity as Sp1 (Fujimura et al., 2007).  During limb development, Sp8 
acts as a transcriptional activator.  However, it also has the capability to act as a 
transcriptional repressor because it has several mSin3a core consensus sequences and 
polyalanine tracts (Kawakami et al., 2004).  The 3 transcription factors, Sp5, 8 and 9 are 
expressed in the embryonic mouse forebrain in unique patterns and are also associated 
with forebrain signaling centers (Sahara et al., 2007).    
 Functional Sp1 and Sp3 are present in many different mammalian gene promoters 
including: monocyte chemoattractant protein 1 (MCP-1; Ping et al., 2000), tissue factor 
(Oeth et al., 1997), rat luteinizing hormone-β (LH-β; Kaiser et al., 2000), bovine 
CYP11A (Liu and Simpson, 1997) and the long terminal repeat of the HIV-1 promoter 
(Majello et al., 1994).  Interestingly, NF-κB interacts with both Sp1 and Sp3 to regulate 
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transcriptional activity of various mammalian gene promoters (Majello et al., 1994; Oeth 
et al., 1997; Ping et al., 2000).  In addition, Sp1 can regulate the LH-β gene promoter in 
response to GnRH suggesting a role for Sp1 in transcriptional regulation in gonadotrope 
cells (Kaiser et al., 1998; 2000).  Therefore, the Sp family of transcription factors can 
play a critical role in the transcriptional regulation of gonadotropic genes. 
 
 
 Progesterone Receptor.  Progesterone receptor is expressed in many tissues and 
consists of 2 isoforms; PR-A and PR-B.  Progesterone receptor-A is a truncated form of 
PR-B as PR-B contains an additional 164 amino acids at the N-terminus (Schott et al., 
1991; Kraus et al., 1993).  The transcriptional activity of PR-A is both cell- and gene-
dependent, whereas PR-B acts as a stronger transcriptional activator (Cheng et al., 
2001a).  In addition, there is a variation in the ratio of PR-A:PR-B isoforms within target 
tissues indicating that cell-specific responses are due to the differential expression of 
these isoforms (Shyamala et al., 1998; Mulac-Jericevic and Conneely, 2004).  
 However, little is known about the role of the PR isoforms in the pituitary gland.  
Turgeon and Waring (2006) determined PR-A and PR-B mRNA levels in rat and mouse 
cultured pituitary cells as well as LβT2 cells.  It was concluded that PR-A was the most 
abundant isoform in both cell lines.  They also established roles for E2 and P4 in PR 
isoform expression within these cell lines.  Total PR mRNA within rat pituitaries is up-
regulated by E2 (Turgeon et al., 1999; Sanchez-Criado et al., 2004).  Also, rat and mouse 
pituitary cultures responded to E2 stimulation with increased expression of both PR 
isoforms, whereas PR-A and -B mRNA levels did not respond to E2 in LβT2 cells 
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(Turgeon and Waring, 2006).  Additionally, the PR-B isoform has a more robust response 
to E2 in rat than mouse pituitary cultures, decreasing the PR-A:PR-B isoform ratio 
(Turgeon and Waring, 2006).  Therefore, regulation of PR isoforms by E2 in 
gonadotropes contributes to LH secretion differences between the rat and mouse.  
Luteinizing hormone secretion is regulated by either GnRH self-priming or P4 
augmentation, which are both estrogen and transcription-dependent events (Turgeon and 
Waring, 2006). 
 Transcriptional regulation of human GnRHR gene expression by P4 is different at 
the pituitary and placental levels (Cheng et al., 2001a).  For instance, human GnRHR 
promoter activity was decreased in both pituitary and placental cells following 
overexpression of PR-A.  However, overexpression of PR-B in the presence of the human 
GnRHR promoter demonstrated cell-dependent transcriptional activity because it 
functioned as a repressor in the pituitary and an activator in the placenta (Cheng et al., 
2001a).  An et al. (2005) also indicated differential roles for the PR isoforms in regulating 
the human GnRHR promoter in TE-671 (human neuronal medullablastoma) cells.  
Progesterone receptor-A acted as a transcriptional repressor, whereas PR-B functioned as 
an activator following treatment with P4.  Thus, PR-A can act on the GnRHR promoter in 
a gene-specific manner and PR-B could be a transdominant regulator of PR-A (An et al., 
2005).  Additionally, these results indicate that PR-A is more dominant compared to PR-
B.  Overall, P4 may regulate the GnRH system by different pathways utilizing the 2 
different PR isoforms (An et al., 2005). 
  
74 
 
Gonadotropin-Releasing Hormone Receptor in Swine 
In addition to its physiological importance, the porcine GnRHR gene is located on 
porcine chromosome 8, in close proximity to a quantitative trait locus (QTL) for 
ovulation rate (Rohrer et al., 1999).  Thus, the GnRHR gene is both a physiological and 
positional candidate for genes influencing reproductive traits, such as ovulation rate 
(Jiang et al., 2001; Campbell et al., 2003b).  In addition to the QTL for ovulation rate on 
chromosome 8, other QTLs have also been identified for prenatal survival, teat number, 
litter size and uterine capacity (Rohrer et al., 1999; King et al., 2003).  Therefore, the 
porcine GnRHR gene may represent a candidate gene for these traits as well.  The 
identification of additional QTLs associated with reproductive traits and correlation of 
these markers with physiological mechanisms could dramatically improve breeding 
programs within the swine industry.   
Genomic sequencing of the porcine GnRHR gene revealed differences in 
promoter sequences between the Chinese Meishan and White Crossbred lines of pigs 
(Jiang et al., 2001).  In addition, our laboratory has identified additional bp alterations 
between these lines that result in functional differences in GnRHR promoter activity 
(McDonald, 2005).  The Chinese Meishan is a very prolific breed farrowing about 4 to 5 
more piglets per litter compared to occidental breeds, largely due to increased ovulation 
rate.  Furthermore, GnRHR mRNA levels were higher in ovariectomized Meishan gilts 
compared to ovariectomized white crossbred gilts (Bass, 2005).  Therefore, this breed 
represents an excellent model to study the porcine GnRHR gene and its effects on 
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ovulation rate, a major contributor to litter size (Christenson et al., 1993; White et al., 
1993; King et al., 2003).   
 
Genes Influencing Prolificacy 
 
 
Sheep 
 
 The FecB (Booroola) genotype is associated with the physiological and genetic 
characteristics of the Booroola Merino, one of the most prolific breeds of sheep in the 
world (Bindon, 1984) as well as Garole and Javanese sheep (Souza et al., 2001; Wilson et 
al., 2001; Mulsant et al., 2001; Davis et al., 2002).  The FecB genotype has been 
associated with increased ovulation rate and litter size, due to a single natural mutation 
(Bindon, 1984; Campbell et al., 2003a).  Ewes with the FecB genotype ovulated more 
small follicles compared to wild type ewes.  Although there was a difference in ovulation 
rate between ewes carrying the FecB genotype and wild type ewes, they both had 
identical gonadotropic hormonal concentrations (Campbell et al., 2003a).  Therefore, 
rather than enhanced FSH and LH levels, the increased ovulation rate is likely due to 
mechanisms that alter responsiveness of the ovary to gonadotropic stimulation as a result 
of the FecB genotype (Campbell et al., 2003a). 
Further studies indicated that sheep with the FecB genotype contained a natural 
mutation in the highly conserved intracellular serine threonine kinase signaling domain 
within the bone morphogenetic protein receptor 1B (BMPR-1B) gene located on 
chromosome 6 (Souza et al., 2001; Wilson et al., 2001).  Bone morphogenetic proteins 
(BMPs) such as BMP-2, -4 and -6 bind to BMPR-1B through common pathways and are 
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members of the transforming growth factor-β (TGF-β) superfamily (Campbell et al., 
2006).  Bone morphogenetic proteins are multifunctional proteins that regulate growth 
and differentiation in various cell types (Wilson et al., 2001).  Expression of BMPR-1B 
was detected in oocytes and granulosa cells within the ewe ovary, suggesting an 
important role for BMPR-1B in development of these cell types (Wilson et al., 2001).  
The BMPRs present within the ewe ovary may be involved in differentiation of granulosa 
cells by stimulating FSH action (Souza et al., 2002).  A recent study by Campbell et al. 
(2006) indicated a major function of BMPs in controlling ovarian somatic cell function.  
Increased differentiation of granulosa and theca cells following stimulation with BMPs, 
gonadotropins and insulin growth factor-1 (IGF-1) were detected in ovarian tissue from 
animals with the FecB genotype compared to controls.  Overall, the FecB genotype causes 
the maturation of ovarian follicles and disrupts the normal follicular mechanism for 
selection in ewes (Campbell et al., 2006). 
An additional genotype that influences prolificacy in sheep is FecX1 (Inverdale; 
Davis et al., 2001).  Sheep with the FecX1 genotype contain a mutation in the BMP15 
gene, another member of the TGF-β superfamily that has been mapped to the X 
chromosome (Galloway et al., 2000).  The BMP15 gene is expressed in oocytes, 
representing an important gene for female fertility.  However, natural mutations in the 
BMP15 gene can cause an increase in either ovulation rate or infertility phenotypes 
(Galloway et al., 2000).  Heterozygous genotypes for the BMP15 gene (FecX1/FecX+) 
were associated with increased ovulation rates and multiple births (Davis et al., 1991), 
whereas homozygous genotypes (FecX1/FecX1) were associated with primary ovarian 
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failure (Davis et al., 1992).  The BMP15 gene influenced fecundity in the Inverdale 
(Davis et al., 1991), Hanna (Davis et al., 1991), Belclare (Hanrahan et al., 2004), 
Cambridge (Hanrahan et al., 2004), and Lacaune (Bodin et al., 2002) breeds of sheep. 
Investigators examined the BMPR-1B and BMP15 genes in Small Tailed Han 
sheep, a prolific breed in China, to determine their association with prolificacy (Chu et 
al., 2007).  This breed of sheep contains mutations in both the BMPR-1B and BMP15 
genes.  Extensive analysis of these 2 genes in the Small Tailed Han indicated that ewes 
carrying both BMPR-1B and BMP15 mutations had greater litter sizes compared to ewes 
harboring either single mutation.  Therefore, using both BMPR-1B and BMP15 genes for 
marker-assisted selection will help increase litter size in sheep and contribute to an 
increase in economic value to sheep producers (Chu et al., 2007). 
 
Mice 
 Ovulation rate is partially regulated by activity of gonadotropins in circulation 
and ovarian sensitivity to these hormones (Land and Falconer, 1969).  To examine 
sensitivity of the ovary to gonadotropins among mouse strains, a line selected for 
increased litter size and reduced body size was compared to unselected mice after 
administration of FSH followed by hCG.  The number of oocytes ovulated were used to 
measure ovarian sensitivity to these hormones (Durrant et al., 1980).  Gonadotropin 
treatment resulted in increased ovulation rate and decreased early embryonic death for 
selected compared to unselected mice, indicating differences in ovarian sensitivity to 
gonadotropins between lines (Durant et al., 1980).  Pomp and associates (1988) suggested 
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that selection of mice for large litter size resulted in increased ovulation rates during 
subsequent generations due to either a decrease in LH receptors or factors related to 
growth.  In order to understand how increased litter size and mature body weight affected 
reproduction, Kirkpatrick et al. (1998b) identified QTLs for prolificacy and growth in 
mice.  They found 4 chromosomal regions that were associated with litter size.  However, 
2 of these regions associated with litter size were also related to a growth QTL, 
potentially impacting the positive genetic relationship among these traits (Kirkpatrick et 
al., 1998b). 
 Pre-implantation embryonic development has also been used as a selection marker 
for litter size in mice (Al-Shorepy et al., 1992).  An allele of the ped gene has been 
correlated with increased cleavage rates during embryonic development.  The increased 
rate of cleavage associated with the ped gene could result in larger litter sizes.  Therefore, 
alleles of the ped gene, or loci in close proximity to the ped gene, may be one of the 
genes involved in prolificacy of mice (Al-Shorepy et al., 1992).  Another gene that could 
potentially impact prolificacy in mice is the inhibin α-subunit gene.  Cho et al. (2001) 
constructed a transgenic mouse that harbored the rat inhibin α-subunit gene.  
Overexpression of the rat inhibin α-subunit gene led to a disruption in the inhibin:activin 
ratio, causing various reproductive defects including reduced ovulation rates and fertility.  
Since, inhibin and activin are important for normal gametogenesis and fertility, the 
inhibin α-subunit gene is a likely candidate gene for prolificacy in mice (Cho et al., 
2001).  Overall, mice have many potential QTLs for prolificacy, however many gene 
associations remain to be determined.  
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Swine 
 Females from the Chinese Meishan breed are very prolific, producing 
approximately 4 to 5 more piglets per litter compared to occidental breeds (Haley and 
Lee, 1993).  Therefore, the Chinese Meishan breed has been widely studied to determine 
potential genes that impact prolificacy.  Since estrogen and its receptor play an important 
role in the reproductive function in mammals, Rothschild and associates (1996) 
investigated whether the ER gene has an impact on litter size in pigs.  A specific allele of 
the ER gene, initially found in the Meishan, was associated with increased litter size.  
However, a beneficial ER allele was associated with increased litter size at first parity 
and the average of all parties in the Large White breed (Rothschild et al., 1996).  Short et 
al. (1997) investigated 4 white-crossbred, commercial swine lines to determine 
associations between the ER gene and growth and reproductive traits.  These scientists 
identified a specific allele for the ER gene that was correlated with increased litter size 
and number of piglets born alive (Short et al., 1997). 
 In addition to the ER gene, a polymorphism in the prolactin receptor (PRLR) gene 
may also be associated with increased litter size (van Rens et al., 2003).  However, it is 
still unknown whether the polymorphism causes increased litter size or if it is merely a 
marker for a linked gene.  For example, a 50% Landrace/50% Meishan crossbred line 
indicated that the PRLR gene, or a closely linked gene, was associated with reproductive 
traits such as ovarian weight, uterine capacity, ovulation rate and placental weight.  
Therefore, the changes in these traits may eventually lead to differences in litter size (van 
Rens et al., 2003).  
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CHAPTER III 
 
MATERIALS AND METHODS 
 
 
Lines of Swine 
 
 The gonadotropin releasing hormone receptor (GnRHR) gene promoter from 3 
lines of swine with divergent ovulation rates were utilized in these studies.  A control 
white-crossbred line (Control) was used that displays reproductive traits common to sows 
used in commercial hog production.  The Index line was developed at the University of 
Nebraska-Lincoln (UNL) by Dr. Rodger Johnson and was selected based on an index of 
ovulation rate and embryonic survival at 50 days of gestation (Johnson et al., 1984).  
After more than 14 generations of selection, females from this line ovulated 
approximately 7 more oocytes per estrous cycle, resulting in 1.4 more piglets per litter 
compared to the Control line (Johnson et al., 1999).  The Chinese Meishan is a highly 
prolific breed, producing approximately 4 to 5 more piglets per litter compared to 
occidental breeds, largely due to increased ovulation rate (Christenson et. al, 1993; White 
et al., 1993).  Therefore, the Chinese Meishan represents a unique model to study genes 
that influence ovulation rate, such as the GnRHR gene promoter. 
 
GnRHR Gene Promoter Isolation 
Our laboratory isolated the porcine GnRHR gene promoter by inverse PCR using 
primers specific for the 1154 bp of 5’ untranslated region previously reported by Jiang 
and associates (2001; GenBank Accession No. AF227685).  Genomic DNA preparations 
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were made by a partial restriction digest using Sau3AI or EcoRI.  Fragments were self-
ligated using a high concentration of T4 DNA ligase (4 U/μl, New England Biolabs, 
Beverly, MA) and a low concentration of DNA (3 μg/μl).  Subsequently, PCR was 
performed on the circularized pieces of DNA, with primers selected from the known 
flanking sequence.  The PCR primers that were chosen were in reverse orientation 
compared to traditional PCR primers.  Polymerase chain reaction products were 
subcloned and sequenced at the UNL Genomics Core Research Facility.  Sequencing data 
representing 5197 bp of 5’ flanking region for the porcine GnRHR gene is available in 
GenBank (Accession No. AY166667; Cederberg et al., unpublished data).  Based on this 
sequence, Index and Meishan full-length promoters were isolated from genomic DNA 
using primers specific for the Control promoter.  Subsequently, the Index and Meishan 
promoters were also sequenced. 
 
 
Plasmid Preparation 
 
Reporter Vectors.  The full-length Control GnRHR gene promoter was sub-
cloned into the pGL3 basic vector (Figure 3.1; Promega Corp., Madison, WI) using SacI 
and SmaI restriction endonuclease sites.  Therefore, the test vector consisted of the full-
length GnRHR gene promoter fused to the cDNA encoding luciferase.  The Index and 
Meishan full-length promoters were sub-cloned into luciferase reporter vectors as 
described above, utilizing SacI and XhoI endonuclease sites and SacI and NheI sites, 
respectively.  The Rous Sarcoma Virus promoter fused to the cDNA encoding β-
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Figure 3.1.  The full-length porcine GnRHR gene promoter was sub-cloned into the 
pGL3-basic vector by SacI and SmaI restriction endonuclease recognition sequences.   
5118 bp
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galactosidase (RSV- βgal, Stratagene, La Jolla, CA.) was used as a control to normalize 
the transfections.   
 
Block Replacement Mutations.  Primers were designed to replace a specific 
element within the GnRHR gene promoter with a restriction enzyme site.  Polymerase 
chain reaction was used to replicate both the sense and anti-sense strands of the DNA 
using specific primers (Table 3.1; Integrated DNA Technologies, Coralville, IA) for the 
region to be mutated.  The PCR reaction consisted of 10X AccuPrime Pfx reaction mix 
(buffer, 1 mM MgSO4 and 0.3 mM dNTPs; Invitrogen Life Technologies Corp., 
Carlsbad, CA), 10 μM primers, 50 ng/μl DNA template, AccuPrime Pfx DNA 
polymerase (Invitrogen Life Technologies Corp.) and Millipore water to bring the final 
volume to 50 μl.  The PCR cycling conditions to generate the mutation in each strand 
were as follows: Step 1 - 94°C for 2 min; Step 2 - 94°C for 15 sec; Step 3 - 55°C for 30 
sec; Step 4 - 68°C for 2 min; Step 5 - repeat step 2 through 4, 35 times; and Step 6 - 68°C 
for 10 min. 
The sequences that were generated from the above PCR reaction were utilized in 
a second PCR reaction to design the template DNA.  The second PCR reaction used the 
same PCR cycling conditions as previously described.  After completion of the second 
PCR reaction, the products were purified using the QIAquick PCR Purification Kit 
(Qiagen, Inc., Valencia, CA).  To replace specific transcription factor binding sites, block 
replacement mutation vectors contained: a PstI restriction endonuclease site in place of 
the GATA element at -845/-840 bp (Mµ845GATA-4pGL3) or a Bcu/SpeI site substituted 
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for the GATA element at -1694/-1689 bp (Mµ1690GATA-4pGL3) within the Meishan 
promoter; an EcoRI site replacing the NF-κB element at -1699/-1694 bp (C/Iµ1699NF-
κBpGL3) or an EcoRI site in place of the NF-κB binding site at -1689/-1684 bp 
(C/Iμ1689NF-κBpGL3) specific to the Control/Index promoter; and a NotI  (µSF-1pGL3) 
or SacI (µOct-1pGL3) site in exchange for the SF-1 (-1760/-1753) or Oct-1 (-1731/-
1724) binding sites, respectively, within homologous portions of the promoter from all 
three swine lines. 
The PCR reaction was purified with the QIAquick PCR Purification Kit (Qiagen, 
Inc., Valencia, CA).  Five volumes of buffer PB1 was added to one volume of the PCR 
sample, mixed and placed in a QIAquick spin column within the 2-ml collection tube that 
was provided.  Next, the sample was centrifuged using a Biofuge Pico microcentrifuge 
(Kendro Lab Products, Hanau, Germany) at 16,000 x g for 1 min.  The flow-through was 
discarded and the spin column was placed back into the same collection tube.  Next, the 
column was washed with 750 µl of buffer PE and centrifuged at 16,000 x g for 1 min.  
The flow-through was discarded and the spin column was placed back in the same tube 
and centrifuged for 1 min.  The QIAquick column was placed in a clean 1.5-ml 
microcentrifuge tube and DNA was eluted from the QIAquick column upon addition of 
50 µl of buffer EB and centrifugation at 16,000 x g for 1 min.  After PCR purification, 
vectors containing the full-length GnRHR gene promoter and PCR products were double 
digested with restriction endonucleases to ligate the PCR product (insert) into the 
digested vector containing the full-length GnRHR gene promoter (template).  Following 
the double restriction digest, the insert and template were gel extracted and quantitated.  
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To set up ligations, insert to template ratios were 1:0 (control), 1:1, 1:5 or 1:10.  The 
ligation reaction containing T4 ligase (5U/μl, Fermentas, Glen Burnie, MD) and T4 ligase 
buffer (Fermentas) was incubated overnight at 15°C. 
 
 Gel Extraction.  Plasmid fragments were extracted from agarose gels with the 
Perfectprep® Gel Cleanup Kit (Eppendorf, Westbury, NY).  The excised gel slice was 
weighed with a maximum of 400 mg in a 2-ml microcentrifuge tube.  Next, 3 volumes of 
binding buffer were added for every volume of each gel slice (1 mg of weight equaled 1 
µl of volume).  Next, gel slices were incubated at 50°C for 5 to 10 min in a heat block 
and vortexed every 2 to 3 min.  After the gel slice was completely dissolved, an equal 
volume of isopropanol was added to the original gel slice volume and mixed by 
inversion.  The sample (up to 800 µl) was placed in a spin column in a 2-ml collection 
tube and centrifuged using a Biofuge Pico (Kendro Lab Products) at 6,000 to 10,000 x g 
for 1 min.  Next, the filtrate was discarded and the spin column was replaced in the same 
collection tube.  If the sample was larger than 800 µl the sample was reloaded and 
centrifuged again.  Diluted wash buffer was prepared by adding 600 µl of 100% ethanol 
to 150 µl of concentrated wash buffer.  Next, 750 µl of diluted wash buffer was added to 
each spin column and columns were centrifuged for 1 min at 6,000 to 10,000 x g.  The 
filtrate was discarded and the spin column was replaced in the same collection tube.  The 
spin column in the collection tube was centrifuged for an additional min at 6,000 to 
10,000 x g to remove any residual wash buffer.  The spin column was then placed in a 
new 2-ml collection tube, 30 µl of elution buffer was added to the center of the spin 
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column and it was centrifuged for 1 min at 6,000 to 10,000 x g.  The plasmid fragments 
were quantitated with a Pharmacia GeneQuant spectrophotometer (Pfizer, New York, 
NY) using A260 and A280 values and allowed to ligate overnight at 15 °C.   
 
Transformation.  Plasmids were transformed utilizing Rb-Cl competent DH5α 
cells (Invitrogen Life Technologies Corp.).  A total of 5 µl of each plasmid ligation 
reaction was added to 50 µl of DH5α cells, gently mixed and incubated on ice for a total 
of 30 min.  The reaction was then heat shocked for 30 sec at 42°C on a heat block and 
incubated on ice for 2 min.  Next, 200 µl of SOB media (2% tryptone, 0.5% yeast extract, 
8.55 mM sodium chloride, 250 mM potassium chloride, 2 M magnesium chloride) was 
added to each reaction and placed in a 37°C shaking incubator for 1 h.  Plasmids were 
plated (50-200 µl) on LB agar plates (Sigma Chemical Co., St. Louis, MO) containing 
ampicillin and incubated inverted at 37°C overnight.  Approximately 16 h later, colonies 
were counted, evaluated, stored at 4°C for up to 1 mo and utilized in alkaline lysis mini 
plasmid preparations. 
 
 Alkaline Lysis Mini Plasmid Preparation.  Plasmid DNA was extracted from 
Rb-Cl competent DH5α cells (Invitrogen Life Technologies Corp.) for screening 
purposes.  A single colony containing an ampicillin resistant plasmid in Rb-Cl cells was 
inoculated overnight and grown in 2 ml of LB media (Sigma Chemical Co.) containing 
0.05 mg/ml ampicillin shaking at 37°C.  Cells were pelleted by centrifuging 1 ml of 
culture at 16,000 x g for 1 min with a Biofuge Pico microcentrifuge (Kendro Lab 
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Products).  The supernatant was removed and the cell pellet was resuspended in 100 µl 
GTE [50 mM glucose, 25 mM Tris-Cl, 10 mM ethylenediaminetetraacetic acid (EDTA)] 
and incubated at room temperature for 5 min.  Next, 200 µl of NaOH/SDS (0.2 N NaOH, 
1% (wt/vol) sodium dodecyl sulfate) was added to each sample, mixed and incubated on 
ice for 5 min.  Following the incubation, 150 µl of 5 M potassium acetate (29.5 ml glacial 
acetic acid, potassium hydroxide (KOH) pellets, pH 4.8) was added to each sample, 
vortexed for 2 s, and incubated on ice for an additional 5 min.  The samples were 
centrifuged at 16,000 x g for 3 min and the supernatant was placed in a clean 1.5-ml 
microcentrifuge tube.  The supernatant was mixed with 800 µl of 100% ethanol and 
incubated at room temperature for 2 min.  The samples were then centrifuged at 16,000 x 
g for 1 min to pellet plasmid DNA and RNA.  The supernatant was then removed and the 
pellet was washed with 1 ml of 70% ethanol.  The samples were centrifuged for an 
additional min at 16,000 x g, the supernatant was removed again, and the pellet dried at 
room temperature. Once dried, the pellet was resuspended in 1X tris-
ethylenediaminetetraacetic acid (TE, pH 8.0).  Following resuspension, 1 µl of RNase A 
was added to each sample and incubated at 37°C for 30 min.  Plasmids were later 
screened by restriction digests for confirmation prior to being utilized in a support 
protocol. 
 
 Midi Plasmid Purification.  Plasmids were prepared for transfection using a 
Plasmid Purification Midi Kit (Qiagen, Inc.) and confirmed with restriction enzyme 
digests.  An overnight culture, shaking at 37°C, was inoculated with 100 ml of LB broth 
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containing 0.05 mg/ml ampicillin and a bacterial stock containing the vector of interest.  
The bacterial cells were harvested by centrifugation at 6,000 x g for 15 min at 4°C using 
a Sorvall RC2-B centrifuge (Du Pont Co., Newton, CT).  The bacterial pellet was 
resuspended in 4 ml of buffer P1 and completely vortexed until no cell clumps remained.  
Next, 4 ml of lysis buffer P2 was added followed by a 5 min incubation at room 
temperature.  Then, 4 ml of pre-chilled precipitation buffer P3 was added to each sample 
and incubated on ice for 15 min.  Following incubation on ice, samples were centrifuged 
at 20,000 x g for 30 min at 4°C using a Sorvall RC2-B centrifuge (Du Pont Co.). 
 Each resin column was equilibrated prior to the addition of sample (cell lysate) 
with 4 ml buffer QBT.  After each sample was added to the columns, they were washed 
twice with 10 ml of buffer QC.  Next, the plasmid DNA was eluted upon the addition of 5 
ml of buffer QF to each column.  The plasmid DNA was precipitated by the addition of 
3.5 ml of room temperature isopropanol and centrifuged at 15,000 x g for 30 min at 4°C 
using a Sorvall RC2-B centrifuge (Du Pont Co.)  The supernatant was decanted and 
pellets were washed with 2 ml of room temperature 70% ethanol and centrifuged at 
15,000 x g for 10 min at 4°C using a Sorvall RC2-B centrifuge (Du Pont Co.).  Next, the 
pellets were air dried for 5-10 min and resuspended in approximately 250 µl of Millipore 
water.  The purified plasmids were quantitated utilizing a Lambda EZ 150 
spectrophotometer (Perkin Elmer, Boston, MA) and screened using restriction enzymes.  
To confirm that vectors contained the insert, they were sequenced prior to use in transient 
transfection assays.  Finally, vectors were stored at -20°C until use. 
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Cell Culture 
 αT3-1 cells (Dr. Pam Mellon, Salk Institute, La Jolla, CA) were maintained on 
150-mm cell culture plates (Corning Inc., Corning, NY) in 20 ml of αT3-1 media.  The 
media was comprised of high glucose Dulbecco’s Modified Eagle Medium (DMEM; 
Mediatech Inc., Herndon, VA) with 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 5% horse serum and 5% fetal bovine serum (Gibco, Grand Island, NY).  
The cultures of the αT3-1 cells were maintained at 37°C in a humidified 5% CO2 in air 
environment. 
 
Transient Transfections 
 Day 1.  At approximately 85% confluency, αT3-1 cells were trypsinized, counted, 
and plated for transfection utilizing a liposome-mediated protocol.  The media was 
aspirated from the cells and they were washed with 10 ml of 1X phosphate-buffered 
saline (PBS) 2 times.  Cells were trypsinized by adding 3 ml of 1X trypsin-EDTA 
(Mediatech Inc.) and incubated for 5 min at 37°C in a humidified 5% CO2 in air 
environment.  After the cells detached from the plate, 7 ml of αT3-1 media was added to 
disperse cell clumps and cells were transferred to a 50-ml conical tube.  A 100 µl sample 
of cells was diluted in 900 µl of 1X PBS and 10 µl of the dilution was loaded onto a 
hemacytometer to perform cell counts.  Approximately 2 x 106 αT3-1 cells were plated in 
a 6-well culture plate (Corning Inc., Corning, NY) to achieve 50% confluency at 
transfection.  Each well contained 2 ml of αT3-1 media. 
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 Day 2.  A 1.5-ml microcentrifuge tube for each test vector contained 291 µl of 
serum-free DMEM and 9 µl of Fugene6 (Roche Diagnostics Corp., Indianapolis, IN).  
Each test vector was transfected in triplicate and 0.9 µg/well of test vector and 0.1 
µg/well of the control vector (RSV-βgal) were added to each 1.5-ml microcentrifuge 
tube.  The reaction was incubated at room temperature for approximately 45 min.  
Following incubation, 96 µl of the reaction (DMEM, Fugene6 and vectors) was added to 
each well. 
 
 Day 3.  Transfected αT3-1 cells were harvested approximately 24 h later.  The 
media was aspirated from the wells and rinsed twice with 1 ml of 1X PBS.  Following the 
rinses, 200 µl of Lysis Buffer (Galacto-Light kit; Applied Biosystems, Bedford, MA), 
which contained 1 M dithiothreitol (DTT), was added to each well.  The 6-well plates 
were incubated and shaken at 4°C for at least 10 min.  The cell lysates were harvested by 
pipetting and washing the plates with the buffer.  Next, the cell lysates and Lysis Buffer 
were transferred to a 0.5-ml microcentrifuge tube and centrifuged at 4°C for 2 min at 
16,000 x g using a Spectrofuge 16M microcentrifuge (E&K Scientific, Campbell, CA).  
Cell lysates (20 µ1) were transferred in duplicate into a white 96-well Microflux2 plate 
(Thermo Labsystems, Franklin, MA) for luciferase and β-galactosidase assays.  The β-
galactosidase assay was incubated at room temp for 30-60 min prior to analyzing its 
activity using the Wallac Victor2 instrument (Perkin Elmer).  The plates were analyzed 
for luciferase and β-galactosidase activity utilizing the Wallac Victor2 instrument (Perkin 
Elmer).  Luciferase values were divided by β-galactosidase values to adjust for 
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transfection efficiency.  Transient transfections utilized three different plasmid 
preparations and were completed a minimum of three times. 
 
Protein Extraction 
 
 A Nuclear and Cytoplasmic Extraction Reagent Kit (NE-PER®; Pierce 
Biotechnology, Rockford, IL) was utilized to obtain nuclear protein extracts from αT3-1 
cells for electrophoretic mobility shift assays (EMSAs).  Four 150 mm plates of αT3-1 
cells at 85% confluency were rinsed once with 10 ml of cold 1X PBS.  Next, cells were 
removed from the plates with 10 ml of TNE buffer (10 mM Tris-Cl, 140 mM sodium 
chloride (NaCl), and 1 mM EDTA, pH of 8.0).  Once cells were removed from the plates, 
they were centrifuged for 5 min at 500 x g and 4°C using a Beckman TJ-6 centrifuge 
(Beckman, Palo Alto, CA).   
 The supernatant was completely removed from each cell pellet.  The dried cell 
pellet was resuspended in ice-cold CER I reagent (Pierce Biotechnology), by vortexing 
for 15 s, and incubated on ice for 10 min.  Phosphatase Inhibitor Cocktail Set II (100X 
stock containing 200 mM imidazole, 100 mM sodium fluoride, 115 mM sodium 
molybdate, 100 mM sodium orthovanadate and 400 mM sodium tartrate dehydrate; 
CalBiochem, La Jolla, CA) and Protease Inhibitor Cocktail [100X stock containing 104 
mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, 80 µM aprotinin, 2 mM 
leupeptin, 4 mM bestatin, 150 µM pepstatin A and 140 µM E-64; Sigma Chemical Co., 
St. Louis, MO] were added with the CER I reagent.  Next, ice-cold CER II reagent 
(Pierce Biotechnology) was added to the cells, vortexed vigorously for 5 s and incubated 
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on ice for 1 min.  Lysed cells were then centrifuged using a Spectrafuge 16M 
microcentrifuge at 16,000 x g (E&K Scientific, Campbell, CA) for 5 min at 4°C.  The 
supernatant was then transferred to a clean pre-chilled 1.5-ml microcentrifuge tube and 
stored at -80°C.  The insoluble pellet was resuspended in ice-cold NER reagent (Pierce 
Biotechnology) containing protease and phosphatase inhibitors.  The pellet was vortexed 
for 15 s and then incubated on ice for a total of 40 min, vortexing for 15 s every 10 min.  
Lastly, the lysed nuclei were centrifuged at 16,000 x g for 10 min at 4°C using a 
Spectrafuge 16M microcentrifuge (E&K Scientific).  The supernatant (nuclear extract) 
was then immediately transferred to a clean pre-chilled 1.5-ml microcentrifuge tube.  The 
total protein concentration of nuclear extracts was measured using the BCA™ Assay Kit 
(Pierce Biotechnology).  Nine standards were used for the standard curve and compared 
to unknown samples.  A microplate (Sarstedt, Inc., Newton, NC) was used and 25 µl of 
each standard and unknown was loaded onto the plate in triplicate.  A working reagent 
was prepared by mixing 50 parts of BCA™ Reagent A with 1 part of BCA™ Reagent B 
(50:1, Reagent A:B).  The working reagent (200 µl) was added to each well and mixed 
thoroughly on a plate shaker for 30 s.  Next, the plate was covered and incubated at 37°C 
for 30 min.  Following incubation, the plate was cooled to room temperature and light 
absorbance was measured on a Spectra Max 250 plate reader (Molecular Devices, 
Sunnyvale, CA) at 562 nm.  After the nuclear extracts were quantitated, they were stored 
at -80°C in 100 µl aliquots until use. 
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Electrophoretic Mobility Shift Assays 
 
Oligonucleotides were annealed prior to use in EMSAs by adding 1 µl of the 
antisense DNA (50 µM), 1 µl of the sense DNA (50 µM), 1 µl of 10X NET buffer (1 M 
NaCl, 10 mM EDTA, and 100 mM Tris-Cl, pH 7.5) and Millipore water to bring to a 
final volume of 10 μl.  The mixture was heated to 95°C for 10 min to denature the 
oligonucleotides, incubated at 37°C for 30 min to anneal the oligonucleotides and 
incubated at 25°C for an additional 30 min.  Oligonucleotides had a final concentration of 
5 µM and were stored at -20°C. 
T4 polynucleotide kinase (PNK; Fermentas, Inc., Hanover, MD) was used to end 
label the oligonucleotides with [γ-32P]ATP.  One µl of the annealed oligonucleotide, 1 µl 
of 10X T4 PNK Buffer A, 4 µl of Millipore water, 1 µl of T4 PNK, and 3 µl of [γ-
32P]ATP were incubated together for 30 min in a 37°C water bath.  After incubation, 35 
µl of Millipore water was added to each reaction.  MicroSpin™ G-25 columns 
(Amersham Biosciences Corp., Piscataway, NJ) were equilibrated by centrifuging at 
3,000 x g for 1 min using a Mikroliter microcentrifuge (Hettich AG, Bach, Switzerland).  
Each reaction was added to an equilibrated MicroSpin™ G-25 column (Amersham 
Biosciences Corp.) and centrifuged for 2 min at 3,000 x g using a Mikroliter 
microcentrifuge (Hettich AG).  Next, 5 µl of 10X NET buffer was added to each reaction.  
Four ml of scintillation fluid was added to 1 µl of each reaction in a scintillation vial and 
counted using a 1900TR liquid scintillation counter (Packard Instrument Co., Meriden, 
CT). 
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Electrophoretic mobility shift assays (EMSAs) utilized a 5% polyacrylamide gel that 
consisted of 6.25 ml of 38% acrylamide, 2% bisacrylamide; 5 ml of 10X TGE buffer 
(0.25 M tris base, 1.9 M glycine, 10 mM EDTA, pH 8.3); 150 µl of 10% ammonium 
persulfate, 50 µl of TEMED and Millipore water which was added to bring the final 
volume to 50 ml.  After polymerization, the gel was pre-run at 100 V for at least 30 min 
in 1X TGE buffer (25 mM tris base, 190 mM glycine, and 1mM EDTA, pH 8.3).  A 
master mix was prepared consisting of 4 μl of 2X Dignam D buffer [20 mM HEPES, pH 
7.9, 20% glycerol, 0.1 M potassium chloride (KCl), 0.2 mM EDTA, 0.5 mM 
phenylmethanesulfonyl fluoride (PMSF; added fresh), 0.5 mM DTT (added fresh)], 1 μl 
of 20 mM DTT, 2 µg poly(dI·dC) (Amersham Biosciences) and 5 µg of αT3-1 nuclear 
extracts.  The total volume was brought up to 18 µl with Millipore water and incubated 
on ice for 15 min.  Following incubation, either 1 μl of homologous, heterologous, or 
consensus oligonucleotide competitors were added.  Consensus oligonucleotides (Table 
3.2; Integrated DNA Technologies) that were used in EMSAs included GATA, 
glucocorticoid receptor (GR), nuclear factor-1 (NF-1), nuclear factor-κB (NF-κB), 
nuclear factor-Y (NF-Y), octamer transcription factor-1 (Oct-1), mutated    (μOct-1), and 
steroidogenic factor-1 (SF-1).  Assays which utilized unlabeled competitor 
oligonucleotides were added with 1 μl of radiolabeled probe and the reaction was 
incubated at room temperature for 20 min.  To determine which proteins comprised 
specific binding complexes, a rabbit polyclonal antibody directed against GATA-1, -2, 
and -4 (Santa Cruz Biotechnology, Santa Cruz, CA), a rabbit polyclonal antibody 
directed against the p65 (Calbiochem, La Jolla, CA) p50 (Santa Cruz Biotechnology),
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TABLE 3.2.  OLIGONUCLEOTIDES CONTAINING CONSENSUS 
TRANSCRIPTION FACTOR BINDING SITES USED AS COMPETITORS IN 
ELECTROPHORECTIC MOBILITY SHIFT ASSAYSa 
 
 
 
Transcription Factorb Binding Sequence 
GATA 5’- CAC TTG ATA ACA GAA AGT GAT AAC TCT -3’ 
GR 5’- AGA GGA TCT GTA CAG GAT GTT CTA GAT -3’ 
NF-1 5’- TTT TGG ATT GAA GCC AAT ATG ATA -3’ 
NF-κB 5’- AGT TGA GGG GAC TTT CCC AGG C -3’ 
NF-Y 5’- AGA CCG TAC GTG ATT GGT TAA TCT CTT -3’ 
Oct-1 5’- TGT CGA ATG CAA ATC ACT AGA A -3’ 
μOct-1 5’- TGT CGA ATG CAA GCC ACT AGA A -3’ 
SF-1 5’- CAA GTT CAC CTT GAT CTT TC -3’ 
 
aThe complement strand was annealed for each consensus oligonucleotide prior to 
use in gel shift assays. 
 bGR = glucocorticoid receptor; NF-1 = nuclear factor-1; NF-κB = nuclear factor- 
κB; NF-Y = nuclear factor-Y; Oct-1 = octamer transcription factor-1; μOct-1 = mutated 
octamer transcription factor-1; SF-1 = steroidogenic factor-1. 
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 and p52 (Upstate, Charlottesville, VA) subunits of NF-κB, polyclonal SF-1 antibodies 
(gifted by Dr. Ken-ichirou Morohashi, National Institute for Basic Biology, Okazaki, 
Japan), a rabbit polyclonal antibody directed against Oct-1 (Santa Cruz Biotechnology), 
or an equal mass of rabbit IgG (Santa Cruz Biotechnology) was used.  Prior to addition of 
the probe labeled with [γ-32P]ATP, the master mix was incubated with GATA antibodies 
for 2 h at 4°C, NF-κB antibodies for 30 min at room temperature, SF-1 antibodies for 2 h 
at room temperature, or Oct-1 antibodies for 1 h at room temperature.  After addition of 
the radiolabeled probe, the reactions were incubated at room temperature for 20 min.  
Reaction samples were then loaded to the polyacrylamide gel subjected to electrophoresis 
at 40 mA for approximately 1.5 hours.  Next, the polyacrylamide gel was transferred to 
blotting paper (3 mm; Whatman, Maidstone, England), dried on a Fisherbiotech Gel 
Dryer Model FB-GD-45 (Fisher Scientific, Pittsburgh, PA) and exposed to Blue Sensitive 
Radiographic Film (Marsh Bio Products, Inc., Rochester, NY) for 20-24 h at -80°C.  The 
film was later developed using an SRX-101A medical film developer (Konica Corp., 
Wayne, NJ). 
 
Statistical Analysis 
 Data were analyzed using analysis of variance (ANOVA) within the general 
linear models (GLM) procedure of the Statistical Analysis System (SAS, 2001).  Least 
significant differences was used to compare means for luciferase activity among test 
vectors.  Means for luciferase activity of test vectors were compared with control vectors 
using Dunnett’s t-test. 
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CHAPTER IV 
 
 
Three Steroidogenic Factor-1 Binding Sites Confer Gonadotrope-Specific Activity 
Whereas GATA-4 and Nuclear Factor-κB Elements Contribute to Divergent  
Line-Specific Activity of the Porcine GnRH Receptor Gene Promoter 
 
 
Abstract 
 
The interaction between GnRH and its receptor is critical for regulation of 
reproductive function.  Additionally, the porcine GnRH receptor (GnRHR) gene is 
located near a quantitative trait locus (QTL) for ovulation rate.  Thus, the GnRHR gene 
represents both a physiological and positional candidate for genes influencing ovulation 
rate.  Transient transfection of gonadotrope-derived αT3-1 cells with luciferase reporter 
constructs containing the GnRHR promoter from 3 swine lines with divergent ovulation 
rates (Control, Index or Meishan) revealed gonadotrope-specific activity that was 
significantly elevated for the Meishan promoter.  Our first objective was to identify 
elements within an important distal fragment, the swine upstream promoter enhancing 
region (SUPER; -1779/-1667), conferring cell-specific activity of the porcine GnRHR 
promoter.  Electrophoretic mobility shift assays (EMSA) using αT3-1 nuclear extracts, 
radiolabeled oligonucleotides spanning SUPER and an antibody directed against SF-1, 
revealed a binding site for SF-1 at -1760/-1753 bp of proximal promoter.  Transient 
transfection of αT3-1 cells with reporter vectors containing a block replacement mutation 
of the SF-1 binding site within the context of the full-length Control promoter reduced 
luciferase activity by approximately 30% compared to the full-length Control promoter 
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(P < 0.05).  Previously, transient transfection assays indicated that additional line-specific 
elements may lie between -1000 and -500 bp of 5’ flanking region for the porcine 
GnRHR gene.  Therefore, our second objective was to identify line-specific elements 
within both the -1000/-500 bp promoter region and SUPER.  Sequence analysis of the -
1000/-500 fragment identified a bp substitution (-845 bp) unique to the Meishan GnRHR 
gene promoter.  Inclusion of a GATA-4 antibody resulted in a supershift of the 
DNA:protein complex confirming that GATA-4 binds to the Meishan GnRHR promoter.  
Transient transfection of αT3-1 cells with a vector containing a block replacement 
mutation of the GATA-4 element reduced luciferase activity by approximately 20% (P < 
0.05) compared to the full-length Meishan promoter.  Another single bp substitution 
within SUPER (-1690 bp) allowed GATA-4 to bind to the Meishan promoter, whereas 
the p65/p52 subunits of NF-κB bound to the homologous Control/Index promoters.  
Transient transfection of αT3-1 cells with vectors containing the block replacement 
mutations of either the GATA-4 or NF-κB binding sites within the context of their native 
promoters resulted in a 50 and 60% reduction of luciferase activity, respectively.  Thus, a 
bp alteration (-845) in the Meishan GnRHR promoter recruits unique binding factors 
whereas SUPER contains both cell- and line-specific elements, contributing to the 
enhanced activity of the Meishan promoter. 
 
Introduction 
 
 Gonadotropin-releasing hormone (GnRH) is a decapeptide hormone that is 
released in a pulsatile manner from the hypothalamus and travels through the 
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hypothalamo-hypophoseal portal system to the anterior pituitary gland (Carmel et al., 
1976; Levine et al., 1982).  Gonadotropin releasing hormone binds to its cognate receptor 
on the plasma membrane of gonadotrope cells within the anterior pituitary gland, 
resulting in the synthesis and secretion of the gonadotropins, luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH; Clayton and Catt, 1981; Clarke et al., 1983).  
Luteinizing hormone is responsible for ovulation in the female and testosterone 
production in the male, whereas FSH is important for follicular recruitment and 
development in the female and spermatogenesis in the male.  Furthermore, GnRH 
binding to its G-coupled protein receptor (GPCR) stimulates the up-regulation of at least 
4 gonadotropic genes: the common glycoprotein α-subunit, the LH-β and FSH-β subunits 
(Hamernik and Nett, 1988; Gharib et al., 1990), and the GnRH receptor (GnRHR) itself 
(Sealfon and Millar, 1995).  The gonadotropins, in turn, act on the gonads to cause the 
production of steroid hormones.  The steroid hormones can act in a negative feedback 
loop at the level of the anterior pituitary and hypothalamus to control the production of 
the gonadotropins and GnRH, respectively (Nakai et al., 1978; Conn and Crowley, 1994; 
McNeilly et al., 2003).  Thus, the interaction between GnRH and its receptor represents a 
critical point for regulation of reproduction function in mammals.   
 The GnRHR gene promoter has been previously isolated and studied in various 
species including the mouse, rat and human.  The mouse GnRHR gene promoter was the 
first to be isolated and analyzed (Tsutsumi et al., 1992; Clay et al., 1995).  Cell-specific 
activity of the mouse GnRHR gene promoter is regulated by a tripartite basal enhancer 
that consists of 3 elements; steroidogenic factor-1 (SF-1; -244/-236 bp), activating 
101 
 
protein-1 (AP-1; -336/-330 bp) and a GnRHR activating sequence (GRAS; -391/-380 bp; 
Duval et al., 1997a, 1997b).  Each of these elements contribute equally to activity of the 
mouse GnRHR promoter.  Steroidogenic factor-1 is an orphan member of the nuclear 
receptor superfamily that is common to promoters of all gonadotropic genes and the AP-1 
element confers GnRH responsiveness of the mouse GnRHR gene (Norwitz et al., 1999; 
White et al., 1999).  In addition, GRAS regulates activin responsiveness of the mouse 
GnRHR gene promoter.  The functional activity of GRAS is dependent on the 
organization of a multi-protein complex which is made up of Smad3/4, AP-1, and a 
member of the forkhead family of DNA binding proteins, FoxL2 (Ellsworth et al., 
2003a).  In addition to the tripartite enhancer, another enhancer element critical to 
maximal GnRH-stimulated activity of the mouse GnRHR gene, termed the sequence 
underlying responsiveness to GnRH-1 (SURG-1; Norwitz et al., 1999), was identified.   
The rat GnRHR gene promoter is regulated by the same tripartite enhancer as the 
mouse.  However, the rat promoter possesses a distal enhancer, GnRHR specific 
enhancer (GnSE), which also contributes to cell-specific expression of the rat GnRHR 
gene (Pincas et al., 2001).  This distal GnSE contains binding sites for GATA and LIM 
homeodomain-related factors and also interacts with an SF-1 recognition site (Pincas et 
al., 1998; Pincas et al., 2001).  Despite characterization of placental-, granulosa/luteal 
cell- and neuronal-specific promoters as well as identification of elements responsive to 
GnRH, cAMP, P4 and E2 (Cheng and Leung, 2005), functional analysis of the 5’ flanking 
region for the human GnRHR gene has only revealed an SF-1 binding site required for 
gonadotrope-specific expression (Ngan et al., 1999).  Interestingly, prolonged treatments 
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with GnRH indicated that an upstream AP-1 element is involved in transcriptional down-
regulation of the GnRHR gene (Cheng et al., 2000b) and an Oct-1 binding site has been 
shown to act as a constitutive repressor of GnRHR gene transcription (Cheng et al., 
2002b).  
In addition to its established physiological importance, the porcine GnRHR gene 
is located in close proximity to a quantitative trait locus (QTL) associated with ovulation 
rate on chromosome 8 (Rohrer et al., 1999).  Therefore, the porcine GnRHR gene 
represents both a physiological and positional candidate for genes influencing ovulation 
rate.  To understand the relationship between the GnRHR gene and ovulation rate, our 
laboratory has utilized 3 swine lines with divergent ovulations rates; a Control white-
crossbred line, an Index line and the Chinese Meishan.  The Index line was selected for 
over 14 generations based on an index of embryonic survival and ovulation rate (Johnson 
et al., 1984).  These females ovulate 7 more oocytes per estrous cycle compared to the 
Control line, resulting in 1.4 more piglets per litter (Johnson et al., 1999).  Chinese 
Meishan females produce approximately 4 to 5 more pigs per litter than females from 
occidental breeds, largely due to an increased ovulation rate (Christenson et al., 1993; 
White et al., 1993).   
Identification of mutations within gene promoters that are correlated with 
enhanced physiological or quantitative traits is not unprecedented.  The porcine 
corticotropin-releasing hormone (CRH) gene is located in proximity to QTLs for growth 
and carcass composition on chromosome 4 and therefore, is a positional candidate for 
genes associated with these traits (Murani et al., 2006).  A single bp alteration within the 
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promoter of the CRH gene had no significant effect on growth and carcass composition in 
swine lines, but it may contribute to differences in meat quality among lines (Murani et 
al., 2006).  Several polymorphisms within the promoters of genes specific to the 
mammary gland in dairy cattle have positive effects on milk production.  Kuss et al. 
(2005) identified a single bp substitution in the bovine αs1-casein-encoding gene 
promoter.  Animals harboring this polymorphism displayed higher milk content traits and 
increased amounts of αs1-casein in their milk.  Furthermore, the bovine acyl-
CoA:diacylglycerol acyltransferase1 (DGAT1) gene contains several polymorphisms in 
German Angeln dairy cattle resulting in higher milk yield traits compared to other breeds 
(Sanders et al., 2006). 
In 1994, Weesner and Matteri sequenced the cDNA for the porcine GnRHR gene.  
Jiang and associates (2001) identified 1154 bp of proximal promoter for the porcine 
GnRHR gene.  Based on this sequence, our laboratory has isolated 5118 bp of 5’ flanking 
region for the porcine GnRHR gene promoter from the Control, Index and Meishan lines 
of swine and constructed luciferase reporter vectors containing each of these promoters.  
Transient transfection of reporter vectors into the gonadotrope-derived αT3-1 cell line 
revealed divergent luciferase activity among the 3 swine lines (McDonald, 2005).  We 
have also established polymorphisms within the 5’ flanking sequence of the GnRHR 
genes among swine lines.  Previously, we identified a single bp alteration unique to the 
Meishan located at -1235 bp of 5’ flanking region that allows the p65 and p52 subunits of 
NF-κB and an Sp-1 like protein to bind to the Meishan GnRHR gene promoter but not the 
Control promoter (McDonald, 2005).  In addition, transient transfection assays indicated 
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that additional line-specific elements may lie between -1000 and -500 bp of 5’ flanking 
region for the porcine GnRHR gene.  Recently, we identified a critical upstream enhancer 
region, termed the swine upstream promoter enhancing region (SUPER), located at -
1779/-1667 bp that contributed to cell-specific activity of the porcine GnRHR gene 
promoter (Cederberg et al., unpublished data).  Therefore, the objectives of this study 
were to identify line-specific elements within the -1000/-500 bp promoter region as well 
as cell- and line-specific elements within the recently identified SUPER that contribute to 
activity of the porcine GnRHR gene promoter. 
 
Materials and Methods 
 
Materials.  The antibody directed against the p65 subunit of NF-κB (catalog no. 
PC137) was purchased from Calbiochem (La Jolla, CA) and the antibody specific for the 
p52 subunit of NF-κB (catalog no. 06-413) was from Upstate (Charlottesville, VA).  The 
specific antibodies for the p50 subunit of NF-κB (catalog no. sc-114X), GATA-1 (catalog 
no. sc-1234X), GATA-2 (catalog no. sc-9008X), GATA-4 (catalog no. sc-1237), octamer 
transcription factor-1 (Oct-1; catalog no. sc-232X) and normal rabbit IgG (catalog no. sc-
2027) were all obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  The SF-
1 antibody was gifted by Dr. Ken-ichirou Morohashi (National Institute for Basic 
Biology, Okazaki, Japan).  For experiments using electrophoretic mobility shift assays 
(EMSAs), competitive oligonucleotides containing consensus binding sites for GATA, 
glucocorticoid receptor (GR), nuclear factor-1 (NF-1), NF-κB, nuclear factor-Y (NF-Y), 
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Oct-1, mutated (μOct-1) or SF-1 (See Table 3.2) were synthesized by Integrated DNA 
Technologies (Coralville, IA). 
 
 
Plasmids.  Using primers specific for the porcine GnRHR gene promoter 
originally isolated from the Control line (Cederberg et al., unpublished data), we 
identified promoters from genomic DNA of the Meishan and Index lines.  Full-length 
GnRHR gene promoters (-5118) from the three genetic pig lines were sub-cloned into the 
pGL3 basic reporter vector (Promega Corp., Madison, WI).  Plasmids harboring block 
replacement mutations were comprised of 5118 bp of 5’ flanking sequence for the 
GnRHR gene with individual elements mutated to contain: a PstI site replacing the 
GATA binding site at -845/-840 bp (Mµ845GATA4pGL3) or a Bcu/SpeI site substituted 
for the GATA element at -1694/-1689 bp (Mµ1690GATA4pGL3) within the Meishan 
promoter; an EcoRI site in place of the NF-κB binding site at -1699/-1694 bp 
(C/Iμ1699NFκBpGL3) or an EcoRI site replacing the NF-κB element at -1689/-1684 bp 
(C/Iµ1689NF-κBpGL3) within the Control and Index promoters; and a NotI (µSF-
1pGL3) or SacI (µOct-1pGL3) site in exchange for the SF-1 (-1760/-1753) or Oct-1 (-
1731/-1724) binding sites, respectively, within the promoters for all 3 swine lines.  
Overlap extension PCR mutagenesis was performed through two rounds of PCR in order 
to specifically mutate the binding element of interest.  The first round of PCR utilized 
primers replacing the binding site of interest with a restriction site, and the second round 
used product from the first round as template to anneal and replicate the mutated element 
and flanking sequence.  To verify that the correct mutations had been introduced, vectors 
were sequenced at the University of Nebraska-Lincoln Genomics Core Research Facility 
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before use in transient transfection experiments. The vector used as a control for 
transfection efficiency in all experiments contained the Rous sarcoma virus promoter 
fused to the cDNA encoding β-galactosidase (RSV-β-gal, Stratagene, La Jolla, CA).  A 
Plasmid Midi Kit (Qiagen, Valencia, CA) was used to isolate transfection quality DNA.   
 
 
Cell Culture and Transient Transfections.  Cultures of αT3-1 cells (Dr. Pam 
Mellon, Salk Institute, La Jolla, CA) were maintained at 37° C in a humidified 5% CO2 
in air atmosphere.  The αT3-1 cells were cultured in high-glucose Dulbecco’s Modified 
Eagle Medium (DMEM;  Mediatech, Herndon, VA) supplemented with 5% fetal bovine 
serum, 5% horse serum, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin sulfate (Gibco, Grand Island, NY).  Transient transfections were carried out 
using a liposome-mediated protocol (Fugene6, Roche Diagnostics Corp., Indianapolis, 
IN) according to manufacturer’s instructions.  Briefly, 2 x 106 cells were plated in 6-well 
culture dishes the day prior to transfection.  Cells were transfected with a 3:1 Fugene6 to 
DNA ratio.  A total of 1 μg of DNA, 0.9 μg of luciferase test vector and 0.1 μg of RSV-β-
gal control vector, were used per well.  Approximately 20-24 h post-transfection, cells 
were washed twice with ice-cold 1X PBS and harvested with 200 μl of lysis buffer 
[Tropix Lysis Buffer, Applied Biosciences, Bedford, MA and 1 mM dithiothreitol 
(DTT)].  Lysates were cleared by centrifugation at 16,000 x g for 2 min at 4° C.  Lysates 
(20 μl) were immediately analyzed according to manufacturer’s instructions for both 
luciferase (Promega Corp.) and β-gal (Tropix, Applied Biosystems, Bedford, MA) 
activity using a Wallac Victor2 microplate reader (PerkinElmer Life Sciences, Boston, 
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MA).  Luciferase values were divided by β-gal values to adjust for transfection 
efficiency.   
 
Electrophoretic Mobility Shift Assays.  Nuclear protein extracts were obtained 
from approximately 2.8 x 108 αT3-1 cells using the NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL).  The nuclear extracts were 
treated with protease (catalog no. P8340, Sigma Chemical Co., St. Louis, MO) and 
phosphatase (catalog no. 524625, Calbiochem, La Jolla, CA) inhibitor cocktail solutions 
to prevent enzymatic degradation of proteins.  The amount of protein present in the 
extracts was determined using a bicinchoninic acid (BCA) Protein Assay (Pierce).  
Oligonucleotides were end-labeled with [γ-32P]ATP using T4 polynucleotide kinase 
(Fermentas Inc., Hanover, MD) and purified using sephadex G-25 spin columns 
(Amersham Biosciences Corp., Piscataway, NJ).  Nuclear extracts (5 μg) were incubated 
in 20 μl reactions containing 2X Dignam D buffer [20 mM HEPES, pH 7.9, 20% 
glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM PMSF (added fresh), 0.5 mM DTT (added 
fresh)], 20 mM DTT, 2 μg of poly(dI•dC) (Amersham Biosciences) and, where indicated, 
a rabbit polyclonal antibody directed against the p65, p52 and p50 subunits of NF-κB, 
GATA-1, -2 and -4, Oct-1, SF-1, or an equal amount of rabbit IgG.  Prior to addition of 
the radiolabeled probe, the master mix was incubated with GATA antibodies for 2 h at 
4°C, NF-κB antibodies for 30 min at room temperature, SF-1 antibodies for 2 h at room 
temperature, or Oct-1 antibodies for 1 h at room temperature.  Following incubation, 
radiolabeled probe (100,000 cpm) and 50-fold molar excess of either homologous or 
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heterologous unlabeled competitor was added.  Where indicated, 50-fold molar excess of 
unlabeled oligonucleotides containing consensus binding sequences for GATA, GR, NF-
1, NF-κB, NF-Y, Oct-1, μOct-1, or SF-1 were also added.  The final reactions were 
incubated at 25° C for 20 min before bound probe was separated from free probe at 40 
mA for 1.5 h on a 5% polyacrylamide gel that had been pre-run at 100 V for 1 h in 1X 
TGE [25 mM tris base, 190 mM glycine and 1 mM EDTA, pH 8.3].  Gels were 
transferred to blotting paper, dried, and exposed to Blue Sensitive Radiograph film 
(Marsh Bio Products Inc., Rochester, NY) for 20-24 h at -80° C before being developed 
in a SRX-101A medical film developer (Konica Corp., Wayne, NJ).   
 
 
Statistical Analysis.  Data were analyzed using analysis of variance (ANOVA) 
within the general linear models (GLM) procedure of the Statistical Analysis System 
(SAS, 2001).  Least squares means for luciferase activity were compared among test 
vectors using least significant differences.  Means for luciferase activity of test vectors 
were compared with control vectors using Dunnett’s t-test.  All transfections were 
performed a minimum of three times using different plasmid preparations.  Additionally, 
each plasmid was transfected in triplicate wells within each transfection.  
 
Results 
 
 A single bp alteration unique to the Meishan GnRHR gene promoter allows 
for divergent binding of GATA-4.  Sequence analysis of the -1000 to -500 5’ flanking 
region revealed 4 single bp alterations among the 3 pig lines.  Electrophoretic mobility 
shift assays were performed using αT3-1 nuclear extracts and radiolabeled 
109 
 
oligonucleotides spanning the 4 single bp substitutions identified between -1000 and -500 
bp of proximal promoter to determine if differential binding existed among the swine 
lines.  Only the oligonucleotide representing the bp substitution at -845 bp formed a 
specific binding complex in the Meishan oligonucleotide, whereas binding was absent in 
the Control/Index oligonucleotides (Figure 4.1A).  Addition of unlabeled 
oligonucleotides containing consensus binding sites for GR, NF-1 or GATA resulted in 
ablated binding of the specific complex by the consensus GATA oligonucleotide, 
indicating that a member of the GATA family of transcription factors comprised the 
binding complex (Figure 4.1A).  Addition of an antibody directed against GATA-4, but 
not GATA-1 or -2, induced a supershift of the DNA:protein complex (Figure 4.1B).  
Therefore, GATA-4 binds to the sequence spanning the bp substitution at -845 bp of the 
Meishan GnRHR gene promoter and represents an important factor for line-specific 
activity of the Meishan promoter.  
 
 Block replacement mutation of the GATA-4 binding site located at -845 bp of 
proximal promoter reduced luciferase activity of the Meishan GnRHR gene 
promoter.  To determine the functional significance of the GATA-4 binding site unique 
to the Meishan promoter, αT3-1 cells were transiently transfected with luciferase reporter 
vectors containing either the full length Meishan promoter (M5000pGL3), a block 
replacement mutation of the GATA-4 binding site within the context of the full-length 
Meishan promoter (Mμ845GATA-4pGL3) or promoterless control (pGL3).  Reporter 
vectors containing the GATA-4 block replacement mutation (Mμ845GATA-4pGL3) 
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Figure 4.1.  The transcription factor, GATA-4, comprises the specific complex binding 
to the sequence spanning a bp substitution (-845) unique to the Meishan GnRHR gene 
promoter. (A) Electrophoretic mobility shift assays were performed by incubating αT3-1 
nuclear extracts with radiolabeled oligonucleotides spanning the bp alteration at -845.  
Specificity of the DNA:protein complex was tested by the addition of 50-fold molar 
excess of either unlabeled homologous or heterologous DNA.  In addition, 50-fold molar 
excess of unlabeled oligonucleotides containing consensus binding sequences for GR, 
NF-1 or GATA were added to the reaction.  (B) To determine the specific proteins which 
comprised the DNA:protein complex binding to the oligonucleotide spanning the 
substitution at -845 bp, antibodies directed against GATA-1, -2 and -4 or an equal mass 
of rabbit IgG were added.   
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reduced luciferase activity (P < 0.05) by approximately 20% compared to the native 
Meishan promoter (Figure 4.2).  Despite the reduced luciferase activity in cells 
transfected with Mμ845GATA-4pGL3, these values still remained numerically higher 
than those obtained for the full-length Control promoter (15- to 25-fold over promoterless 
control) in previous transfections.  This suggests that additional unidentified element(s) 
within the Meishan proximal promoter contribute to its enhanced activity. 
 
Binding of SF-1 to a recognition site located at -1760/-1753 bp of proximal 
promoter represents the first factor comprising the swine upstream promoter 
enhancing region (SUPER).  A transcription factor binding site search identified a 
putative SF-1 binding site located within SUPER.  An oligonucleotide spanning the SF-1 
binding site located at -1760/-1753 bp of 5’ flanking region of the porcine GnRHR gene 
promoter was used in EMSAs.  Incubation of radiolabeled oligonucleotide with αT3-1 
nuclear extracts and the addition of either homologous or heterologous DNA identified a 
specific binding complex (Figure 4.3).  Inclusion of unlabeled oligonucleotides 
containing consensus binding sites for NF-Y or SF-1 resulted in competition by the 
consensus SF-1 oligonucleotide (Figure 4.3).  Addition of an antibody directed against 
the DNA binding domain of SF-1 ablated the DNA:protein complex (Figure 4.3).  Thus, 
SF-1 interacts with the binding site (-1760/-1753) located within SUPER, an important 
distal enhancer of the GnRHR gene promoter.   
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Figure 4.2.  Functional significance of the GATA-4 binding site specific to the Meishan 
GnRHR gene promoter.  Transient transfections of αT3-1 cells with luciferase (LUC) 
reporter vectors containing the native, full-length Meishan promoter (M5000pGL3), a 
block replacement mutation of the GATA-4 binding site within the context of the full-
length Meishan promoter (Mμ845GATA-4pGL3) or promoterless control (pGL3) were 
performed.  Cells were harvested 24 h following transfection and assayed for LUC and β-
galactosidase (β-gal) activity.  Luciferase values were divided by β-gal values to adjust 
for transfection efficiency.  Differences between vectors are indicated by bars with 
unique letters (P < 0.05). 
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Figure 4.3.  The oligonucleotide spanning the region located at -1779/-1749 bp of the 
porcine GnRHR gene promoter binds SF-1 in αT3-1 cells.  Electrophoretic mobility shift 
assays were performed by incubating αT3-1 nuclear extracts with radiolabeled 
oligonucleotides spanning -1779/-1749 bp of proximal promoter.  Specificity of the 
DNA:protein complex was tested by the addition of 50-fold molar excess of either 
unlabeled homologous or heterologous DNA.  Next, 50-fold molar excess of unlabeled 
oligonucleotides containing consensus binding sequences for NF-Y or SF-1 were added.  
To determine the specific protein which comprised the binding complex, an antibody 
directed against the DNA binding domain of SF-1 or an equal mass of rabbit IgG were 
included.   
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The SF-1 binding site within SUPER is functionally significant to the porcine 
GnRHR gene promoter.  Luciferase reporter vectors containing the native full-length 
Control promoter (C5000pGL3), a block replacement mutation of the SF-1 binding site 
(μSF-1pGL3) or promoterless control (pGL3) were transiently transfected into αT3-1 
cells.  Cells containing the block replacement mutation vector of the SF-1 binding site 
(μSF-1pGL3) resulted in approximately a 30% reduction in luciferase activity (P < 0.05) 
compared to cells transfected with the full-length Control promoter (Figure 4.4).  
Therefore, this SF-1 binding site represents an additional distal member of the cell-
specific promoter for the porcine GnRHR gene.  Two functional SF-1 binding sites 
located at -315/-307 and -179/-171 bp of proximal promoter have previously been 
identified (Cederberg et al., unpublished data).  In addition, identification of this element 
allowed us to further refine the boundaries of SUPER from -1779/-1667 to -1760/-1667 
bp upstream of the translational start site for the porcine GnRHR gene.   
 
Putative Oct-1 and NF-κB elements identified within SUPER do not 
contribute to functional activity of the porcine GnRHR gene promoter.  Putative 
Oct-1 and NF-κB binding sites were identified within SUPER.  The NF-κB element was 
specific to the homologous Control/Index promoters, whereas the Oct-1 binding site was 
present in all 3 swine lines.  Electrophoretic mobility shift assays utilizing αT3-1 nuclear 
extracts and radiolabeled oligonucleotides spanning the NF-κB binding site located at - 
1689/-1684 bp of proximal promoter formed a specific binding complex (Data not 
shown).  Inclusion of antibodies specific for the p65, p50 and p52 subunits of NF-κB 
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Figure 4.4.  Functional significance of the SF-1 binding site within the porcine GnRHR 
gene promoter.  Transient transfections of αT3-1 cells with luciferase (LUC) reporter 
vectors containing the native, full-length Control promoter (C5000pGL3), a block 
replacement mutation of the SF-1 binding site within the context of the full-length 
Control promoter (μSF-1pGL3) or promoterless control (pGL3) were performed.  Cells 
were harvested 24 h following transfection and assayed for LUC and β-galactosidase (β-
gal) activity.  Luciferase values were divided by β-gal values to adjust for transfection 
efficiency.  Differences between vectors are indicated by bars with unique letters (P< 
0.05). 
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 resulted in a supershift of the p65 and p52 subunits of NF-κB (See Appendix I, Panel A).  
In addition, EMSAs using αT3-1 nuclear extracts and a radiolabeled oligonucleotide 
spanning the Oct-1 element located at -1731/-1724 bp of 5’ flanking region revealed a 
specific binding complex (See Appendix II, Panel A).  However, αT3-1 cells transiently 
transfected with luciferase reporter vectors containing block replacement mutation 
vectors for either the NF-κB (C/Iμ1689NF-κBpGL3) or Oct-1 (μOct-1pGL3) elements 
did not differ in luciferase activity compared to the full-length porcine GnRHR gene 
promoter (See Appendices I and II, Panel B).  Thus, despite recruitment of binding 
factors in αT3-1 cells, the Oct-1 and NF-κB elements were not functionally relevant to 
cell- or line-specific activity of the porcine GnRHR gene promoter. 
 
A single bp substitution within SUPER confers divergent binding between 
the Meishan and Control/Index GnRHR gene promoters.  Sequence analysis 
identified a single bp alteration located within SUPER at -1690 bp of proximal promoter 
between the Meishan and homologous Control/Index promoters.  Electrophoretic 
mobility shift assays utilizing αT3-1 nuclear extracts and radiolabeled oligonucleotides 
spanning the bp substitution (-1690) between the Meishan and Control/Index promoters 
revealed a specific binding complex for both swine lines (Figure 4.5A).  Sequence 
analysis of this region identified potential NF-κB and GATA elements in the Meishan 
and Control/Index promoters.  Addition of antibodies directed against the p65 and p52 
subunits of NF-κB resulted in a supershift of the DNA:protein complex for the 
Control/Index oligonucleotide.  However, the specific binding complex associated with 
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Figure 4.5.  The p65 and p52 subunits of NF-κB bind to the homologous Control/Index 
promoters, whereas GATA-4 binds to the Meishan promoter within the 5’ flanking region 
spanning the -1690 bp substitution.  Electrophoretic mobility shift assays were performed 
with αT3-1 nuclear extracts and radiolabeled oligonucleotides spanning the -1690 bp 
substitution between the Control/Index and Meishan swine lines.  A)  To determine the 
specificity of the DNA:protein complex, 50-fold molar excess of either unlabeled 
homologous or heterologous DNA were added.  B)  To determine specific proteins which 
comprised the DNA:protein complex binding to the oligonucleotide spanning the 
substitution at -1690 bp, antibodies directed against the p65, p50, and p52 subunits of 
NF-κB, GATA-1, -2 and -4, or an equal mass of rabbit IgG were added.  
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the Meishan oligonucleotide was supershifted by an antibody specific for GATA-4 
(Figure 4.5B).  Therefore, the single bp alteration in the Meishan promoter forms a 
GATA element that allows GATA-4 binding instead of the p65 and p52 subunits of NF-
κB which bind to the Control/Index promoters. 
 
Block replacement mutations of the GATA-4 and NF-κB binding sites in the 
Meishan and Control/Index promoters, respectively, reduced luciferase activities of 
both the Meishan and Control/Index GnRHR gene promoters.  Transient 
transfections of αT3-1 cells with luciferase reporter vectors containing either the native, 
full-length Meishan (M5000pGL3) and Control (C5000pGL3) promoters, block 
replacement mutations of the GATA-4 (Mμ1690GATA-4pGL3) and NF-κB 
(C/Iμ1699NF-κBpGL3) binding sites within the context of their respective full-length 
promoter or promoterless control (pGL3) were performed.  Reporter vectors containing 
the block replacement mutation of the GATA-4 binding site (Mμ1690GATA-4pGL3) 
resulted in approximately a 50% reduction in luciferase activity (P < 0.05) compared to 
the native Meishan promoter.  Further, αT3-1 cells transfected with the reporter vectors 
containing the block replacement mutation of the NF-κB binding site (C/Iμ1699NF-
κBpGL3) reduced luciferase activity (P < 0.05) by approximately 60% compared to cells 
containing the native Control promoter (Figure 4.6).  Thus, this single bp substitution 
contributes to the line-specific activity of the porcine GnRHR gene promoter. 
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Figure 4.6.  Functional significance of the GATA-4 and NF-κB elements specific to the 
Meishan and Control/Index GnRHR gene promoters, respectively.  To confirm the 
importance of the GATA-4 binding site within the Meishan promoter and the NF-κB 
element within the Control/Index promoters, block replacement mutations of each 
binding site were constructed within the context of their respective full length promoter.  
Transient transfections of αT3-1 cells with luciferase (LUC) reporter vectors containing 
both full-length promoters (M5000pGL3 and C5000pGL3), block replacement mutations 
of the GATA-4 (Mμ1690GATA-4pGL3) and NF-κB (C/Iμ1699NF-κBpGL3) elements or 
promoterless control (pGL3) were performed.  Cells were harvested 24 h following 
transfection and assayed for LUC and β-galactosidase (β-gal) activity.  Luciferase values 
were divided by β-gal values to adjust for transfection efficiency.  Differences between 
vectors are indicated by bars with unique letters (P < 0.05). 
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The working models for cell- and line-specific activity of the porcine GnRHR 
gene promoter have been updated as a result of these studies.  In addition to the 
proximal SF-1 binding sites located at -315/-307 and -179/-171 bp of proximal promoter, 
an additional distal SF-1 element located at -1760/-1753 bp of 5’ flanking region can be 
added to the cell-specific promoter of the porcine GnRHR gene (Figure 4.7A).  This is a 
unique result because no previously identified gonadotropic gene promoters are regulated 
by 3 SF-1 binding sites.  In addition to the cell-specific activity of the porcine GnRHR 
gene promoter, we can also add to our working model for line-specific activity.  Our 
laboratory previously identified a single bp substitution unique to the Meishan promoter 
located at -1235 bp relative to the translational start site of the porcine GnRHR gene.  
This bp alteration allows the p65 and p52 subunits of NF-κB and an Sp1-like protein to 
bind to the Meishan promoter, whereas they do not bind to the homologous Control/Index 
promoters (Figure 4.7B).  Another bp substitution located at -845 was identified in the 
Meishan promoter.  This single bp alteration allows GATA-4 to bind to the Meishan 
promoter, whereas it is absent in the Control/Index promoters (Figure 4.7B).  
Furthermore, an additional distal polymorphism (-1690) within SUPER allows GATA-4 
to bind to the Meishan promoter, whereas the p65 and p52 subunits of NF-κB bind to the 
homologous Control/Index promoters (Figure 4.7B).  Therefore, the 3 identified elements 
unique to the Meishan promoter contribute to its enhanced activity over the Control/Index 
promoters. 
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Figure 4.7.  Working models for (A) cell- and (B) line-specific activity of the porcine 
GnRHR gene promoter.  (A)  In addition to the previously identified proximal SF-1 
binding sites (-315/-307 and -179/-171), another SF-1 binding site (-1760/-1753) located 
within the important distal region of the promoter termed SUPER can be added to our 
working model for the cell-specific promoter of the porcine GnRHR gene.  (B)  Our 
laboratory previously identified a single bp alteration at -1235 bp of 5’ flanking region 
allowing the p65/p52 subunits of NF-κB and an Sp1-like protein to bind to the Meishan 
GnRHR gene promoter.  An additional bp substitution located at -845 bp of proximal 
promoter allows GATA-4 to bind to the Meishan promoter.  None of these factors were 
capable of binding to the Control promoter.  However, another polymorphism (-1690) 
within the critical distal portion of promoter called SUPER allows binding of the 
transcription factor GATA-4 to the Meishan promoter (GATA element, dotted box), 
whereas the p65 and p52 subunits of NF-kB bind to the homologous Control/Index 
promoters (NF-κB element, diagonal box). 
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Discussion 
 
Our laboratory is primarily interested in transcriptional regulation of the porcine 
GnRHR gene.  Recently, we identified a critical enhancer region of the porcine GnRHR 
gene promoter termed the swine upstream promoter enhancing region (SUPER) located 
at -1779/-1667 bp of 5’ flanking region.  Removal of this region resulted in a dramatic 
decrease in promoter activity (Cederberg et al., unpublished data).  In this study, results 
from EMSA experiments further refined SUPER to -1760/-1667 bp of proximal 
promoter.  In addition, we identified both cell- (-1760/-1753) and line-specific (-1690) 
elements within SUPER.  Therefore, these results amplify the importance of SUPER in 
transcriptional regulation of the porcine GnRHR gene.   
 The first element identified within SUPER represents a new member of the cell-
specific porcine GnRHR gene promoter.  We identified an SF-1 binding site located at -
1760/-1753 bp of proximal promoter.  Previously, our laboratory identified 2 additional 
SF-1 elements located at -315/-307 and -179/-171 bp of proximal promoter that are also 
critical to cell-specific activity (Cederberg et al., unpublished data).  Steroidogenic factor-
1 binding sites are important in the regulation of the GnRHR gene in other mammalian 
species such as the mouse (Duval et al., 1997a), human (Ngan et al., 1999), sheep (Duval 
et al., 2000) and rat (Pincas et al., 2001).  Additionally, SF-1 has also been implicated in 
the regulation of other gonadotrope-specific genes including the LHβ- (Keri and Nilson, 
1996; Wolfe, 1999), FSHβ- (Brown and McNeilly, 1997; Jacobs et al., 2003) and α- 
(Barnhart and Mellon, 1994) subunit genes.  Interestingly, the rat GnRHR receptor 
promoter is regulated by both distal and proximal regions, similar to the porcine GnRHR 
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gene promoter.  In addition to a proximal tripartite enhancer originally identified in the 
mouse (Duval et al., 1997a), the rat GnRHR gene promoter is comprised of an important 
distal region, the GnRHR specific enhancer (GnSE; -1135/-753).  Specifically, the GnSE 
helps confer gonadotrope-specific expression via its interaction with a proximal region 
located at -275/-226 bp of proximal promoter that includes an SF-1 binding site within 
the tripartite enhancer (Pincas et al., 2001).     
The utilization of 3 SF-1 binding sites is unprecedented for gonadotropic genes.  
However, these recognition sites do not contribute equally to cell-specific activity of the 
porcine GnRHR gene promoter.  Block replacement mutation of the 3’ gonadotrope 
specific element (GSE) eliminated promoter activity, indicating that this SF-1 binding 
site is absolutely critical to expression of the GnRHR gene in gonadotrope derived αT3-1 
cells.  Mutation of the GSE located at -315/-307 bp reduced promoter activity by 
approximately 20% (P < 0.05; Cederberg et al., unpublished data).  Consistent with this 
GSE, mutation of the SF-1 binding site located at -1760/-1753 bp identified in this study 
resulted in a 30% reduction in promoter activity.  Thus, these 2 SF-1 recognition sites are 
necessary but not sufficient for expression of the porcine GnRHR gene in gonadotrope-
derived cells.  Transcription of some genes expressed within gonadotropes is regulated by 
2 GSEs.  The equine LHβ-subunit gene is regulated by 2 SF-1 sites located between -
185/-100 and -55/-48 bp relative to the translational start site (Wolfe, 1999).  Mutation of 
the 2 GSEs, individually (proximal or distal) or in combination decreased LHβ-subunit 
promoter activity by 14, 34, and 24% (P < 0.05), respectively in LβT2 cells.  However, it 
did not attenuate basal expression of the promoter in αT3-1 cells (Wolfe, 1999).  Thus, 
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the activity of the equine LHβ-subunit gene is partially conferred by 2 GSEs in LβT2 but 
not αT3-1 cells (Wolfe, 1999).  The mouse FSHβ-subunit gene is regulated by 2 proximal 
GSEs and a downstream NF-Y element.  Mutation of the 2 GSEs individually or in 
combination does not affect promoter activity in LβT2 cells.  However, when the 2 GSEs 
were mutated in combination with the downstream NF-Y binding site promoter activity 
was reduced by 50% (Jacobs et al., 2003).  The use of a single GSE by promoters for 
genes encoding the GnRHR is much more common.  Functional activity of the mouse 
GnRHR gene promoter is partially conferred by an SF-1 binding site located at -244/-236 
bp of 5’ flanking region.  Mutation of this GSE within the context of 600 bp of 5’ 
flanking region reduced promoter activity by approximately 60% in αT3-1 cells (Duval et 
al., 1997a, 1997b).  Activity of the human GnRHR gene promoter was increased by 
150% upon overexpression of SF-1 in αT3-1 cells.  Consistent with this, the addition of 
antisense oligonucleotides for SF-1 mRNA reduced activity of the human GnRHR gene 
promoter by 61% (Ngan et al., 1999).  
The pig has served as a unique model to understand the relationship between the 
porcine GnRHR gene promoter and a QTL for ovulation rate located on chromosome 8.  
Three swine lines with divergent ovulation rates were utilized to analyze transcriptional 
regulation of the porcine GnRHR gene promoter; Control, Index and Chinese Meishan.  
Transient transfection of αT3-1 cells with reporter vectors containing the Control, Index 
and Meishan promoters indicated divergent activity among the lines of swine.  
Previously, our laboratory identified a single bp alteration unique to the Meishan located 
at -1235 of proximal promoter.  This bp substitution allowed the p52 and p65 subunits of 
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NF-κB and an Sp1-like protein to bind to the Meishan promoter compared to the 
Control/Index promoters (McDonald, 2005).  In the current study, we identified 2 
additional single bp substitutions in the Meishan promoter, located at -845 and -1690 bp 
of proximal promoter.  The single bp substitutions at both -845 and -1690 bp of 5’ 
flanking region formed GATA-4 binding sites in the Meishan promoter.  Block 
replacement mutations of the -845 and -1690 bp alterations within the context of the full-
length Meishan promoter significantly reduced promoter activity by approximately 20 
and 50%, respectively (P < 0.05), indicating that these elements contribute to the 
enhanced activity of the Meishan GnRHR gene promoter.  In contrast to the Meishan-
specific GATA-4 element, the single bp alteration within the Control/Index promoter 
located at -1690 bp of 5’flanking region formed an NF-κB binding site, interacting with 
the p65/p52 subunits of NF-κB.  Block replacement mutations of this specific binding site 
within the context of the full length Control/Index promoter also significantly reduced 
promoter activity by approximately 60% (P < 0.05).  Consequently, the 3 identified 
elements unique to the Meishan promoter contribute to its enhanced activity over the 
Control/Index promoters.  Although it could be argued that the GATA-4 and NF-κB 
elements at -1690 contribute equally to activity of the Meishan and Control/Index 
promoter, respectively, since mutation of these sites reduced activity similarly (50% for 
Meishan vs. 60% for Control/Index promoters).  However, it is still unknown how 
different elements within the porcine GnRHR gene promoter interact with one another. 
To date, GATA-4 has not been implicated in the regulation of any GnRHR genes 
except the pig.  However, GATA family members are important in the regulation of other 
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gonadotropic genes.  For example, mutation of a GATA element identified in the human 
α-subunit gene promoter decreased activity by 2.5-fold in gonadotrope-derived αT3-1 
cells and 15-fold in JEG-3 human placental cells, suggesting that GATA binding factors 
have a functional role in transcriptional regulation of the human α-subunit gene (Steger et 
al, 1994).  Recognition sites for GATA factors have also been implicated in 
transcriptional regulation of genes within other reproductive tissues.  GATA-4 is 
involved in transcription of several genes essential for gonadal development and function 
such as genes that encode the hormones, inhibin α and Mullerian inhibiting substance, the 
steroidogenic acute regulatory (sTAR) protein, and SF-1 (Tremblay and Viger, 2001).  
Binding sites for GATA proteins also play a role in activity of the neuronal-specific 
enhancer for the GnRH gene within the hypothalamus (Lawson et al., 1996).  Further, 
gonadotropin-regulated genes in the adult ovary are controlled by GATA-4.  GATA-4 
mRNA and/or protein has been found in thecal and interstitial cells (McCoard et al., 
2001; Gillio-Meina et al., 2003) as well as the granulosa cell layer of healthy follicles 
(Heikinheimo et al., 1997; McCoard et al., 2001; Vaskivuo et al., 2001; Gillio-Meina et 
al., 2003).  In addition to the female, GATA-4 has also been detected in male 
reproductive tissues.  Within the testis, GATA transcription factors have been identified 
in both Sertoli (Viger et al., 1998; Ketola et al., 1999; 2000; 2002; Anttonen et al., 2003;) 
and Leydig (Ketola et al., 1999; 2000; 2002) cells.  Thus, GATA elements are abundant 
in genes associated with reproduction, playing an important role in transcriptional 
regulation of these genes. 
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Previously, our laboratory identified a functional NF-κB element unique to the 
Meishan GnRHR gene promoter.  In the current study, we also identified a functional 
NF-κB binding site specific to the homologous Control/Index GnRHR gene promoters 
located at -1690 bp of 5’ flanking region.  The transcription factor, NF-κB is important in 
regulating the immune system but also plays a role in embryonic development, the 
development and physiology of tissues (mammary gland, bone, and skin) and the central 
nervous system (Hayden and Ghosh, 2004).  To date, NF-κB has not been linked to 
regulation of any other gonadotrope-specific genes besides the porcine GnRHR gene.  
Although NF-κB has not been implicated in the regulation of gonadotrope-specific genes, 
it can regulate other genes within the anterior pituitary such as the pituitary 
proopiomelancortin (POMC) gene.  In response to stress, corticotropin-releasing 
hormone regulates NF-κB activity which is associated with activation of the pituitary 
POMC gene (Karalis et al., 2004).  Although transcriptional regulation of downstream 
genes have not been investigated, activation of NF-κB complexes was detected in 
somatotrope cells following stimulation with interleukin-1 (Parnet et al., 2003).  In 
addition to the important role NF-κB plays in transcriptional regulation of corticotropic 
and somatotropic genes within the anterior pituitary gland, the current study 
demonstrated that it is also critical in the regulation of gonadotropic genes (i.e., the 
porcine GnRHR gene). 
Although the 3 elements unique to the Meishan promoter represented a portion of 
its enhanced activity in αT3-1 cells, further studies need to be performed to determine if 
additional binding sites contribute to its activity.  For instance, reporter vectors 
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containing block replacement mutations of the 3 elements in combination should be 
utilized to determine if the enhanced GnRHR promoter activity in the Meishan line can 
be fully explained by only these 3 transcription factor binding sites.  Despite the reduced 
luciferase activity in cells transfected with each Meishan block replacement mutation, 
however, these values still remained numerically higher than those obtained for the full-
length Control promoter (15- to 25-fold over promoterless control).  Thus, it is likely that 
other elements involved in transcriptional regulation of the Meishan GnRHR gene have 
yet to be identified.  
In summary, we added an additional SF-1 binding site located at -1760/-1753 bp 
of 5’ flanking region to our working model for the cell-specific promoter of the porcine 
GnRHR gene (Figure 4.7A).  Thus, we have demonstrated the importance of the 3 GSEs 
in transcriptional regulation of the porcine GnRHR gene.  In addition to cell-specific 
elements, we identified 3 functional elements that contribute to the enhanced activity of 
the Meishan GnRHR gene promoter in αT3-1 cells (Figure 4.7B).  Each respective 
element is formed due to single polymorphisms among lines within the GnRHR gene 
promoter.  At -1235 bp of proximal promoter, the Meishan promoter contains a NF-κB 
and Sp1-like binding site, whereas 2 GATA-4 binding sites are located at -845 and -1690 
bp of 5’ flanking region.  Alternatively, the single bp substitution at -1690 of proximal 
promoter maintains an NF-κB binding site within the Control/Index promoter.  
Ultimately, we could interchange the GnRHR gene promoter in Control and Meishan 
swine lines to determine if reciprocal GnRHR promoter exchange will result in a 
functional alteration of ovulation rate. 
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Appendix I 
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A)  Electrophoretic mobility shift assays revealed a specific binding complex in the 
oligonucleotide spanning -1689/-1667 bp of the porcine GnRHR gene promoter.  
Addition of antibodies specific to the p65, p50 and p52 subunits of NF-κB or rabbit IgG 
resulted in a supershift of the p65 and p52 subunits of NF-κB.  B)  Reporter vectors 
containing the native, full length Control promoter (C5000pGL3), a block replacement 
mutation of the NF-κB element within the context of the full length Control promoter 
(C/Iμ1689NF-κBpGL3), or promoterless control (pGL3) were transiently transfected into 
αT3-1 cells.  Luciferase (LUC) activity did not differ between the vector containing the 
block replacement mutation (C/Iμ1689NF-κBpGL3) and the full length promoter 
(C5000pGL3).  Therefore, the identified NF-κB binding site did not contribute to 
functional activity of the porcine GnRHR gene promoter. 
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Appendix II 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
A)  Examination of the oligonucleotide spanning -1737/-1707 bp of the porcine GnRHR 
gene promoter using EMSAs identified a specific binding complex.  Addition of 
unlabeled oligonucleotides containing consensus binding sites for Oct-1 resulted in 
competition for binding.  Consistent with this, addition of an unlabeled oligonucleotide 
containing a mutated Oct-1 (μOct-1) binding site was unable to ablate binding.  This 
indicated the -1737/-1707 oligonucleotide contained an element that bound the Oct-1 
transcription factor.  B)  Reporter vectors containing the native, full length Control 
promoter (C5000pGL3), a block replacement mutation of the Oct-1 element within the 
context of the full length Control promoter (μOct-1pGL3), or promoterless control 
(pGL3) were transiently transfected into αT3-1 cells.  Luciferase (LUC) activity did not 
differ between the vector containing the block replacement mutation (μOct-1pGL3) and 
the full length promoter (C5000pGL3).  Therefore, the identified Oct-1 binding site did 
not contribute to functional activity of the porcine GnRHR gene promoter. 
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